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Populärvetenskaplig sammanfattning 
 
Malaria är en av vår tids viktigaste sjukdomar ur ett globalt perspektiv. Malaria är en 
parasitsjukdom som överförs av myggor. Under de senaste femton åren har det skett en 
minskning av malariaförekomst och dödlighet tack vare kontrollinsatser i bred skala. Trots 
detta utgör sjukdomen ett ständigt hot mot liv och hälsa för ca 40 % av jordens befolkning 
som lever i de dryga 90 länder där malaria förekommer och över 600.000 dör av sjukdomen 
varje år. Majoriteten av dessa är barn yngre än 5 år och gravida kvinnor i Afrika, söder om 
Sahara.  
 
Tillgång till en snabb och korrekt parasitbaserad diagnos för att rikta behandling till de med 
en bekräftad infektion är en mycket viktig hörnsten i malariakontroll.  Detta är viktigt för att 
undvika överdiagnostik, baserat på kliniska observationer, och för att förhindra 
överanvändning av anti-malarialäkemedel. Detta är viktigt för att minimera risken för att 
resistens mot läkemedlen utvecklas. Emellertid ställer olika endemiska sammanhang olika 
krav på dessa diagnostiska hjälpmedel. Nya moderna verktyg såsom snabbtest (RDT), 
baserade på påvisande av malariaspecifika proteiner i blodprov, har möjliggjort ökad tillgång 
till en känslig och korrekt diagnos. De nya snabbtesterna har många fördelar; de är enkla att 
utföra och bedöma, de kräver varken tillgång till utrustning eller elektricitet och lämpar sig 
därför väl för användande både inom akut- och primärhälsovård världen över. Snabbtester har 
dock också nackdelar, främst med avseende på känslighet och precision.  
 
I denna avhandling har nyttan av snabbtester jämfört med mikroskopi och molekylära 
metoder (PCR), både bland feber patienter i ett lågendemiskt/pre-elimineringsområde 
(Zanzibar), och bland barn under fem år med en bekräftad malariainfektion i ett relativt 
högendemiskt område (Tanzania), utvärderats. Vårdpersonalens tillit till resultatet på 
snabbtesten studerades också i Zanzibar. Resultaten visade att snabbtestets känslighet för 
påvisande av parasiter hade sjunkit sedan en tidigare undersökning då det fanns mycket 
malaria på Zanzibar, medan vårdpersonalen hade fortsatt högt förtroende för testresultatet, 
d.v.s. endast de med positivt resultat fick behandling med malarialäkemedel. Barnen i 
Tanzania följdes upp vid nio tillfällen med mikroskopi, PCR och två olika snabbtester, 
baserade på två olika malariaspecifika proteiner, upp till dag 42 efter insatt 
malariabehandling. Detta gjordes för att beräkna hur lång tid de olika diagnostiska metoderna 
kvarstod positiva samt deras förmåga att upptäckta nya episoder av malaria, något som 
förekommer ofta i högendemiska områden. En av de utvärderade snabbtesterna visade 
positivt resultat i medeltal fyra veckor efter den första malariainfektionen och kunde därför 
inte upptäcka nya episoder. 
 
Hur parasite DNA kan påvisas i snabbtester utvärderades också. Detta kan användas för 
övervakning av markörer för resistens hos parasiterna och för kvalitetskontroll av snabbtester. 
 
   
Att utveckla tester som är tillräckligt känsliga för att kunna hitta asymtomatiska bärare av 
mycket låga parasitnivåer, vilka utgör en risk för fortsatt smitta i områden där malarian 
närmar sig eliminering, är en utmaning. De nuvarande snabbtesterna är inte tillräckligt 
känsliga. DNA påvisning med PCR är den metod som har det som krävs avseende 
diagnostisk känslighet men som genom höga krav på både tid, kunskap och utrustning inte 
utgör ett alternativ. Under senare år har LAMP (loop-medierad isotermal amplifiering) en 
snabb, känslig och relativt enkel molekylär metod börjat testas och som i framtiden 
förhoppningsvis kommer att lämpa sig också för diagnostik och övervakning av malaria i 
endemiska områden utanför specialutrustade laboratorier. Ett LAMP test utvärderades för 
påvisande av malariaparasiter på insamlade prov från både feberpatienter och 
asymptomatiska bärare i Zanzibar. LAMP påvisade parasiter med lika hög känslighet som 
PCR också hos de asymptomatiska bärarna med mycket låga parasitnivåer, vilket visar att 
metoden är lovande för framtida användning i endemiska områden. 
 
Resultaten  i de fyra delstudierna i denna avhandling utgör viktiga data avseende nyttan av 
nya diagnostiska verktyg för bättre påvisning och övervakning av malaria i olika endemiska 
sammanhang. 
  
  
ABSTRACT 
Nearly half of the world’s population is at risk for malaria and over 600,000 die from the 
disease every year. Access to prompt and correct parasite based diagnosis in order to target 
treatment to those with a confirmed malaria infection and improved malaria surveillance are 
cornerstones in malaria control. The availability of modern diagnostic tools such as rapid 
diagnostic test (RDT), polymerase chain reaction (PCR) and loop mediated isothermal 
amplification (LAMP) represent new opportunities besides microscopy for improved 
sensitive and accurate parasite-based diagnosis. However, there are different demands on 
diagnostic tools for different health care settings and endemic contexts. 
The performance of RDT was compared to blood smear microscopy and PCR among febrile 
patients in a low endemic/pre elimination area (Zanzibar). Although the sensitivity of RDT 
was found to be relatively low (76.5%) the health care workers were highly adherent to test 
results in prescribing antimalarial drugs. 
Parasite clearance and detection of recurrent infections was assessed by different diagnostic 
methods after malaria treatment in febrile children in a relatively high endemic area of 
mainland Tanzania. Median clearance time was two days for PCR and microscopy whereas 
the clearance times were seven and 28 days for the pLDH and HRP2 based RDTs, 
respectively. pLDH based RDT was a better tool than HRP2 based for treatment follow up 
and detection of recurrent infection 
The usefulness of RDT as a source of parasite DNA was evaluated through different parasite 
DNA extraction methods. DNA extraction efficacy varied with test device and extraction 
method. There was no difference in PCR detection rates between RDT and filter paper 
samples collected from the field. This confirms the usefulness of RDTs stored under field 
conditions as a modern tool for molecular malaria surveillance and RDT quality control. 
A LAMP kit was compared to conventional PCR methods for detection of parasite DNA 
from dried blood spots collected among both fever patients and asymptomatic individuals in 
Zanzibar. The LAMP kit had a sensitivity of 98% for detection of Plasmodium(P) falciparum 
among fever patients and a sensitivity of > 92% and 77% for detection of P. falciparum and 
P. malariae among asymptomatic individuals. The high diagnostic accuracy of the LAMP kit 
for detection of low density parasitaemias from minute blood volumes preserved on filter 
papers supports its role for improved case detection in areas of low density malaria infections.  
The results in this thesis provide important data on the usefulness of new diagnostic tools for 
improved case detection and surveillance of malaria in different endemic contexts. 
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1 INTRODUCTION 
1.1 GENERAL BACKGROUND TO MALARIA 
Malaria has had a major impact on the development of life and health of mankind 
historically. Malaria is not just a disease commonly associated with poverty, evidence 
suggests that it is also a cause of poverty and a major hindrance to economic development [1, 
2]. Throughout history, the contraction of malaria has played a prominent role in the fates of 
government rulers, nation-states, military personnel, and military actions [3]. 
Malaria is a parasitic disease caused by a protozoan of the genus Plasmodium (P). There are 
more than 100 species of Plasmodiae infecting a wide range of vertebrates including reptiles, 
birds and humans. Prehistoric man in the old world was subjected to malaria [4] and 
Hippocrates (5 century BC) was the first physician who described the clinical picture of 
malaria (fever and enlarged spleen) and its relation to season of the year and area where 
patients lived. The awareness of the association of fever with stagnant water and swamps, the 
breeding places for the mosquito vector, led to various methods of drainage already at that 
time. The name malaria comes from the Italian mal aria meaning bad air, derived from the 
belief that the disease was caused by the malodorous air surrounding marshy areas.  
In 1880 Alphonse Laveran, a French army surgeon stationed in Algeria, was the first who 
described a malaria parasite in the human blood and shortly after that in 1897 Roland Ross 
(Scottish physician working in India) found a developing form of a malaria parasite in the 
body of a mosquito which had feed on a patient with plasmodia in the blood. Ross later 
described the complete life cycle of malaria [5]. Both these findings as well as the discovery 
of therapeutic effect of malaria infection on neurosyphilis by Julius Wagner-Jarregg in 1917 
generated Nobel prizes [6].  
 
1.1.1 The life cycle 
The life cycle of malaria parasites is complex and requires that the parasite goes through a 
number of highly specialized intra- and extracellular stages both in the human host and in the 
mosquito vector (definite host). There are 5 species of malaria infecting humans (P. 
falciparum, P. vivax, P. ovale, P.  malariae and P. knowlesi). 
The malaria parasite is injected into the human host from the bite of an infected female 
Anopheles mosquito. The sporozoite stage is injected with the saliva and transported to the 
liver within an hour, where they develop into exoerythrocytic schizonts in the parenchyma 
cells (hepatocytes) of the liver. This development takes 7-15 days depending on malaria 
species. With P. vivax and P. ovale some of these sporozoites differentiate into liver 
hypnozoites, which can remain dormant for many months before they develop further into 
schizonts and cause relapses of malaria disease. The mature liver schizonts contain up to 
30,000 merozoites which are released into the blood stream through the burst of infected liver 
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cells. There they invade the erythrocytes (RBC) within a few minutes and the disease-causing 
asexual stage is initiated. The merozoite is transformed to an early trophozoite, the ring form, 
with a nucleus and cytoplasm surrounding a vacuole. The trophozoite matures into an 
erythrocytic schizont within 24 (P. knowlesi) to 72 (P. malariae) hours. During maturation 
the trophozoite feeds on the erythrocytic hemoglobin (Hb) forming microscopically visible 
pigment (hemozoin). The mature schizont contains between 8 (P. malariae) and 32 (P. 
falciparum) merozoites, which cause cell rupture and the merozoites are released into the 
blood stream where they rapidly re-invade new RBCs. All of the clinical symptoms of 
malaria, including fever, chills and anemia, are caused by the asexual cycle in RBCs. During 
the asexual cycle, some of the parasite cells develop into male and female gametocytes. 
Gametocytes circulate in the blood stream up to several weeks, being available to be taken up 
by a feeding mosquito. The male and female gametes fuse in the mosquito gut to form a 
zygote that develops into an ookinete. The ookinete crosses the gut wall to form an oocyst, 
where division (sporongy) occurs generating thousands of sporozoites. After oocyst rupture, 
sporozoites migrate to the salivary glands of the insect, from which they eventually can be 
injected into the human host during subsequent feedings [7]. 
 
Figure 1.  The P. falciparum life cycle   
 
                                                          (With kind permission from Dr. Cristine Sisowath) 
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1.1.2 The malaria parasite 
There are 5 species of malaria infecting humans. Their characteristics are presented in Table 
1.  
P. falciparum 
P. falciparum is found in tropical areas i.e. in most parts of Africa, Asia and Latin America. It 
is the most disease causing human malaria parasite. P. falciparum is responsible for over 90% 
of the malaria morbidity worldwide [8].  P. falciparum was in year 2010 estimated to be the 
cause of approximately 660,000 deaths, especially in Africa among children and pregnant 
woman [6, 8]. This is a decrease from over 1 million/year before year 2000 (6).  
The P. falciparum parasite belongs to the lineage Laverania subgenus and has been suggested 
to be of more recent origin compared to other malaria species due to the low level of 
polymorphism within the P. falciparum genome [9, 10]. However, other researchers have 
found that the P. falciparum parasites co-evolved with its human host [11, 12] and recent 
reports have shown that P. falciparum can infect both monkeys and gorillas, which may 
constitute a reservoir complicating efforts to eliminate the parasite [12, 13]. 
P. falciparum is the species causing the highest parasite load because each schizonts can 
harbor up to 32 merozoites that are able to infect RBCs of all ages. This enables the infection 
to become hyper parasitemic with parasite densities of more than 5% causing massive lysis of 
RBCs and subsequent anemia, a common cause of severe malaria in children. P. falciparum 
has a tertian (48 hour) cycle even though fever paroxysms generally do not show a distinct 
periodicity.  
Maturing stages of P. falciparum are expressing cyto-adherent proteins, forming knobs on the 
RBC surface. The P. falciparum Erythrocyte Membrane Protein1 (PfEMP1), encoded by the 
var gene family, plays a major role in cytoadherence [14]. The knobs make the infected cells 
“sticky”, binding uninfected RBCs to their surface forming rosettes [15, 16]. These proteins 
also mediate binding of the infected RBC to the endothelial of the deep vessels, known as 
sequestration. This prevents the infected RBCs from being cleared from the circulation by the 
spleen [17]. The sequestered parasites clog in the vessels hampering the blood circulation.  
When this occurs in the brain it can result in cerebral malaria [18], a complication that stands 
for a large proportion of malaria deaths. 
  
P. vivax 
This species is found mostly in Asia, Latin America, and in some parts of East Africa. P. 
vivax normally requires the Duffy blood group antigen, expressed on the RBC surface to 
invade the cell and is therefore seldom seen in West Africa where Duffy negativity is 
common [19]. However, a recent report has shown P. vivax infections among some Duffy 
negative individuals in Africa [20].  P. vivax is generally seen as a benign form of malaria 
even though there are several reports on severe manifestations in the last years [21]. P. vivax 
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has a tertian cycle with more distinct intervals between fever paroxysms. P. vivax has a 
dormant liver stage, hypnozoites that can activate and invade the blood (relapse) several 
months or years after the initial infection. Strains of P. vivax can develop in the mosquito in 
temperate climates where they often do not produce primary attacks shortly after the infective 
bite, instead the clinical symptoms arise up to nine months later [22].   
 
P. ovale 
P. ovale is found mostly in Africa (especially West Africa) and on the islands of the western 
Pacific. It is biologically and morphologically very similar to P. vivax. However, and in 
contrast to P. vivax, it can infect individuals who are negative for the Duffy blood group. 
Genetic studies have shown that P. ovale actually comprises two non-recombining species 
that are sympatric in Africa and Asia and these are morphologically identical [23]. Mixed 
infections with P. falciparum are common. Like P. vivax, P. ovale has long been considered 
to have a dormant hypnozoite stage that can persist in the liver and cause relapses, but Richter 
et al. have questioned whether such a stage actually exists for P. ovale [24]. P. ovale also has 
a tertian cycle. Both P. vivax and P. ovale preferably invades young RBC, i.e., reticulocytes, 
which make parasite densities therefore seldom exceed 1%. 
 
P. malariae 
P. malariae is distributed over most of the malaria endemic area and is the only human 
malaria species that has a quartian (72 hours) cycle [22, 25]. If untreated, P. malariae often 
causes a long-lasting, chronic infection which often remains latent and can in some cases 
probably last a lifetime (23). Infections with P. malariae can in chronically infected patients 
cause serious complications such as nephrotic syndrome [26]. In Africa mixed infections with 
P. falciparum and P. ovale are common, and all three species can even occur simultaneously.  
P. malariae preferably invades RBCs older than 100 days making parasite densities seldom 
exceed 1%. 
 
P. knowlesi  
P. knowlesi is found in Southeast Asia as a natural pathogen of long and pig-tailed macaques. 
It has recently been shown to be a significant cause of zoonotic human malaria in that region, 
particularly in Malaysia where it accounts for up to 70% of human malaria cases [27]. So far 
there is no evidence that P. knowlesi can develop gametocytes in humans and be transmitted 
from human to human [28]. P. knowlesi has a 24-hour replication cycle and can rapidly 
progress from an uncomplicated to a severe infection; fatal cases have been reported [29]. 
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Table 1. 
 
P. 
falciparum 
P. 
vivax 
P. 
ovale 
P. 
malariae 
P. 
knowlesi 
Temperature for 
mosquito sporogony 
min. 18 °C min. 16 °C 
  
27 °C 
Incubation period (days) 9-14 12-16 16-18 
18-40 
or more 
10-12 
Hypnozoites no yes yes no no 
Erythrocytic cycle 
(hours) 
48 48 50 72 24 
Erythrocyte preference 
(age) 
all young young old 
 
Merozoites per schizont 8 - 32 12 - 16 6 - 10 6 - 12 10- 16 
Sequestration yes no no no no 
Parasite densities           
% erythrocytes infected 
(range) 
<0.1 - 40 % <0.1-2% <0.1-1% <0.1-1% <0.1 – 25% 
Fever pattern irregular tertian tertian quartian daily 
Clinical severity + - +++ + + + + + - +++ 
Duration of untreated 
infection  (years) 
1 - 1 1/2 3 - 4 3 - 4 3 - 50 
 
Relapses no yes yes no no 
Drug resistance + + + + - - - 
min.= minimum                                                                                                            [22, 25, 28-31] 
 
1.1.3 The vector 
Natural transmission of malaria occurs through the bite of a female mosquito of the genus 
Anopheles (A). Gametocyte stages of the parasite are ingested with the blood meal. Although 
there are more than 400 species described, only around 40 are considered of importance for 
malaria transmission [32]. Their effectiveness to transmit malaria is highly dependent on the 
feeding behavior, in terms of night or day, in or outdoor, human or animal preference. The 
main vectors for transmission of P. falciparum in Africa are A. gambiae and A. funetus which 
both are very efficient.  In south of Sweden the A. messeae is present, probably being the 
mosquito spreading malaria in Sweden at the time when Carl von Linnaeus in 1735 described 
a malaria like disease and its association with water [33]. 
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The malaria incidence is highly dependent on the mosquito numbers. In most areas endemic 
for malaria there are transmission peaks in association to rainy seasons, when breeding places 
for mosquitos are plentiful. 
 
1.1.4 The endemic situation 
In 2013, 97 countries had ongoing malaria transmission (Figure 2 map). 
There were an estimated 207 million cases of malaria in 2012 and 627,000 deaths. 90% of all 
malaria deaths occured in sub-Saharan Africa. In 2012, malaria killed an estimated 482, 000 
children under five years of age, equivalent to 1300 children every day, or one child almost 
every minute. 
Between 2000 and 2012, the scale-up of interventions helped to reduce malaria incidence 
rates by 31% and mortality rate by 49% in the WHO African Region, the corresponding 
global reduction was 25% and 42%, respectively [34].  
The goals set by the World Health Assembly and the Roll Back Malaria (RBM) partnership 
to reduce the numbers of malaria cases and deaths recorded in 2000 by 50% or more by the 
end of 2010 and by 75% or more by 2015 have and will not be achieved. Several factors like 
weak public health systems in some low-income countries, poverty and political instability, 
drug-resistant parasites, increasing insecticide-resistance and outdoor biting habits of 
mosquitos, are all contributing to that these goals will not be achieved [35]. 
Figure 2
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1.1.5 Measurement of malaria transmission 
Measurement of malaria transmission has traditionally been based on the sporozoite infection 
rate (SR), i.e. fraction of infectious mosquito in the population. It is also used to determine 
the entomological inoculation rate (EIR), i.e., the number of bites by infectious mosquitoes 
per person per unit time. The EIR estimates the level of exposure to P. falciparum-infected 
mosquitoes [36].  Also spleen rate, i.e. number of palpable enlarged spleens /100 individuals 
of similar ages (usually children 2-9 years), has been used to measure endemicity [37]. SR, 
EIR and spleen rate are useful surveillance tools in areas with high and stable transmission, 
but less useful in low endemic areas with unstable transmission. Nowadays parasite rate 
(PfPR), i.e. P. falciparum parasite carriers /100 individuals, as determined by microscopy, 
rapid diagnostic test (RDT) or polymerase chain reaction (PCR), and annual parasite 
incidence (API), i.e. cases/year/1000 inhabitants, are the most commonly used tools.   
The level of malaria transmission/endemicity can be divided into the following: 
 Hypoendemic: Low intermittent transmission, spleen rate  0-10%, PfPR  < 10%  
 Mesoendemic: Regular seasonal transmission, spleen rate 11-50%, PfPR 11-50% 
 Hyperendemic: Seasonally high malaria transmission, spleen rate > 50%, in adults > 
25%, PfPR  > 50% 
 
 Holoendemic: Perennial high transmission, spleen rate > 75%, in adults low spleen 
rate, PfPR  > 75% in infants 0-11 months 
(spleen rate in children 2-9 years,   PfPR in children 2-9 years) 
 Transmission is considered stable in hyper- and holo- (high) endemic areas and unstable in 
hypo- and meso- (low) endemic areas [37, 38]. 
 
1.2  CLINICAL PRESENTATION 
Clinical malaria is primarily characterized as a febrile disease. Patients with malaria typically 
become symptomatic a few weeks after the infective mosquito bite when the parasite has 
entered the erythrocytic stage, although the host's previous exposure and immunity to malaria 
affects the symptomatology and incubation period. An uncomplicated malaria infection can 
include the following clinical symptoms:  
 Fever 
 Fatigue 
 Splenomegaly 
 Myalgia 
 Cough 
 Headache 
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Paroxysm of fever, chills, and sweats typically occur every 24, 48 or 72 h, depending on 
species. The periodicity is often not observed in P. falciparum infections. Children in 
endemic areas often develop fever in combination with cough, stomach pain and diarrhea, 
symptoms that often overlap with other childhood viral or bacterial infections.    
Severe manifestations of P. falciparum malaria primarily in non-immunes and small children 
may include the following: 
 Severe anemia  (Haemoglobin (Hb) <5g/100 mL) 
 Nausea and vomiting 
 Acute respiratory distress 
 Cerebral  malaria 
 Hyper parasitaemia  (>5% infected RBC)  
 Hypoglycemia  (<2.2 mmol/L) 
Severe anaemia and hypoglycemia are features of severe malaria more commonly seen in 
children than in adults [39]. Among adults cerebral malaria is the most common severe 
manifestation and cause of death [40, 41].  
 Clinical episodes with P. vivax and P. ovale are commonly uncomplicated. However for P. 
vivax severe complications like significant hepatomegaly, thrombocytopenia, acute renal 
failure, and severe anemia have increasingly been reported e.g. among Indian patients 
hospitalized for P. vivax complications (42). 
P. malariae does not have a hypnozoite stage, but patients infected may have a prolonged, 
asymptomatic erythrocytic infection that becomes symptomatic many years after leaving the 
endemic area. Chronic infections with P. malariae can cause nephrotic syndrome because 
immune complexes may cause structural glomerular damage in the kidney [25]. 
P. knowlesi often causes severe disease due to the rapid multiplication with the 24 hour cycle  
of the parasite.  A cerebral malaria-like syndrome has not been reported, but consciousness 
may be impaired secondary to the severity of illness in the context of multiorgan failure or 
hypoglycemia. Anemia is seldom reported, whereas thrombocytopenia is the most frequently 
reported blood abnormality [28]. 
 
1.2.1  Malaria in pregnancy 
Malaria in pregnancy is associated with an increased risk of maternal anemia, low infant birth 
weight and premature births with increased risk of infantile death [6]. 
Pregnant women are more susceptible than non-pregnant women to malaria, and this 
susceptibility is greatest in first and second pregnancy. Susceptibility to pregnancy-associated 
malaria probably represents a combination of immunological
 
and hormonal changes 
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associated with pregnancy, combined with the unique ability of a subset of infected RBC to 
sequester in the placenta [42]. 
 
1.2.2 Immunity 
Genetic factors like red cell polymorphism causing sickle-cell trait (carriers of Hb-S) and 
thalassemia have proven to have protective effect against P. falciparum malaria.  Also 
glucose-6-phosfate dehydrogenase (G6PD) deficiency and Duffy blood group negativity have 
proven to have a protective effect against P. falciparum and P. vivax infection, respectively. 
These factors are primarily present in areas endemic for malaria. Malaria selection has played 
a major role in the distribution of all these polymorphisms [43] and this so called “malaria 
hypothesis” is thus an example of an interaction between human genetics and infectious 
diseases [44]. 
Acquired immunity 
Infants are protected during their first months of life through transfer of maternal antibodies 
and also by fetal Hb [45]. Young children in endemic areas exhibit an “antidisease immunity” 
after being exposed to multiple episodes of malaria during their first years. The acquisition of 
immunity against malaria is, however, species and strain specific [46]. The protection is 
more rapidly acquired in high endemic areas and results in reduced mortality or severe 
clinical disease already by the age of 5 years. Sterilizing immunity against infection is never 
fully achieved, and an asymptomatic carriage of relatively low densities of parasites is 
common among adults.  In the absence of continual exposure, the immunity against clinical 
disease may be relatively short lived [47].  
 
1.2.3 Diagnosis and Treatment 
Diagnosis of malaria is mainly based on detection of parasites by microscopy, RDT or PCR 
and will be further presented in the next section.    
The first known remedy for treatment of malaria associated symptoms was already used 
among Indians in South America in 17th century and known as “fever bark tree”. Carl von 
Linnaeus gave it the name Cinchona officinalis and its active compound, quinine, remains an 
efficient antimalarial drug, today primarily recommended for treatment of severe malaria. 
During the World War II the devastating effects of malaria among military troops triggered 
the development of new drugs such as chloroquine (CQ), proguanil, amodiaquine (AQ) and 
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later sulphadoxine-pyrimethamine(SP). Following the Vietnam War the US army developed 
mefloquine (MQ) and halofantrine to protect their soldiers from malaria. 
Today the most widely used drug against P. falciparum comes from the Chinese traditional 
use (already some 2000 years ago) of artemisinin (Qinghaosu) (ART), the Sweet Wormwood 
(Artemisia annua). Due to the fast and effective action of artemisinin, and its derivatives, it is 
now recommended for first line treatment in combination with slower acting partner drugs 
(artemisinin combination therapy-ACT) against uncomplicated P. falciparum malaria [48]. 
The commonly used partner drugs are AQ, lumefantrine (Lu), MQ, SP and piperaquine (PQ). 
Parenteral artemisinin has been shown to be the most effective drug for treatment of severe 
malaria [49].  
CQ is used for treatment of the non- falciparum malaria infections and remains effective 
against most P. vivax, all P. ovale, all P. malariae [50] and P. knowlesi [28]. 
Malarone (atovaquone-proguanil), MQ and doxycycline are today commonly used as malaria 
chemoprophylaxis in travelers visiting malaria endemic areas. 
 
1.2.4 Antimalarial drug resistance in P. falciparum   
Development of drug resistance is probably a step-wise process from first showing increased 
tolerance against the drug action until being able to survive a full dose of treatment.  
Spread of CQ resistance against P. falciparum developed from Southeast Asia and Colombia 
in the late 1950s and spread over most endemic areas within 20 years. CQ has remained 
effective only in some areas of Central America [51] but it appears that CQ-sensitive P. 
falciparum parasites may re-emerge after cessation of CQ use in some areas [52, 53].  CQ-
resistance in Africa led to major increase in mortality and morbidity in the 1990s  [54]. More 
recently developed antimalarials such as SP and MQ have had shorter life span from 
introduction to development of resistance [55]. Other drugs such as AQ has shown to be 
effective in Africa, whereas resistance is widespread in South America were it has been 
extensively used since 1950s.  
The use of artemisinin in combination with a long-lasting partner drug with a different mode 
of action has been widely recommended to avoid the development of artemisinin resistance, 
but mono-therapy with artemisinin should be avoided. There are recent reports of 
development of resistance against artemisinin mono-therapy in four countries of the Greater 
Mekong region [56, 57] and also against both components of ACTs in Cambodia [58]. 
Despite this, the treatment recommendations are strongly emphasizing ACT, since there are 
no better alternatives.  
 Resistance to antimalarial drugs has been associated with certain genetic polymorphisms. 
The most well investigated are presented below: 
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 Plasmodium falciparum chloroquine transporter (Pfcrt) gene where the K76T 
exchange of a lysine in the wilde type to a threonine is the main molecular marker for 
CQ-resistance, but has also been associated with AQ resistance [59, 60]. Pfcrt K76 
(wild type) has also been associated with reduced susceptibility to Lumefantrine [61, 
62]. 
 
 Plasmodium falciparum multidrug resistance 1(Pfmdr1) gene which belongs to the 
ATP binding cassette (ABC) transporters. Single Nucleotide Polymorphism (SNPs) at 
several amino acid positions have shown to be associated with resistance against a 
variety of antimalarials [63]. The most frequently studied SNPs are N86Y, Y184F 
and D1246Y [64]. Resistance against MQ and Lu has also been associated with copy 
number variations (CNV) in the Pfmdr1-gene [65]. 
 
 Mutations in the dihydrofolate reductase (DHFR) gene and dihydropteroate synthase 
(DHPS) gene have a strong correlation with resistance to SP [66].  
 
 Artemisinin resistance has recently shown a strong association with single point 
mutations in the "propeller" region of the P. falciparum kelch protein gene on 
chromosome 13 (kelch13). These mutations are now detected throughout mainland 
Southeast Asia from southern Vietnam to central Myanmar [67]. 
 
1.2.5 Therapeutic efficacy studies 
The standard way to access the efficacy of antimalarial drugs for treatment of P. falciparum 
is through clinical trials following parasite clearance by microscopy during a follow up of 
between 28 and 42 days after initiation of treatment. Usually patients are followed daily (or 
more frequently) up to day three and thereafter on day 7 followed by weekly, for clinical and 
parasitological assessments. Prolonged initial clearance time can be an early warning sign of 
increased tolerance of the parasites [68, 69].  
During follow up, re-appearing parasites have to be genotyped to distinguish a new infection 
(reinfection) from treatment failure (recrudescence). The PCR genotyping involves stepwise 
analysis of highly polymorphic markers in the parasite genes, merozoite surface proteins 1 
and 2 (msp-1, msp-2) and glutamate- rich protein (glurp).  WHO and Medicines for Malaria 
Venture (MfMV) have developed a standard for interpretation of these genotyping data. For 
each marker, recrudescence is defined as the presence of at least one matching allelic band 
and re-infections is defined as the absence of any matching allelic band in samples at 
enrolment (day 0) and at day of recurrent infection [70, 71]. 
The outcome of these efficacy studies are, however, influenced not only by the true 
susceptibility of the parasite to the test drug but also several factors such as immune status of 
study participants, the individual drug bioavailability, as well as an often complex 
interpretation of PCR results [72]. 
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1.3 MALARIA CONTROL 
Between 2000 and 2012, a scale-up of malaria interventions has saved an estimated 3.3 
million lives. 90%, or 3 million, of these are in the under-five age group in sub-Saharan 
Africa [34, 73]. Malaria control mainly focus on four areas: 
 Access to parasitologically confirmed diagnosis 
A diagnosis based on microscopy or RDT should be accessible at point of care and WHO 
now recommends that treatment should be based on a confirmed diagnosis [48]. This is in 
order to avoid over diagnosis based on clinical observations leading to overuse of anti-
malarial drugs. Overuse contributes to the risk of drug resistance development and foreseeing 
of other causes of fever (35). The volume of RDT sales to the public and private sectors of 
endemic countries has increased from 88 million in 2010 to 205 million in 2012 and the 
proportion of suspected malaria cases receiving a diagnostic test in the public sector increased 
from 37% to 61% in Africa [34]. The number of patients tested by microscopic examination 
has also increased to >180 million in 2012, with India accounting for a majority of slide 
examinations. 
 Access to treatment 
Access to prompt treatment with effective antimalarial drugs in order to decrease morbidity 
and mortality and to interrupt transmission is a cornerstone in malaria control [34]. 
 Preventive treatment 
Pregnant women are the vulnerable group most frequently targeted. They may receive, 
“intermittent preventive treatment” (IPTp) with antimalarial drugs given most often at 
antenatal consultations during the second and third trimesters of pregnancy, regardless of 
whether the woman is infected with malaria or not. 
Intermittent preventive treatment in infants (IPTi) with SP is recommended by WHO in areas 
with moderate to high malaria transmission in sub-Saharan Africa that have less than 50% 
prevalence of Pfdhps mutation in the P. falciparum parasite [74]. 
 Mosquito control 
Bed nets 
Malaria vector control is intended to protect individuals from infective mosquito bites. The 
most effective is long lasting insecticide treated nets (LLINs), which are distributed to 
targeted vulnerable groups, i.e. pregnant women and children under 5 years of age, free of 
charge in many endemic areas. WHO recommendations are full coverage of all people at risk 
of malaria [75]. In 2013, an estimated 136 million impregnated bed nets (ITNs)/LLINs were 
delivered to endemic countries, a major increase over the 70 million bed nets that were 
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delivered in 2012 [34]. There are signs of mosquito resistance against insecticides used, 
primarily pyrethroids, and global actions are now taken against this threat by WHO and 
RBM. 
Indoor Residual Spraying  
In 2012, 135 million people (4% of the global population at risk of malaria) were protected 
by indoor residual spraying (IRS). IRS is the process of spraying the inside of dwellings with 
an insecticide where mosquitos often rest after taking a blood meal. To be effective on a 
population basis more than 80% of the households in an area should be sprayed. Mosquitoes 
are killed or repelled by the spray, preventing the transmission of the disease. Several 
pesticides have historically been used for IRS, the first and most well-known being DDT 
which has a residual efficacy of more than 6 months [76].  Recommendations are now 
increasingly to use non-pyrethroids for IRS because LLINs are impregnated with pyrethroids 
and pyrethroid resistance is increasing [34]. 
 
1.3.1 T3: Test, Treat and Track initiative 
On World Malaria day 2012, WHO launched the new initiative T3 urging endemic countries, 
donors and the malaria community to scale up diagnostic testing, treatment and surveillance 
of malaria to strengthen these three fundamental pillars for control and elimination of malaria. 
 
1.3.2 Integrated management of childhood illness 
WHO and United Nations children’s fund-UNICEF have developed a strategy called the 
Integrated Management of Childhood Illness (IMCI). IMCI is an integrated approach to child 
health that focuses on the well-being of the children under five years of age. IMCI aims to 
reduce death, illness and disability, and to promote improved growth and development among 
children. The IMCI guidelines was developed to improve case management and preventive 
interventions against leading causes of childhood mortality, i.e. pneumonia, diarrhea, malaria, 
measles and malnutrition [77].  
Previous versions of guidelines for malaria treatment have recommended that febrile children 
below 5 years should be treated presumptively for malaria in high endemic areas [78]. 
However, there is now increasing evidence that it is safe to withhold antimalarial treatment to 
fever patients with a negative malaria RDT result, including also children below five years 
[48, 79-81]. Treatment with ACTs should therefore be restricted to children with a confirmed 
diagnosis. It is recommended that RDT should be used for diagnosis in areas where 
microscopy is not available or its quality cannot be guaranteed. The use of RDT for diagnosis 
has recently been implemented in local versions of IMCI guidelines, e.g. Ghana and Zanzibar 
[82, 83]. Adherence to the new guidelines can, however, be problematic in high endemic 
areas where children can develop malaria shortly after a negative test result [84]. 
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1.3.3 Malaria elimination efforts 
Malaria elimination is the interruption of local mosquito-borne malaria transmission, i.e. the 
reduction to zero of the incidence of malaria infection in a defined geographical area. After 
elimination, continued surveillance is required to prevent re-establishment of transmission. At 
present, eight of the 97 countries with ongoing malaria transmission are classified by WHO 
as being in the malaria elimination phase [34].  
In countries becoming low endemic and approaching a pre-elimination phase, new demands 
on diagnostic tests arise (Figure 3). A higher proportion of individuals in these areas will 
harbor parasitaemias below the detection limit of both microscopy and RDT [85]. These 
subpatent infections are important reservoirs for further transmission. To find and treat these 
carriers of low density parasitaemias is a prerequisite for an elimination strategy to be 
successful [86-88].  
In malaria elimination settings, remaining parasite reservoirs are increasingly clustered in 
small geographical areas (hot spots) and parasite carriers have shifted from mainly being 
pregnant women and small children, to older children and men [35]. 
 
 
Figure 3. The usefulness of diagnostic approaches/tests in relation to parasite densities and 
parasite prevalence stages 
.  
                              (A research agenda for malaria eradication, PloS Medicine 8(1), 2011 ) 
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1.3.4 Challenges in controlling malaria 
Resources of health structure and commitment of health staff in endemic countries 
contributes to how successful malaria control activities will be [89]. The main challenges are 
performance and availability of diagnostics at the peripheral level and access to efficacious 
drugs. Provision of counterfeit and old drugs leading to substandard doses is still being 
provided in the private sector. Furthermore, access to and coverage of vector control are 
important factors. In many countries endemic for malaria, both health systems and resources 
for control programs have improved markedly in recent years, which have contributed to the 
decline in malaria incidence during the last decade. 
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2 MALARIA DIAGNOSIS 
2.1 GENERAL BACKGROUND 
A prompt and correct malaria diagnosis is a prerequisite for improved malaria control. It is 
important in order to restrict antimalarial treatment to those with a confirmed diagnosis, and 
for a rational and cost-effective use of antimalarial drugs [48, 73, 90-92]. Absence of parasite 
based diagnosis leaves health care workers with only clinical algorithms to diagnose malaria. 
The non-specific nature of symptom-based malaria diagnosis results in substantial over-
diagnosis and overtreatment. Given that malaria is the most common diagnosis among 
African febrile children and one of the most common in adults, over- but also under-diagnosis 
have substantial public health implications [93, 94]. With decreasing malaria transmission as 
seen in many areas, the importance of a parasite based diagnosis increases. In high endemic 
areas a large proportion of people, including asymptomatic individuals, have parasitaemia 
most of the time. Thus, the detection of malaria parasites does not necessarily mean that they 
are responsible for the patient’s illness, since they may reflect only a coincidental infection. 
A correct malaria diagnosis plays an important role in the monitoring of treatment efficacy 
and to evaluate the impact of interventions, such as distribution of ITN/LLINs or IRS.  
 
A comparison of diagnostic tools is presented in Table 2. 
 
2.1.1 Clinical diagnosis 
A common teaching in high endemic areas has been “fever equals malaria unless proven 
otherwise”. In many African settings parasite based diagnostic tools are not available or not 
fully functional why diagnosis based on clinical observations is still the only option. Clinical 
malaria diagnosis leads to overdiagnosis and overtreatment with antimalarial drugs. Among 
reasons for overdiagnosis are that malaria traditionally is the common cause of fever, a more 
acceptable diagnosis and missing malaria is indefensible [94]. Clearly many lives have been 
saved due to access to rapid presumptive malaria treatment at community or home-based 
level [73], but this has also led to massive overtreatment with considerable burden on the 
already depleted financial resources of poor countries [95]. Symptoms of malaria often 
overlap with other bacterial diseases such as pneumonia [96] and clinical malaria diagnosis 
has therefore led to over estimation of malaria burden [97]. 
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2.2 MALARIA MICROSCOPY 
Shortly after Laveran described the malaria parasite, Romanowsky in Russia developed a 
method to stain the parasites, which together with improvement of microscopes made it 
possible to more thoroughly study them [98]. Romanowsky used a mixture of eosin and 
methylene blue giving the nucleus purple color and the cytoplasm blue color. The same 
technique remains the basis for the presently most used staining methods of malaria parasites, 
i.e. Giemsa and Field stain.  
Microscopy allows for the identification and differentiation of malaria species, determination 
of parasite stages including gametocytes and the quantification of parasite density. 
Microscopy is still the method of choice for treatment follow up and investigation of malaria 
treatment failures. Microscopy is still considered gold standard against which other 
diagnostic methods are evaluated [99].  
Malaria microscopy requires examination of both thin and thick smears from the same 
patient. Preferably capillary blood should be used for the preparation of blood films since 
various additives for venous puncture such as EDTA can affect the parasite morphology 
making it more difficult to distinguish the different species. A thick smear consists of 
approximately 10 microliter (µL) and a thin of 5µL blood. Optimal malaria microscopy is 
performed with microscopes fitted with x10 paired eyepieces and a x100 oil immersion 
objective (total magnification x1000) [100]. 100 or 200 microscopic fields (0.2-0.5 µL) are 
normally examined before a malaria infection can be excluded. In remote areas without 
access to electricity, microscopy can still be performed using a mirror reflecting daylight 
through the specimen into the eyepieces.   
 
2.2.1 Giemsa staining method 
Giemsa is a classical stain used for malaria microscopy [101].  It consists of commercially 
available Giemsa powder, glycerol and methyl alcohol (methanol). The stock solution is 
mostly purchased ready prepared and should be mixed with a phosphatase buffer solution of 
pH 7.2 prior to staining of the blood smears [100]. Under field conditions in endemic areas 
often ordinary tap water is used and that works generally well, even though a pH differing 
from 7.2 can affect the purple-blue contrast in the specimens. Usually a concentration of 5% 
Giemsa for 20-30 minutes is used for both thin and thick smears. The staining solution should 
be prepared within two hours prior to use. Before staining the thin smear slide should shortly 
be dipped in pure methanol to fix the cells. In the thick smear on the other hand, the cells 
should be lysed making it possible to examine a more dense layer. The sensitivity of a thick 
smear is 15-20 times higher than a thin film but does not allow for species determination. In 
the thin smear the parasites are seen within the RBC with the different characteristics of the 
species in terms of size, granulation and effect on the infected RBC, which generally allows 
for species identification if the number of parasites is not very low (Figure 4). 
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Figure 4.  Morphological characteristics of malaria parasites 
                  
(Garcia: Diagnostic Medical Parasitology 5 ed.) 
 20 
2.2.2 Field staining method 
An alternative method to Giemsa is Field stain, which primarily is used for staining of thick 
smears. It consists of two solutions, methylene blue and eosin, and gives an excellent staining 
result in a few seconds if the instructions are followed carefully. Field stain also has the 
advantage of being very stable, allowing the same staining solutions to be used for several 
weeks. On the other hand, the staining can be uneven and the slide must therefore initially be 
scanned to find an area where both the blue and purple stains are taken up by the parasites. It 
is often recommended to study the colors of the leucocytes to get an idea of where to look for 
the parasites.  
Malaria microscopy, when using Giemsa or Field stain, has an estimated cost of 0,3-1.3 USD 
per examination depending on number of examinations/year [102, 103]. 
 
2.2.3 Parasite quantification 
There are different methods for quantification of parasites in blood smears. Until recently, 
this was only applicable to P. falciparum infection for estimation of severity of disease and 
treatment outcome. However, there are now reports on high parasitaemias also among severe 
P. knowlesi cases [28], which probably makes quantification important also for P. knowlesi.  
The most common technique used in endemic areas is based on counting parasites in the 
thick smear against a standard number of white blood cells (WBC). The number of parasites 
are generally counted against 500 or 200 WBC, which with an estimated 8000 WBC per µL 
of blood gives a factor of 16 or 40 for calculation of parasites per µL based on the simple 
mathematical formula: 
        (parasites counted / number of WBC counted) x 8000 = parasites per µL (p/µL)  
In case of very low parasite densities the numbers are often counted in 200 microscopic fields 
equivalent to 0.3-0.5 µL. The numbers are then given as parasites/200 microscopic fields.  
Another quantification method is to estimate the percentage of infected RBCs in a thin blood 
smear [104, 105]. For this method the parasite density is reported as % of the RBC infected.  
The thick smear method has a higher sensitivity and is the first choice in endemic areas. 
However, it is difficult to estimate number of parasites per WBC in high parasitaemias and 
the density is therefore often underestimated [106]. Then, estimation of % infected RBCs in a 
thin smear provides a more accurate result.  
Other methods based on semiquantative estimates (+- ++++) are still used in some endemic 
areas [107]. All methods for estimation of parasite density are associated with potential errors 
due to varying WBC count and a parasite loss of up to 20% during staining of thick smears 
[105, 106, 108, 109].  In thin smears there is often an uneven distribution of parasites and if 
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not a cell counting ocular is used, the estimation of RBC per microscopic field can be 
arbitrary.  
Parasite enumeration provides useful clinical management guidance and is a useful tool for 
clinical trials where serial examinations of blood smears are used to determine the 
parasitological response to antimalarial treatment [110]. 
 
2.2.4 Sensitivity and specificity of malaria microscopy 
Microscopy remains the gold standard for assessing the outcomes of drug and vaccine trials, 
and for serving as a reference standard in the evaluation of new tools for malaria diagnosis 
[111].  
The sensitivity of malaria microscopy is highly dependent on the quality of the smear, the 
staining and not at least the skills of the microscopist. The risk of false negative results 
increases with decreasing parasite densities [112]. Under optimal conditions down to 5-10 
p/µL (requiring more than ten minutes of thick smear examination) can be detected by an 
experienced microscopist, whereas under field conditions, a detection level of about 50–100 
p/µL blood is more realistic [113]. In areas with poor microscopy quality control, less skilled 
microscopists and poor equipment, an even higher detection limit is likely [111]. However, 
overestimation, i.e. interpretation of artefacts or other dots as parasites “to be on the safe 
side” as well as errors in species identification are also common problems [112]. Hence, wide 
ranges of malaria microscopy specificities have been reported [114, 115]. Moreover, 
evaluation of the sensitivity and specificity of malaria microscopy against PCR has shown 
varying results [116]. 
 
2.2.5 Advantages and disadvantages of microscopy 
Advantages 
Microscopy is a cheap, well established and informative method, which allows for 
assessment of species, stage and quantification of malaria parasites. Further, the finding of 
malaria pigment digested by neutrophils as a sign of a previous high parasitaemia as well as 
the effect on the parasite morphology by antimalarial drugs is of value ([117, 118]. In the 
hands of an experienced technician, microscopy can also provide additional information such 
as anemia, signs of bacterial infection with raised WBC and presence of other 
haemoparasites. Blood smears are also permanent and can be used for extraction of DNA. 
Disadvantages 
Microscopy is a labour-intensive, time consuming method (30min-1 hour) where the quality 
is highly dependent on the smear preparation, the glass slides, the fixation, the staining, the 
microscope and the skills of the microscopist. Field microscopy often falls short of these 
requirements. In the era of declining malaria incidence in many areas, it is challenging to 
keep up the motivation for careful microscopic examination if more than 95% of the slides 
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are negative. The examination is also prone to relatively high degree of subjectivity [119]. All 
these factors may influence compliance to test results among health care providers and 
despite a parasite based diagnosis, treatment decisions may still be  based on clinical 
observations [93, 120-122]. 
 
2.2.6 Fluorescent staining techniques 
Acridine orange  
An alternative staining of blood smears is the use of fluorescent dyes, particularly with 
acridine orange. The technique uses a fluorescent dye with affinity to the nucleic acid in the 
parasite.  A common technique is thin smears fixed with methanol, stained with 0.01% 
acridine orange and read in a fluorescence microscope in 400-600X magnification [123, 124]. 
Compared with conventional Giemsa staining, acridine orange has shown good diagnostic 
performance, with sensitivities of 81%-100% and specificities of 86%-100% [125]. However, 
the sensitivity decreases rapidly with lower parasite densities, and species differentiation is 
not possible [125, 126]. The most notable advantage of acridine orange over Giemsa staining 
is its promptness; results are readily available within 10 min. The simple design of an 
interference microscope has made direct acridine orange staining an accurate, rapid, simple 
and economically viable method for malaria diagnosis [123]. The microscopist, however, 
must learn to distinguish the stained cells of the parasite from other stained cells containing 
nucleic acids, such as WBCs or RBCs containing Howell Jolly bodies as well as cell debris 
and artefacts which could appear fluorescent [124].  
Quantitative buffy coat  
The quantitative buffy coat (QBC) method uses a combination of acridine orange staining 
and micro capillary tubes. After centrifugation the tubes are observed under the fluorescence 
microscope in the area just near the buffy coat region where parasites are concentrated. The 
sensitivity of the QBC method under field conditions is comparable with Giemsa staining but 
does not allow for parasite quantification or species identification [111, 127]. The method is 
also considerably more expensive which limits its usefulness for most endemic areas. 
 
2.3 ANTIGEN BASED DETECTION OF MALARIA – RDT 
2.3.1 General background to RDT 
Malaria RDTs are based on immunocromatic detection of parasite antigens. The introduction 
of RDTs for diagnosis of malaria in the early 1990s has had a major impact on fever 
management in malaria endemic areas. For the first time a health worker in a remote area 
could rapidly and accurately distinguish between parasitaemic and non-parasitaemic febrile 
illness [128].  RDTs have had a major impact on the accessibility to a parasite based malaria 
diagnosis worldwide. The reported rate of diagnostic testing among malaria suspected cases 
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in the African public sector has increased to 61% in 2012, mostly attributed to increased use 
of RDT. Wide scale distribution of RDTs free of charge to public health facilities has become 
a cornerstone in malaria control program recommendations and has also been increasingly 
advocated in a number of malaria endemic countries [34, 129] 
WHO has produced a number of guidelines evaluations and recommendations for the use of 
RDT [130-132], and has also set up standards for the diagnostic performance of RDT with 
minimum requirement of sensitivities of 95% for detection of 100 p/µL (equivalent to 
0.002% parasitaemia) and specificities of minimum 90% for P. falciparum compared with 
microscopy [119, 128, 133]. WHO has also together with the Foundation for Innovative New 
Diagnostics (FIND), established a testing program for evaluation of the performance of 
commercially available RDTs. The first evaluation was published in 2008 followed by yearly 
reports ever since [134].  RDTs are evaluated for sensitivity and specificity in detecting P. 
falciparum and P. vivax at 200 and 2000 p/µL, for false positivity rate, lot variability, invalid 
test rate, heat stability and easy of use. The market for RDTs is enormous with more than 200 
malaria RDT products currently available from more than 100 distributors worldwide 
[135].The volume of RDT sales to the public and private health sectors of endemic countries 
has increased from 88 million in 2010 to 205 million in 2012 [34]. The evaluation program 
together with high number of commercial products and several hundred scientific 
publications evaluating the use of RDTs, are factors that have encouraged the improvement 
and quality of RDTs. Rapid tests combining detection of malaria with that of G6PD 
deficiency as well as pregnancy testing are now available on the market. 
 
2.3.2 Parasite antigens detected by RDT 
Histidine Rich Protein 2 
Histidine Rich Protein 2 (HRP2) is a water-soluble protein produced solely by asexual stages 
and young gametocytes of P. falciparum. HRP2 is a histidine and alanine-rich protein, which 
is localized in several cell compartments including the parasite cytoplasm and is expressed on 
the infected RBC membrane surface. Because of its abundance in P. falciparum, it was the 
first antigen used to develop a malaria RDT. The exact function of HRP2 remains 
incompletely understood. Studies suggest that after secretion by the parasite into the host 
erythrocyte cytosol, HRP2 is transported into the acidic digestive vacuole along with Hb. 
After Hb proteolysis, HRP2 binds the toxic haeme and mediates haemozoin (malaria 
pigment) formation, which is no longer toxic to the parasite [136-138].  
HRP2 is being produced and secreted by the parasite during its growth and development and 
there are increasing concentrations of the protein during parasite maturation. HRP2 may be 
found in plasma, urine, cerebrospinal fluid and histological specimens. The fast secretion 
from the parasite makes HRP2 based RDTs suitable for detection also of parasites which are 
not circulating, i.e. mature stages of P. falciparum sequestered in the deep capillaries or 
placenta during infection in pregnancy [133, 139]. Plasma concentration of HRP2 has shown 
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to be a prognostic factor in African children with severe malaria [140]. HRP2 is also a useful 
tool for drug sensitivity in-vitro assays [141]. 
HPR2 is a very stable protein and has even been used for immunological detection of malaria 
among Egyptian mummies, dated about 3200 BC [142]. Despite its stability there is an 
extensive level of sequence diversity and deletions (up to 40% in parts of South America) of 
the HRP2 gene [143-146]. This has also recently been reported from the African continent 
[147, 148], which has implications for the performance of RDTs based on detection of HRP2.  
HRP2 remains in the circulation up to several weeks after a cleared malaria infection [149-
152]. A positive correlation between blood concentrations of the protein and parasite biomass 
has been reported [153, 154] and a strong correlation between the duration of positivity with 
the HRP2 based RDTs and initial parasite densities has been shown in several studies [149, 
151, 155]. Conversely, a wide range of HRP2 concentrations at the same parasite densities 
has  been found [156]. Varying concentration of HRP2 is dependent on factors like duration 
of infection, if the blood sample is taken soon after appearance of parasites in the blood or 
later during infection. Other factors such as circulating parasites may not mimic the total 
biomass and the anti-HRP2 immune response influences the correlation between parasite 
density and HRP2 concentrations [157]. 
Plasmodium lactate dehydrogenase  
LDH is a 33 kDa oxidoreductase.  It is the last enzyme of the glycolytic pathway, essential 
for ATP generation and one of the most abundant enzymes expressed by the malaria parasite. 
The Plasmodium LDH (pLDH) isoforms can be distinguished from the human isoforms on 
the basis of unique epitopes within the pLDH protein as well as on its enzymatic 
characteristics [158]. There are no reports on antigenic variation in the pLDH gene [159]. 
pLDH from P. vivax, P.malariae, and P.ovale exhibit 90-92% identity with pLDH from P. 
falciparum [160] and monoclonal antibodies recognizing P. falciparum and P. vivax pLDH 
also recognize P. knowlesi in antigen capture tests [161]. However, most pLDH based RDTs 
have not yet been evaluated for detection of P. knowlesi and the available results are 
inconsistent [28, 162]. Detection of pLDH has been incorporated into screening methods for 
the identification and quantitation of parasite growth in in vitro cultures.  
pLDH is produced only by viable parasites and is rapidly cleared from the blood stream 
following successful treatment [28, 149, 162-164]. The lack of antigen persistence after 
treatment could makes the pLDH test more useful compared to HRP2 based tests in 
predicting treatment failure. However, pLDH is produced by all asexual and sexual stages 
including mature gametocytes, meaning tests can persist positive due to gametocytaemia 
[152].  
Aldolase-pan malaria antigen  
Plasmodium aldolase is an enzyme of the parasite glycolytic pathway expressed by the blood 
stages of all five human malaria species [165, 166]. Aldolase is a highly conserved gene 
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across all human malaria species and monoclonal antibodies against Plasmodium aldolase are 
pan-specific in their reaction. Aldolase is a 41 kDa protein, the presence of antibodies against 
p41 in the sera of human adults partially immune to malaria suggested that p41 could be 
involved in immune response against the parasite [167].  
Low concentrations of aldolase are released from the parasites, and thus the sensitivity is 
dependent on the parasite density [133]. The aldolase component in RDTs has performed 
poorly in several studies of the aldolase-PfHRP2 combo tests, with sensitivities of 30-50% 
for detection of P. vivax malaria [133, 162, 168]. and for the other species, aldolase based 
tests perform even worse with sensitivities below 20% [133, 169]. Due to the poor test 
performance of aldolase, this antigen is at the moment not commonly used in commercial 
RDTs and will not further be discussed in this document. 
 
2.3.3 Test principle of RDTs 
RDT is a immunocromatic test based on detection of malaria specific antigens (HRP2, pLDH 
and Aldolase). The test device is delivered in sealed envelopes to protect it from light and 
humidity. The envelope should be opened just before performing the test. The nitrocellulose 
strip is usually in a cassette test device. Capillary (or venous blood) is applied to the test well 
at the proximal end of the test strip, usually 5 µL (up to 20 µL depending on brand) (Figure 
5). At the sample pad, dye labelled antibodies (Ab) is mixed with the blood. A few drops of 
lysing buffer are added to the sample well or a special well next to sample to lyse the cells, 
release the antigen and facilitate antibody recognition. If antigen is present the antibody-
antigen complex is flushed up with the blood-buffer mixture along the test strip until it 
reaches another target Ab (capture) bound to the strip in a thin line. The target Ab binds to the 
antigen-antibody complex which now forms a visible test line. Another Ab specific for 
another epitope on the labelled Ab is binding excess labelled Ab to form a control line. Note, 
the control band becomes positive despite no addition of blood. After passing the test band 
area the lysed blood is flushed into the distal end of the strip making the bands clearly visible 
against a bright background (Figure 5). The result should be interpreted after 15-20 minutes 
(depending on test brand) and not later than 30 minutes. RDTs are delivered as two band tests 
detecting only one malaria species, generally HRP2 based P. falciparum or less commonly 
single pLDH P. vivax or Pan-Plasmodium. Nowadays the most commonly used RDTs use a 
combination of HRP2 and Pan- LDH detection in a three-band format. 
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Figure 5. 
 
Bell et al. Nature Reviews                   Microbiology 4,2006 
 
2.3.4 Interpretation of RDT results 
To perform an RDT and to interpret the result is generally easy to learn, although there are 
many reports on problems and difficulties [131, 146].  
The main obstacles are: 
 To ensure a correct volume of blood is collected and applied into the sampling device 
from the patient’s finger. There are a number of different blood sampling devices 
available on the market out of which several are not very easy to handle [170]. 
 
 To transfer the correct volume of blood into the bottom of the sample well (avoiding 
leaving blood on the wall of the well).  
 
 To dispense the correct number of buffer drops into the correct well. 
 
 To interpret the result at correct time and in good light. 
 
 To correctly interpret weak and faint test lines. A weak band should be interpreted as 
positive [171, 172].  
 
 To recognize and repeat invalid tests (no control band or the blood-buffer mixture has 
not migrated to the distal part of the strip, usually due to insufficient volume of 
buffer) 
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 To correctly interpret results  
 
The two options of P. falciparum positivity (only HRP2-band positive or both bands 
including the Pan band) commonly causes confusion. The two test band positivity is often 
misinterpreted as mixed infection, whereas the reason usually is detection of P. falciparum by 
both HRP2 and Pan-LDH antibodies, whereas a single HRP2 band positivity is usually due to 
a low P. falciparum parasite density since the pLDH based band may be less sensitive [146, 
173, 174]. However, some of the more recently developed pLDH-tests based on monoclonal 
antibodies have shown equal sensitivity as HRP2 based tests for detection of P. falciparum 
[163, 175]. 
2.3.5 Cost effectiveness of RDT 
The cost effectiveness of RDT use is dependent on the price per test as well as factors such as 
parasite prevalence, cost of prescribed treatment and adherence to test result [91, 173, 176]. 
The introduction of the more expensive treatment with ACT has made treatment based on 
parasite based diagnosis cost effective in low and moderate endemic areas where treatment 
based on clinical observations (fever) has led to costly over-prescription [177]. A cost 
effectiveness study performed by Shillcutt et al showed that this was the case also in high 
endemic areas if prescribers of ACTs adhered to RDT result. RDTs were cost-effective 
compared with presumptive treatment up to high prevalence of P. falciparum parasitaemia in 
different sub-Saharan African settings. Relative to microscopy, RDTs were more than 85% 
likely to be cost-effective across all parasite prevalence levels, reflecting their expected better 
accuracy under real-life conditions [102].  At a cost of  0.60 USD per RDT and 1.70 USD per 
ACT adult dose, RDTs are cost-effective with 95% confidence below a threshold of 64% 
malaria prevalence and 99% confidence below 20% prevalence. RDTs become more cost-
effective as the cost of ACT increases (Figure 6) [178].  
The cost-effectiveness of RDTs mainly reflect improved treatment and health outcomes for 
non-malarial febrile illness, plus savings in antimalarial drug costs [102, 177]. A study from 
Senegal showed a major reduction in ACT consumption with considerable cost savings after 
introduction of RDT at all public sector health facilities [176]. In a study from Nigeria RDT 
use was less costly than presumptive treatment and microscopy at 43% parasite prevalence 
level [103]. 
The excess of commercial products available on the market has also had a price-pressure 
effect on RDT kits.   
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Figure 6.  
 
  
  PT= presumptive treatment      (WHO, Determining Cost Effectiveness of Malaria Rapid Diagnostic Test) 
 
 
 
2.3.6 Sensitivity and specificity of RDT 
In spite of over 100 published RDT trial reports, comparative assessment is difficult because 
(1) trials do not share common guidelines; (2) clinical and epidemiologic characteristics of 
the study populations, especially the parasitaemia levels vary; (3) reference standards are 
different; even among those using Giemsa microscopy, reading rules and microscopist skills 
vary; and (4) products of different lots may differ in quality or be damaged by extreme 
temperature or humidity during transportation and storage [111]. 
 
HRP2  
RDTs based on HRP2 antigen detection are estimated to have a detection limit of 50-100 
p/µL. Commercial RDTs evaluated in the WHO-FIND program show sensitivities varying 
from ~50-100% in detecting 200 p/µL. In real life situations the sensitivity is highly 
dependent on endemicity and immune status in the population tested. In low endemic/ pre 
elimination areas were very low parasite densities are common among asymptomatic carriers, 
HRP2 based RDTs are not sensitive enough for detection of asymptomatic parasite carriers 
(active case detection) [88, 179, 180]. False negative result with HRP2 based RDTs are seen 
due to P. falciparum genetic diversity and deletions in some areas [143, 181]. The prozone 
effect seen in samples with high density parasitaemias, due to blocking of binding sites for 
the Ab by excess antigen, can also cause false negative or very faint bands [164, 182]. The 
specificity of HRP2 is highly influenced by the fact that the HRP2 protein circulates in the 
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body up to several weeks after a cleared infection, which may cause false positive results 
[126, 151, 155]. This is especially of concern in high endemic areas were the population often 
are exposed to new infections after a recently cleared one, and health professionals are unable 
to distinguish the RDT positivity due to remaining antigens or a new infection. This can 
affect health workers adherence to and trust in RDT results. This may also frequently result in 
provision of antimalarial treatment to patients not infected [82, 146, 183]. RDTs based on 
HRP2 show higher specificity in low endemic areas where fewer individuals have recently 
gone through a malaria infection and unlikely carry remaining antigen [184, 185].  
Another source of false positive results with HRP2 is cross-reaction with rheumatoid factor, a 
common problem with diagnostic tests based on IgG antibodies [186, 187]. This is, however, 
less of a problem with product based on IgM as either the capture or signal Ab [187]. There 
are also a few reports on cross-reactions with P. vivax and false positivity due to Schistosoma 
mekongi and dengue infection [146, 188]. 
 
pLDH 
pLDH based RDTs has an overall detection limit of 100-200 p/µL for P. falciparum and 200-
500 p/µL for P. vivax, and in most studies sensitivities  >90% compared to microscopy [163, 
164]. However, there is generally more performance variability among pLDH tests as 
compared to HRP2, and pLDH has a generally lower sensitivity at low parasite densities 
[133, 163, 177, 189]. Since pLDH is only produced by live parasites it is not circulating in the 
blood after a cleared  malaria episode, but can produce positive result up to 2 weeks, although 
less frequently (5-10%) compared to HRP2 (>90%) after a cleared malaria episode [163, 
164].  LDH can occasionally remain positive longer due to gametocytaemia [92, 190]. Use of 
LDH based RDTs in high endemic areas where high parasitaemias are frequent is therefore 
considered a better tool than HRP2 [163, 164].   
Assessment of pLDH based tests for detection of P. ovale and P. malariae has shown poor 
results. With overall sensitivities ranging between 18 and 47% for P. malariae and between 
20 and 31% for P. ovale, it is evident that neither test is reliable for the detection of these 
species [169, 191, 192]. However, pLDH antigen based RDTs are neither exposed to prozone 
effect [182] nor genetic diversity making the main source of false negative results low 
parasite densities. There are reports on cross-reactions between P. vivax and P. falciparum 
specific LDH [193] and pLDH can become false positive due to gametocytaemia. LDH has 
also been reported to be more vulnerable to high temperatures [194] even though recent 
evaluations have shown high stability for several pLDH based RDTs similarly as for HRP2 
based tests [174]. 
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2.3.7 The usefulness of RDT 
RDT is a very efficient tool for easy-of-use, rapid, stable and accurate detection of malaria 
infections among fever patients with P. vivax or P. falciparum infections. A disadvantage 
with the use of HRP2/ Pan-LDH combo tests is that it is not possible to distinguish between 
the non-falciparum species, neither detects mixed infections. Other concerns are lot-to-lot 
variability and lack of internal control [146, 195]. However, studies on RDT in practice have 
shown that RDT also is a reliable tool for guidance of treatment of febrile children [80] and 
even effective and safe in the hands of community health care workers [196]. However, an 
important factor for the effectiveness of RDT use is adherence to test result among health 
care workers [73, 197]. 
 
2.4 MOLECULAR METHODS FOR MALARIA DETECTION 
The most sensitive methods for malaria diagnosis are based on molecular detection of 
parasite DNA or RNA. It has been shown that when the malaria incidence in endemic areas 
decline in previously more high endemic areas, a large proportion of individuals carrying 
malaria parasites are asymptomatic with a low parasitaemia, often below the detection limit 
of both RDT and microscopy (Figure 3). These individuals, however, still constitute a risk for 
further transmission [85, 198].  Also in higher endemicity, low parasitaemias are common 
among adults and in chronic infections [85].To diagnose these infections, there is a need for 
molecular methods with high sensitivity [86, 199]. 
 
2.4.1 DNA extraction methods 
Detection of malaria parasites with molecular methods is based on DNA extracted from fresh 
blood or blood dried on filter papers. There are several methods available for DNA 
extraction: 
 Column based methods (e.g. Qiagen), is suitable for larger sample volumes (from 
fresh blood) and for long DNA fragments. The method produces high quality DNA 
stable for long time storage but is rather expensive and labour-intensive [200]. 
 
 Chelex-100 method, gives a high yield suitable for small sample volumes (filter paper 
blood spots) and for short DNA fragments. Chelex is a cheap method but is not stable 
for long time storage and is rather labour-intensive [201]. 
 
 Simple boil and spin methods are fast, cheap and easy but produce crude DNA 
sensitive to inhibition and not suitable for storage. Boil and spin methods are suitable 
mainly for small blood volumes [202, 203]. 
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2.4.2 PCR 
PCR is the most sensitive method for detection of malaria parasites with detection limit 
between 0,5-10 p/µL [28, 85, 204, 205]. In the past two decades, many PCR methods for 
parasite detection have been published. Snounou et al. [206] established one of the earliest 
nested PCR methods targeting the 18S ribosomal(r)RNA gene of the four major human 
Plasmodium species. Later, Rougemont et al. [207] and Kamau et al.[208] developed probe 
based real-time PCRs (qPCR) also targeting the 18S rRNA genes, and Steenkeste et al.[209] 
published a nested PCR method targeting the Cytochrome b (Cyt b) gene in the mitochondrial 
DNA (Mt-DNA). PCR methods can distinguish between all human Plasmodium species, 
identify mixed infections and also benefit antimalarial drug efficacy monitoring, vaccine 
studies, and screening of vulnerable populations such as pregnant woman [210]. The 
possibility to apply PCR methods on extracted DNA from dried blood spots preserved on 
filter papers has made them applicable for screening of large series of samples collected in 
endemic areas [202, 211]. Molecular techniques are also useful tools for screening of blood 
donors, thanks to their high sensitivities.   
PCR methods require sophistic laboratory infrastructures including PCR machines, 
electrophoresis and gel analyzing equipments, well trained staff, have long turn-around time 
and are costly [86, 179, 212, 213]. These requirements are usually impossible to fulfill at 
point of care level in most malaria endemic areas. PCR based molecular methods are 
therefore not suitable for routine diagnosis of malaria.  
Research is ongoing to find more field-friendly options for molecular diagnosis [86, 88, 214]. 
 
2.4.3 Loop Mediated Isothermal Amplification 
The loop mediated isothermal amplification (LAMP) method for amplification of DNA was 
first published by Notomi et al in year 2000 [215]. They developed a method that could 
amplify a few copies of DNA up to 10
9
 under isothermal conditions in less than one hour. 
The method for amplification of P. falciparum DNA was described by Poon et al, in 2006 
[216].  
The LAMP method uses a set of three primer pairs recognizing 4 sites of the target DNA 
which due to a loop formation of the amplified product acts as starting points for new 
primers. This autocycling strand-displacement DNA syntesis makes the amplification highly 
efficient and specific [215]. The amplification can occur under isothermal conditions at 65°C, 
with the use of the Bacillus stearothermophilus (BST) enzyme, robust towards inhibition and 
therefore also suitable for simple and field friendly DNA extraction methods such as the boil 
and spin method [216, 217]. The detection of amplified product can be done already after 15-
40 minutes and is based on either turbidometric measurement of magnesium pyrophosfate, a 
white precipitate produced during DNA-amplification, or alternatively by calcein added to 
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the reagent mixture in its quenched form which upon amplification is released producing 
fluorescence [217, 218]. Due to the very efficient amplification of DNA, there is a high risk 
of contamination something that users need to be aware of. To have a robust system were 
tubes with amplified products never allows to be opened, are of major importance [110, 218].  
The LAMP method has been evaluated for detection of malaria species in a number of studies 
using 18s ribosomal RNA and Mt-DNA gene targets [110, 216, 217, 219, 220]. The LAMP 
method has been compared with microscopy and/or PCR among symptomatic patients or on 
cultivated parasites generally showing sensitivities and specificities of >90%. LAMP has also 
been suggested for detection of Plasmodium in mosquitos [110, 219].  
A Loopamp
TM
 MALARIA Pan/Pf detection kit was produced through a collaboration 
between FIND and Eiken Chemicals, Tokyo, Japan [221]. The kit consists of tubes with 
vacuum-dried reagent mixtures, stable at ambient temperature (<30°C), targeting the Mt-
DNA sequences of all Plasmodium species (Pan-malaria) and P. falciparum, respectively. 
The kit has shown similar accuracy as nested PCR and sensitivities of > 95% at parasite 
densities of  > 1/µL when it was evaluated among patients suspected for having malaria both 
in an endemic setting (Uganda) and in returning travelers (UK) [179, 221]. The kit can be 
used under field conditions with simple extraction methods, only requiring few equipment’s 
like heating-block, centrifuge and a UV-lamp (Figure 7). 
 
 
Figure 7.  
Process of samples with the Loopamp MALARIA Pan/Pf detection kit 
 
Iveth J. González FIND diagnostics, 2013 
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2.4.3.1 Usefulness of Loopamp MALARIA Pan/Pf detection kit 
Today, the cost of a LAMP test using the commercial kit is about the same as for a PCR 
analysis, i.e. 3-5 USD. The cost will potentially decrease with increased use. 
The use of LAMP is considered a promising tool for point of care detection of asymptomatic 
carriers of low parasite densities, below the detection limit for both microscopy and RDT, 
especially in low endemic/ pre-elimination areas [86, 88, 222]. The use of LAMP kit for 
screening of asymptomatic individuals under field conditions needs, however, to be further 
evaluated. A limitation with the LAMP kit is that it like RDTs can not distinguish between 
the non-falciparum species or detect mixed infections, neither quantify parasites. 
 
2.5 MALARIA SEROLOGY 
Diagnosis of malaria using serological methods is based on the detection of antibodies against 
asexual blood stage malaria parasites. Immunofluorescence antibody testing (IFA) or ELISA 
are useful tools in epidemiological surveys for assessing malaria exposure over time, 
especially in low endemic areas [223]. Serology is also useful for screening of potential blood 
donors and occasionally for providing evidence of recent infection in non-immunes. The 
principle of serology is that, following infection with any Plasmodium species, specific 
antibodies are produced within 2 weeks of initial infection, and persist for 3-6 months after 
parasite clearance [224]. Serology is therefore not a suitable method for point of care 
diagnosis of malaria. 
 
2.6 FUTURE MALARIA DIAGNOSTIC OPTIONS 
Mobil phone based microscopy 
There are several studies ongoing to determine the feasibility of using mobile phones to 
capture microscopy images and transfer them to a central database for assessment [225, 226]. 
It could have potential to be a sensitive, robust, easy to use and cost effective system which 
could play a role as an alternative/complement to present diagnostic methods. However, if 
this is going to be a useful tool for diagnosis of malaria it has to be combined with high 
quality sample preparations and staining methods to prepare images suitable for computer 
based analysis. 
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Table 2. Comparison of diagnostic tools for malaria 
 Microscopy RDT Molecular methods 
 
Giemsa 
Acridine 
orange 
HRP2 LDH LAMP PCR 
Sensitivity high/low moderate moderate moderate high high 
Specificity 
high/ 
moderate 
moderat high/low high high high 
Detection limit 
p/ µL 
50 100 50 100-500* 2-5 0,5-10 
Species 
identification 
yes no yes for P.f yes/no 
yes/yes for 
P.f** 
yes 
Quantification yes no no no no yes*** 
Time to result 
minutes 
40-60 10 20 20 60 > 4 hours 
Lab 
requirements 
low moderate no no moderate high 
Technical skills high moderate low low moderate very high 
Costs low moderate moderate moderate moderate 
high/ 
moderate 
Usefulness in 
clinical efficacy 
studies 
yes no no probably probably probably 
 
*for P. vivax    ** with the Loopamp Pan/Pf kit    *** with qPCR     P.f= P. falciparum  
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3  RATIONALE FOR THE DOCTORAL PROJECT  
Malaria is a major problem from a global health perspective. However, during the last years 
there has been a decrease in both malaria morbidity and mortality in many African regions, 
e.g. Zanzibar, following wide scale deployment of combined control interventions with 
artemisinin-based combination therapy (ACT), long lasting insecticide treated nets (LLINs), 
indoor residual spraying (IRS) and intermittent preventive treatment in pregnancy (IPTp). In 
areas where these interventions have been successful, improved case detection and 
surveillance are becoming increasingly important.  
Parasite-based malaria diagnosis is generally recommended by WHO to target treatment to 
patients with confirmed malaria infections. The introduction of RDT has been crucial to 
increase the diagnostic accuracy of malaria. The new rapid tests are easy to perform and 
interpret; they do not require access to electricity and are therefore well suited for use in rural 
hospitals and primary health care worldwide. The global market for these products is 
gigantic, where different endemic contexts may have different requirements. A continuous 
evaluation and development of these products is on-going. Studies on their performance and 
implications for case management among health care workers in different epidemical 
contexts are essential. 
Following improved global malaria control and regional elimination efforts, there is a critical 
need for novel surveillance tools and strategies. Plasmodium DNA extracted from RDTs may 
become a valuable tool for molecular monitoring of malaria and drug resistance surveillance. 
However, comparative evaluation of different extraction methods and the applicability for use 
on field collected RDTs are lacking.    
Currently several countries are targeting malaria elimination. To achieve this goal, molecular 
diagnostics that are sensitive enough to detect carriers of very low parasite densities, below 
the detection limit of both RDT and microscopy, are needed. LAMP is a new promising 
method for field use in endemic areas. The LAMP assay is faster easier and less equipment 
dependent compared to conventional PCR methods but evaluation of its performance and 
usefulness in different endemic settings is needed.  
The four studies in this PhD program will provide new data on the efficiency of diagnostic 
tools for optimized diagnosis and surveillance of malaria in different endemic contexts 
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4 AIMS OF THE THESIS  
4.1 OVERALL OBJECTIVE 
To evaluate the use of modern diagnostic methods to improve diagnosis and surveillance of 
malaria in different endemic contexts. 
 
4.2 SPECIFIC OBJECTIVES 
Study 1- To assess if RDT remains an efficient tool for P. falciparum case detection among 
fever patients in an area of low malaria transmission (Zanzibar). Further, to evaluate 
the adherence to test results among health care workers and the performance of RDT 
as a part of integrated management of childhood illness (IMCI). 
 
Study 2- To assess parasite clearance by microscopy, RDT and PCR. To compare the 
usefulness of two RDT devices based on detection of HRP2 and LDH antigens, 
respectively, for assessment of clearance and detection of recurrent P. falciparum 
infections following treatment with ACT among children in a moderately high 
endemic area of Tanzania.   
 
Study 3- To compare and evaluate different methods of DNA extraction from RDTs and to 
test the field applicability of used RDTs versus filter papers for molecular 
surveillance. 
 
Study 4- To evaluate the accuracy of a newly developed commercial LAMP kit for the 
detection of malaria DNA, both from symptomatic and more importantly 
asymptomatic low density parasite carriers, using extractions from small blood 
volumes spotted on filter papers. 
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5 MATERIALS AND METHODS 
5.1 STUDY SITES 
Study 1 
The study was conducted in 12 primary health care facilities, 6 each including 5 primary 
health care units (PHCU) and 1 primary health care centre (PHCC) in North A (Unguja 
island) and Micheweni (Pemba island), respectively, two rural districts of Zanzibar in May-
July in 2010. Zanzibar has recently undergone a rapid transition from 30% in 2003 to < 3% in 
2010 of P. falciparum infections among fever cases. This has been achieved through wide 
scale implementation of combined malaria control interventions.  
Zanzibar introduced P. falciparum specific RDT for confirmatory malaria diagnosis of fever 
patients in all public health care facilities in 2006. Zanzibar was also among the first regions 
in Africa to incorporate RDT in their local version of IMCI in 2009 [83]. ACT was 
introduced for first line treatment in 2003. 
Study 2  
The study was performed at Mlandizi PHCC in Kibaha district and Fukayosi PHCC in 
Bagamoyo district, both located in the Coast region of Tanzania. The study was conducted in 
Kibaha district in 2009-2010 and in Bagamoyo district in 2011. The region is considered a 
moderately high transmission area for malaria where the predominant species is P. 
falciparum. Malaria transmission occurs throughout the year with peaks following rainy 
seasons in March-May and October-December. ACT was introduced as first line treatment 
for uncomplicated malaria in 2006 in the study area. RDTs were rolled out by the National 
Malaria Control Programme (NMCP) for universal diagnostic testing in the whole country 
from 2009. During the study period (2009-2011) the monthly positivity rates among children 
<5 years varied between 11% and 48% in the study area.   
 
5.2 STUDY POPULATIONS AND SAMPLING 
Study 1 
All patients >2 months age, seeking health care with fever or a history of fever during the 
preceding 24 hours, without symptoms of severe disease, were included. Upon enrolment all 
included individuals underwent RDT testing. All RDT positive patients and a random sample 
of 20% of all RDT negative patients were subjected to additional blood sampling for malaria 
microscopy (thick blood smear) and approximately 100 µL spotted on filter paper (Whatman 
3MM) for molecular analysis. Antimalarial medicines according to national guidelines 
(artesunate-amodiaquine) as well as antibiotics and antipyretics were provided as required.  
The study included a single visit for all included individuals. 
 
 
 40 
Study 2  
Children below 5 years of age (6-59 months) with fever or history of fever during the 
preceding 24 hours and with a confirmed uncomplicated P. falciparum mono-infection with a 
parasitaemia between 2,000-250,000/ µL, willing/able to comply with a 42 day follow up was 
eligible to participate.  All children were treated with arthemeter-lumefantrine (Coartem®, 
Novartis) according to national treatment guidelines.  Enrolled children were requested to 
return for follow up on day 1, 2, 3, 7, 14, 21, 28, 35 and 42. At each visit including day 0, a 
finger prick blood sample was taken for thick and thin smears, two RDTs and approximately 
50 µL spotted on filter paper for PCR analysis from all children.  
Study 3 
The RDT and filter paper samples collected in study 1 were used.  
Study 4  
In addition to the samples described in study 1 a subsample of asymptomatic individuals 
(aged 1 month-85 years) collected during a cross sectional survey performed in North A and 
Micheweni districts of Zanzibar in 2011 were also used in this study. All individuals were 
screened for malaria with RDT and approximately 50 µL blood was spotted on filter paper 
for molecular analysis. 
 
5.3 LABORATORY METHODOLOGIES 
5.3.1 RDTs 
Study 1  
The P. falciparum specific HRP2 based Paracheck Pf (Orchid Biomedical Systems, Goa 
India) was used, which at the time of the trial was the RDT device deployed by The Zanzibar 
malaria control programme (ZMCP).  
Study 2 
Two RDTs, ParaHIT ®f (Span Diagnostics Ltd, Surat, India), detecting P. falciparum-
specific HRP2 antigen and CareStart™ Malaria (G0151), (Access Bio, Inc, NJ, USA), 
detecting P. falciparum-specific LDH antigen were used. ParaHIT was at the time of the 
study, approved by the Tanzanian NMCP and was the most deployed RDT. The single Pf 
CareStart test was chosen based on the heat stability and performance of the CareStart pan-
LDH test for detection of P. falciparum in the WHO-FIND product testing 2009 [134] 
Study 3 
DNA extraction methods were compared using two RDT devices of clinical importance in 
Zanzibar: Paracheck-Pf and a PfHRP2/pan-LDH based RDT, SD-Bioline Malaria Ag P.f/Pan 
(Standard Diagnostic, Inc, USA). Zanzibar had recently changed to SD-Bioline P.f/Pan as 
this test also detects species other than P. falciparum. 
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The field study samples included in study 3 originated from the Paracheck-Pf RDTs 
performed during study 1. 
Study 4 
The fever patients were tested with Paracheck-Pf RDTs performed during study 1. The 
asymptomatic patients in the cross-sectional survey were all screened with SD-BioLine 
Malaria Ag P.f/Pan. 
All RDTs were performed and interpreted on site according to the manufacturer’s 
instructions. Faint bands at the test line positions were determined as positive and band 
intensities were not recorded. 
 
5.3.2 Microscopy 
Study 1 and 2 
Giemsa stained thick blood smears (BS) for microscopy was used in both studies. Slides were 
stained for 20-30 minutes with 5% Giemsa solution and were examined under oil immersion 
(x100 magnification) by two experienced microscopists. A total of 100 (Study 1) or 200 
(Study 2) microscopic fields were examined before a smear was considered negative. 
Asexual parasite densities were calculated by counting parasites against 200 WBC, assuming 
8,000 WBC/μL of blood [100].  All blood smears with discrepant results, defined as >50% 
difference in parasite densities or a positive versus negative result between the readers as well 
as between BS and PCR results, BS and RDT results or RDT and PCR (for pLDH-RDT in 
Study 2) were subjected to a third decisive reading at Karolinska Institutet, Sweden.  
Thin blood smears were also collected on day 0 in Study 2 and stained with Giemsa in order 
to confirm P. falciparum mono-infections. 
Study 2  
Thin blood smears were also examined after staining with an acridine orange solution. The 
smears were fixed in methanol and stained with 0.01% acridine orange and read in a 
fluorescence microscope at x40 magnification. Results were recorded as either negative or 
positive, i.e. parasite counts were not assessed. 
 
 
5.3.3 Preparation of serial dilution of parasites 
Study 3 
For the purpose of estimating the detection limit of parasite DNA extracted from RDTs, serial 
dilutions of in-vitro cultured lab strain 3D7 P. falciparum parasites were prepared. The 
parasite density in the culture was estimated by microscopical examination of a Giemsa 
stained thin film. In contrast to ordinary counting of % infected RBCs, all parasites within the 
 42 
infected RBCs were counted for a more robust assessment of parasites/μL after cell lysis. 
Packed RBCs from the parasite culture was then diluted 1:1 with human serum to achieve a 
hematocrit of approximately 50%, before it was serially diluted with uninfected male whole 
blood. Before preparing the dilutions, the infected and uninfected blood were freeze-thawed 
to lyse all cells. 
Study 4.   
The same method was used for evaluation of detection limit by the Pan/Pf LAMP kit. 
 
5.4 MOLECULAR METHODOLOGIES 
5.4.1 DNA extraction 
Study 1 and 2  
Three punches (approximately equivalent to a total blood volume of 10-15 μL) from all 
collected filter paper samples were extracted using the column-based ABI-6100 Nucleic Acid 
Prep Station protocol (Applied Biosystems, Fresno, CA, USA) [227]. DNA was eluted in 200 
μL buffer and kept frozen until use.  
Discordant samples in Study 1 and samples for genotyping in study 2 were extracted with 
Chelex-100 method using one filter paper punch (~3-5 μL) [211, 228]. 
Study 3  
Two RDT devices seeded with 5 μL blood of parasite concentrations from 200,000 to 
0.02/μL, derived from serial dilutions, were cut into 3 x 3mm pieces from four different 
fragments (1 cm, Proximal, Distal, Whole), all including the proximal third of the 
nitrocellulose strip. For comparison, filter papers (Whatman 3MM) were seeded in parallel 
with 5 μL (approximately equivalent to one 3-mm filter paper punch) of the serial dilutions. 
All cut pieces were extracted with three different methods: 1) a simple elution method [229] 
2) Chelex-100 [230] and 3) a modified version (regarding regents volumes and incubation 
times) of the ABI-6100 protocol [227], for evaluation of extraction efficiency. The final 
elution volumes from the methods were 1) 50 μL, 2) ~190 μL, 3) 200 μL. 
For the field study samples paired RDT and filter paper samples were extracted with the ABI-
6100 Nucleic Acid Prep Station protocol (modified for the RDTs).  
Study 4  
The samples from the asymptomatic individuals were extracted with the Chelex-100 method 
using one filter paper punch [228]. For the samples from Study 1 (fever patients), DNA 
samples with discordant PCR versus LAMP results were subjected to DNA re-extraction with 
the same Chelex method. 
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5.4.2 PCR 
Study 1 
RDT positive samples were analysed with a P. falciparum specific nest PCR-Restriction 
Fragment Length Polymorphism (RFLP) method for single nucleotide polymorphism (SNPs) 
targeting pfmdr1: N86Y, Y184F, D1246Y and pfcrt K76T [63, 231]. The PCR products were 
separated in an ethidium-bromide stained 1% agarose gel by electrophoresis and visualized 
under UV transillumination (GelDoc 2000, BioRad, Hercules, USA). An infection was 
defined as mixed when both alleles were present at a particular locus. Pfmdr1 copy number 
was determined by the comparative ΔΔCt method following a TaqMan probe-based real-time 
PCR [65].  
RDT negative samples were pooled two by two and screened in duplicate for presence of 
Plasmodium DNA with an 18S ribosomal(r) DNA (targeting the rRNA genes) real-time PCR. 
Samples with a cycle threshold (Ct) value <42 were selected for multiplex species 
identification [232]. 
Samples with discrepant RDT and PCR results were re-analysed with a Plasmodium 
Cytochrome b (Cyt b) nested PCR [211]. PCR positivity was defined as a positive PCR that 
could be confirmed by another PCR method or by parasite detection by microscopy. All 
samples with a negative RDT but a positive microscopy and/or PCR were subjected to PCR 
analysis for HRP2 deletions [233]. 
Study 2 
Samples from all time points were analysed in triplicate by 18S rDNA real-time PCR [232]. 
A cut-off value for positivity was set at Ct-value <40. Samples where one out of three had a 
Ct <40 were repeated in triplicates with the same real-time PCR. Samples with repeated 
single Ct-values <40 or a Ct average of >38.5 were subjected to a confirmatory/ decisive P. 
falciparum-specific nested 18S PCR [234]. 
Day 0 and day of recurrent infection samples from children with recurrent PCR positivity, 
were analysed with stepwise genotyping of msp1, msp 2 and glurp according to standard 
operating procedures to differentiate new infections from recrudescence [71]. 
Study 3  
For the purpose of evaluating the three extraction methods from RDTs and filter papers, they 
were analysed for P. falciparum detection limits using three PCR methods: 18S rDNA nested 
PCR, Cyt b nested PCR and 18S rDNA real-time PCR [208, 209, 234]. The same volume of 
DNA was used from each extraction method (2-5 µL depending on PCR method). The P. 
falciparum detection limits were determined as the lowest consecutive positive sample in the 
dilution series. 
For the field study samples (from Study 1) paired RDT and filter paper samples were 
analysed in parallel with the PCR methods described (Study 1).  
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Study 4 
For evaluation of LAMP accuracy for detection of parasite DNA, LAMP results were 
compared with Cyt b nested PCR [209]. The PCR products were visualized under UV light 
and positive PCR products were subjected to an RFLP assay for species identification [211]. 
The detection limit for Cyt b nested PCR was estimated to approximately 2 p/µL. 
Samples with discordant results between Pan and/or Pf-LAMP versus Cyt b nested PCR were 
re-amplified by a SYBR Green real-time PCR assay in triplicate, targeting the Cyt b gene of 
the four major human Plasmodium species  (Xu et al, unpublished data). The PCR reaction 
was carried out in a final volume of 20 µL, containing 5 µL of extracted DNA, 0.25 µM of 
each primer, and 1 × iTaq Universal SYBR® Green Supermix (Bio-Rad, Hercules, CA) The 
real-time PCR results were analysed both by melting curve and gel electrophoresis. Cyt b- 
real-time PCR positivity was confirmed by gel electrophoresis on a 1.5% agarose gel stained 
with GelRed. PCR products were digested by FspBI enzyme (Thermo Fisher, Waltham, MA) 
in RFLP assay for species identification. After overnight digestion in 37°C, the RFLP 
products were run on 2% agarose gel followed by visualization in Gel-doc system (Bio-Rad) 
(Xu et al, unpublished data). The detection limit for Cyt b real-time PCR was estimated to 
approximately 1 p/µL.  
The real-time PCR corrected nested PCR result was defined as gold standard. 
PCR for quantification of parasites was used for PCR positive asymptomatic individuals. 
DNA extracted from dilution series of 20000, 2000, 200, 20 and 2 p/µL of in-vitro cultured 
parasites were analysed with quantitative PCR (qPCR) targeting the Plasmodium 18S rRNA 
gene [235]. A standard curve was developed by plotting known density to quantified 18S 
copy numbers. The asymptomatic DNA samples were quantified by the 18S qPCR using 
plasmid standard [235],  and the parasite densities were calculated by the acquired 18S copy 
numbers and the standard curve. 
 
5.4.3 LAMP 
Study 4 
The extracted  DNA samples were analysed with the Loopamp
TM
 MALARIA Pan/Pf 
detection kit (Eiken Chemical, Tokyo, Japan) according to standard operating procedures  
provided by FIND and the manufacturer’s instructions [236]. Samples were analysed 
individually for Pan (all species) and Pf (P. falciparum) using separate reaction-tubes 
provided by the kit, containing dry-down reaction mixtures. 30 µL of DNA samples (diluted 
1:6 in sterile water) were added to each Pan and Pf reaction tube. Each set of six samples 
were analysed along with a negative (nuclease free water) and a positive (purified plasmid 
DNA) control. After careful mixing of the DNA solution with the reaction mixture, the 
LAMP reaction tubes were incubated at 65°C for 40 minutes followed by a 5-minute 
enzyme-inactivation at 80°C in an LA-500 turbidimeter (Eiken Chemical). The real-time 
turbidity data were electronically recorded from the amplification curves in the control unit. 
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An increase in turbidity exceeding 0.1 Optical Density (OD) units per second was scored as 
positive [221]. 
 
5.5 ETHICAL CONSIDERATIONS 
Field sample collections were conducted in accordance with the Declaration of Helsinki and 
Good Clinical Practice [237, 238]. The studies were approved by the Zanzibar Medical 
Research Ethics Committee (ZAMREC/ST/0021/09) (ZAMREC/0001/JUNE/011) (Study 1), 
the Directorate of Research and Publications, MUHAS (Ref.No.MU//RP/AEC/Vol.XIII/142) 
(Study 2). All four studies were approved by the Regional Ethics Committee, Stockholm 
(2009/387-31).  
All study participants gave written informed consent for their participation. For children, 
proxy-consents from parents/legal guardians were obtained. Study 1 and 2 are registered on 
ClinicalTrials.gov with study identifier “NCT01002066” and “NCT01843764”, respectively. 
 
5.6 DATA ANALYSIS 
Data from Study 1-4 were entered in Microsoft Excel and all statistical analyses were 
performed using STATA 12 (Stata Corp, Texas, USA) software. All frequencies, proportions 
and odds ratios (ORs) were calculated with 95% confidence intervals (CI). Statistical 
significance was defined as p< 0.05. 
Study 1 
Primary endpoint was adherence to RDT results and secondary endpoints included, 1) 
sensitivity, specificity, negative (NPV) and positive (PPV) predictive values for RDT versus 
PCR and blood smear (BS) microscopy and 2) performance of RDT within IMCI assessed as 
a subgroup analysis of the age group <5 years. Adherence to test result was assessed through 
drug prescription across age groups. 
To account for the fact that blood sampling for BS microscopy and PCR among RDT 
negative patients only included a random sample of 20%, we multiplied the absolute number 
of observations in these groups with factors of 5.14 and 5.01 in all calculations of RDT 
sensitivity and specificity against PCR and microscopy, respectively. The corresponding 
confidence intervals (CI) were, however, based on the true sample size. Adjustment for 
clustering at health facility level was done using mixed effect models.  
Study 2 
The primary endpoints were assessment of clearance time and detection of recurrent 
infections by microscopy, RDT and PCR. Secondary endpoints included 1) specificity of the 
two RDTs, 2) identification of PCR adjusted reinfection/ recrudescence and 3) correlation 
between parasite density at enrolment and persistence of HRP2. 
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Categorical variables were compared using Fishers exact test. Pearsons linear correlation (r) 
was calculated in SPSS. Sensitivity and specificity of acridine orange against Giemsa-stained 
blood smear microscopy and both microscopic methods against PCR were calculated. 
Study 3 
The level of DNA extraction efficiency of the different RDT devices was determined through 
several PCR assays. SNPs genotyping outcomes were compared between RDT and filter 
paper extracted DNA by kappa analysis (κ). For determination of pfmdr1copy number 
variations, comparison was done by Wilcoxon rank-sum test due to many incomplete RDT/ 
PCR pairs. 
Study 4 
Sensitivity, specificity, PPV and NPV of the respective Pan and Pf-LAMP assay were 
calculated using real-time PCR corrected nested PCR as gold standard. When calculating the 
Pf-LAMP sensitivity, specificity, NPV and PPV for the asymptomatic individuals, P. 
malariae mono-infections were not included. The corresponding calculations for Pan-LAMP 
were based on P. falciparum and P. malariae mono-infections only. Data were also analysed 
after stratification by covariates that may influence the diagnostic accuracy of LAMP (e.g. 
parasite density and presence of non-falciparum species). Pairwise determination of non-
equivalence between final outcome (including re-extraction) of Pan and Pf-LAMP as well as 
for Pan-LAMP and Pf-LAMP individually versus nested PCR for detection of parasite DNA 
was determined by the McNemar test.  Kappa analysis (κ) for agreement between the 
methods was performed. 
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Table 3. Summary of the methodologies Study 1-4 
*In relation to RDT outcome    NA= not applicable     FP= filter paper     
 
  
Column1 Study 1 Study 2 Study 3 Study 4 
Study design 
Observational   
descriptive 
Exploratory 
descriptive 
Comparative 
methodological 
Comparative 
 methodological 
Study 
population    
age /samples 
Symptomatic          
> 2 months 
Symptomatic         
5-59 months 
Lab strain 3d7    
RDT + FP  
 from Study 1 
Asymptomatic  
>1months           
 DNA from Study 
1 
Study area 
endemicity 
low moderately high NA low 
Sample size 3890 53 855 865 + 465 
Follow up no 
day 1, 2, 3,7, 14, 
21, 28, 35, 42 
NA no 
Methodology 
Evaluation of 
RDT versus 
microscopy and 
PCR , drug 
prescription* 
Estimation of 
clearance and 
detection of 
recurrent infection 
by RDT,  
microscopy and 
PCR 
Evaluation of 
extraction  
methods from 
RDTs, 
comparison of 
RDT and FP field 
samples 
Evaluation of 
LAMP versus 
PCR from FP 
samples 
Laboratory 
tests 
microscopy,  RDT 
and PCR 
microscopy, RDT 
and PCR 
DNA extraction 
and PCR 
LAMP and PCR 
Outcome  
Usefulness of  
RDT, adherence 
Usefulness of 
HRP2 and LDH-
based RDT 
Usefulness of 
RDT for 
molecular 
surveillance and 
field applicability 
Accuracy of 
Pf/Pan-LAMP kit 
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6 RESULTS AND DISCUSSION  STUDY 1-4 
6.1 STUDY 1 
Rapid diagnostic tests in the new context of low malaria transmission in Zanzibar -
usefulness, adherence and performance within the IMCI algorithm 
 
6.1.1 Results 
3890 patients, aged ≥ 2 months were enrolled at the 12 health care facilities. Among these 
121 (3.1%) had a positive RDT result.  
The highest RDT positivity rate 6.1% (32/528) was found among children aged 5-14 years.  
There was an uneven distribution of RDT positivity rates between the two districts, i.e. North 
A 42/2225 (1.9%) and Micheweni 79/1665 (4.7%), and also between their respective health 
facilities with 67.1% (53) of all RDT positive patients in Micheweni district reported from 
only one health facility.  
The three main questions we wanted to answer in this study were: 
1. Does a HRP2 based RDT remain an efficient tool for P. falciparum detection in the 
new context of low malaria endemicity? 
We evaluated the RDT against Giemsa stained BS microscopy but also against PCR as gold 
standard, considering that the importance of low parasitaemias may increase in low endemic 
setting (Table 4). The RDT showed a relatively low sensitivity but a high specificity when 
compared with both BS and PCR. Four of the six patients with negative RDT but positive 
blood smear had high parasite densities (3573-50190/µL).  Further PCR analysis could not 
detect HRP2 deletions in these samples.  
2. Is malaria RDT as an integrated part of IMCI a reliable tool to both identify and rule 
out malaria infections in children < 5 years? 
The results showed no significant difference in RDT performance in children < 5 years 
compared to other age groups (5-14 years, >14 years).  
3. Do primary health care workers continue to adhere to RDT results in this new context 
of low malaria transmission? 
Adherence to RDT results was high, i.e. 99.9%. Only 3/3768 RDT negative patients (all >14 
years) received antimalarial treatment.  RDT negative patients were overall more likely to 
receive antibiotics compared to RDT positives [OR 3.25 (95% CI 2.15–5.01)], except for 
children <5 years, where prescription were equal in both groups. These children were also 
less likely to receive antipyretics compared to other age groups [OR 0.22 (95% CI 0.19–
0.26)]. 
  49 
 
Table 4. RDT sensitivity, specificity, PPV and NPV against PCR and BS microscopy 
    PCR +      PCR – Total BS+  BS- Total 
RDT + 117 4 121 110 11 121 
RDT - 7* 726* 733      6** 733** 739 
Total 124 730 854 116 744 860 
      
Sensitivity (95% 
CI)  
76.5% (69.0–83.9%) 78.6% (70.8–85.1%) 
Specificity (95% 
CI) 
99.9% (99.7-100%) 99.7% (99.5-99.9%) 
Positive 
predictive value 
(95% CI) 
96.7% (91.8-99.1%) 91.7% (84.3-95.4%) 
Negative 
predictive value 
(95% CI) 
99.0% (98.0-99.6%) 99.2% (98.8-99.5%) 
*multiplied with a factor of 5.14      ** multiplied with a factor of 5.01 
 
6.1.2 Discussion 
Compared to a previous report from Zanzibar [197], conducted in 2005 when P. falciparum 
malaria was responsible for  ~30% of fever episodes, the sensitivity of RDT against BS 
microscopy declined from 92% in 2005 to 79% in 2010, whereas the corresponding 
specificity increased from 88% to 99%. The relatively low sensitivity of Paracheck-Pf, i.e. 
below the reported sensitivity for P. falciparum detection for this RDT device in WHO/FIND 
evaluation in 2012 [134] is a concern. The decrease in sensitivity may reflect decreased 
parasite densities in the febrile patients. When the immune status in the population decreases 
as in this new situation of low endemicity in Zanzibar there could be more patients with fever 
caused by rather low density parasitaemia, high enough for detection by good quality 
microscopy and PCR but not enough for detection by RDT. Studies of pyrogenic threshold 
for P. falciparum in immune naive individuals have demonstrated a wide range of parasite 
densities at fever onset [239].  
However, another and maybe a more likely explanation to the lower sensitivity in this study 
is suboptimal performance of individual health care workers. Four of the six RDT-/BS+ 
samples had high parasite densities well above the detection limit for RDT and half of all 
RDT-/BS+ were from the same health facility. This highlights the need for improved 
supervision and control of RDT use. On the other hand, the increased specificity may reflect 
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an overall reduced risk of repetitive malaria infections and remaining antigenemia from a 
previous malaria episode in the new low transmission context in Zanzibar. 
Lot-to-lot variability and exposure to heat and humidity during storage are also factors that 
can result in differences in RDT accuracy.  
 The high adherence to RDT as an integrated part of IMCI indicates that the study staff 
members trusted the RDT results. They were encouraged to adhere to the IMCI guidelines 
which recommend that antimalarial treatment should be based on parasite confirmed 
diagnosis. However, they were free to manage according to their own clinical judgement. The 
high prescription of antibiotics in both RDT positive and negative children of 58% is a 
concern, though still lower than among children 5-14 of 66%. This shows the need for better 
supervision of the health care workers.  
The previous study when P. falciparum malaria was responsible for ~30% of fever episodes 
showed a high adherence among health care workers [197]. It is reassuring that health 
workers continue to adhere to RDT results even when 97 out of 100 tests are negative and 
facilities for alternative diagnosis of fever are scare. The high prescription of antibiotics to 
study participants in all age groups shows the urgent need for studies on fever aetiology and 
the need for diagnosis tools to improve the management of other causes of fever. 
Zanzibar is an area in the frontline of malaria control activities, which make our results 
probably not completely representative for other low endemic areas in sub-Saharan Africa. 
 
6.1.3 Limitations 
The high adherence among the study staff members in this study could be influenced by the 
fact that they had gone through a relatively extensive pre-study training and therefore not be 
representative for health care workers in other parts of Zanzibar. The two districts where the 
study was performed have been exposed to other malaria interventions during several years 
which also may have contributed to the high adherence. 
 
6.2 STUDY 2 
Usefulness of Plasmodium falciparum specific rapid diagnostic tests for assessment of 
parasite clearance and detection of recurrent infections after artemisinin-based 
combination therapy 
 
6.2.1 Results 
There were 53 children who completed the 42-day follow up. At day of inclusion the children 
had a fever history of 1-4 days.  
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Median clearance time for HRP2 was 28 (7->42) days, for LDH 7(2-14) days. PCR had a 
clearance time of 2 (1-28) days, BS microscopy 2 (1-7) days and AO microscopy 2 (1-14) 
days. Three children remained HRP2 positive up to day 42, i.e. the last follow up day.  
 
Figure 8. Positivity rate at each sampling point by the five diagnostic tests 
 
BS-Giemsa stained blood smear, AO-acridine orange stained blood smear, p=children 
 
Estimation of positivity rate is based on all 53 children, except for the HRP2 based RDT 
where the estimation is based on the 43 children without a recurrent infection during follow 
up. The false positivity rates for HRP2 against PCR on days 14, 21, 28, 35 and 42 were 80% 
(32/40), 64% (27/42), 43% (18/42), 24% (10/42) and 7% (3/41), respectively.  
The specificity against BS microscopy was for HRP2 21% on day 14 reaching 87% on day 
42, whereas LDH had a specificity of  ≥ 96% from day 14 and onwards (Table 5).  
There was no significant correlation between parasite density on day 0 and duration of HRP2 
positivity (r=0.13, p=0.38).  
Ten children got a recurrent infection during follow up as assessed by PCR, BS and/or LDH-
based RDT, one on day 14, four on day 21, two on day 28 and three on day 35. Eight of the 
ten children were still positive by HRP2 from the initial infection and this RDT could 
therefore only detect two of the new infections, whereas all other tests turned negative before 
parasite recurrence. LDH based RDT, identified eight at day of recurrence and another one on 
the next follow up visit. Out of the recurrent infections one was defined as recrudescence 
(treatment failure), six as reinfections (new infections) and three could not be determined by 
PCR. Five of the ten children had fever on day of recurrent parasitaemia and one child had 
only symptoms of respiratory tract infection. Four children had no symptoms. 
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Table 5. Specificity of HRP2 and LDH-based RDTs against BS microscopy (gold standard) 
during follow up 
  HRP2 LDH    
Day                      %                                                            CI 95%                        %       CI 95% p-value 
3   NA   20/49 41 27-56   
7 
 
NA   40/53  76 62-86   
14 11/52 21 11-35 51/52 98 90-100 <0.0001 
21 17/50 34 21-49 48/50 96 86-100 <0.0001 
28 29/49 59 44-73 49/49 100 93-100 <0.0001 
35 35/50 70 55-82 48/50 96 86-100 <0.005 
42 45/52 87 74-94 50/52 96 87-100 >0.05 
NA-not applicable 
 
6.2.2 Discussion 
We followed up the 53 enrolled children with five different diagnostic tools to thoroughly 
investigate the clearance time after treatment with ATC (arthemeter-lumefantrine). The mean 
clearance time for PCR, was 2.9 days. This rather long mean clearance time was influenced 
by four children with persistent positivity from the initial infection up to day 7, 14 and 21, 
respectively. In two of these children this may be explained by gametocytes which were 
found during PCR positivity. Also BS microscopy had a longer clearance than expected with 
a mean of 2.0 days. Four (8%) children remained positive up to day 3 and two of them were 
positive with very low parasite densities of 16 and 32/µL, however, with parallel negative 
PCR results. Both PCR and BS persistent positivity could be due to poor compliance since 
only the initial dose of arthemeter-lumefantrine was given under supervision. 
The long clearance time observed for HRP2 (geometric mean 26.4 days), confirms the results 
from several other studies [151, 155]. Long clearance time has a major effect on the test 
specificity making the test unsuitable for assessment of treatment outcome and for diagnosis 
in moderately high endemic areas, especially during the peak transmission season. The long 
persistence of HRP2 antigen in the circulation makes it impossible to distinguish a new 
malaria episode from remaining positivity from a previous infection. This phenomenon can 
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cause incorrect interpretation as treatment failure by health workers reducing their confidence 
in antimalarial drug effectiveness. It may also impair health workers adherence to RDTs and 
have a major effect on the usefulness of these tests, especially in high endemic areas.  
The pLDH-antigen showed, compared with HRP, a faster mean clearance time of 5.5 days, a 
high specificity (≥96% from day14) and may therefore be a better tool for detection of 
recurrent parasitaemia. However, despite a much faster clearance time for LDH-antigen it 
was still longer than for BS microscopy (2.1 days). It may therefore probably not be a useful 
tool for detection of prolonged parasite clearance time as a sign of emerging 
tolerance/resistance to antimalarial drugs.  
The sensitivity for pLDH-based detection of P. falciparum infections among symptomatic 
patients, particularly in moderately-high endemic areas should also be sufficient since 
symptomatic patients generally have parasite densities above the detection limit of around 
100 p/µL. However, in low endemic areas, especially for detection of asymptomatic malaria, 
probably neither of the two antigens would be sufficiently sensitive. 
Importantly, pLDH is also produced by mature gametocytes, which could cause false positive 
result [152]. Gametocyte carriage is more seldom seen after ACT treatment compared to 
other antimalarial drugs and in this study there were only four children with gametocytaemia, 
and they were all negative by the LDH based RDT. 
We saw no correlation between day 0 parasite density and persistent HRP2 positivity 
(r=0.13), which is in contrast to several other studies [151, 155]. Factors like duration of 
infection prior to blood sampling, the immune status (HRP2 antibody levels) of the patient 
and the total parasite biomass, including sequestered parasites, may influence the relation 
between HRP2 and parasite concentration. 
 
6.2.3 Limitations 
This was a small study with a limited number of recurrent infections detected during follow 
up. During patient inclusion there was a stock out of arthemeter-lumefantrine in the first 
study site, which precluded patient enrolment during the high transmission season in 2009. 
When the inclusion of children was continued during the following rainy season the number 
of parasite positive children had dropped markedly due to a massive LLIN distribution in the 
area. We therefore had to move to Bagamoyo district to finalize the study. 
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If it would have been possible to give the full treatment course under supervision, poor 
compliance could have been excluded as a source of prolonged clearance time by the 
diagnostic tools evaluated.  
In clinical trials patients are usually followed daily up to day 3 followed by day 7 and 
thereafter weekly. For a more robust result regarding clearance time in this study, the daily 
sampling could have continued after day three for another one or two days. .  
 
6.3 STUDY 3 
Rapid diagnostic tests for molecular surveillance of Plasmodium falciparum malaria -
assessment of DNA extraction methods and field applicability 
 
6.3.1 Results 
In vitro part 
The P. falciparum DNA detection limit varied with RDT device and extraction method 
(Table 6). Chelex-100 extraction preformed best for both RDT devices as well as for 
extraction from filter paper, with a detection limit of 2 p/µL. The ABI extraction method had 
a 10-fold higher detection limit of 20 parasites/µL. DNA extraction was generally more 
efficient from SD-Bioline Malaria Ag P.f/Pan than from Paracheck-Pf. Increasing the size of 
the nitrocellulose strip fragment did not improve the level of detection. The PCR method 
used for P. falciparum detection influenced the detection limit by 1-2 log units. DNA 
extraction from RDTs was generally equal to or better than DNA extraction from an equal 
volume (5 µL) of blood spotted on filter paper.  
 
  
  55 
Table 6. Sensitivity of DNA extraction methods from in-vitro RDT 
Fragment used for 
DNA extraction  
Simple elution Chelex-100 ABI 
Paracheck-Pf 
1 cm § 2 200 
Proximal NA 20 200 
Distal NA NA 20 
Whole NA NA 20 
                                                        SD-Bioline Malaria P.f/Pan 
1 cm 2 2 20 
Proximal NA 2 20 
Distal NA NA 20 
Whole NA NA 20 
                                                                            Filter paper 
5 µL blood spot 200 2 200 
NA= not applicable, the size of the RDT fragment used for extraction was limited by the extraction volume 
§ = Not estimated due to negative results 
 
Field samples  
There was no significant difference in PCR detection rates in DNA extracted from RDTs and 
filter papers. Out of 855 paired RDT and filter paper field samples, 118 (13.8%; CI 95% 
11.4-16.2%) were PCR positive in both groups of samples (κ=0.94). Among the RDT 
negative field samples (N=734), three (0.4%; CI 95% 0.0-0.9%) and six (0.8%; CI 95% 0.1-
1.5%) were PCR positive from RDT and filter paper extracted DNA, respectively (κ=0.44). 
Among the 121 RDT positive field samples, 115 (95.0%; CI 95% 91.1-99.0%) from RDT 
and 112 (92.6%; CI 95% 87.8-97.4%) from filter papers were PCR positive (κ=0.50). No 
observed difference was found in the ability to detect low density parasitaemias (<100 
parasites/µL) even though the number was small (12).  
There were no significant differences in PCR success rates for the respective SNPs in the 121 
RDT positive samples (Table 7). No sample contained multiple pfmdr1 copy number.  
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Table 7. PCR success rates and agreement of genotyping outcomes in field samples  
 RDT PCR 
success rate 
N=121 
(%; CI 95%) 
Filter paper PCR 
success rate 
N=121 
(%; CI 95%) 
Kappa 
value 
Pfcrt K76T 114 (94.2; 90.0-98.4) 104 (86.0; 79.7-92.2) 0.72 
Pfmdr1 N86Y 112 (92.6; 87.8-97.3) 109 (90.1; 84.7-95.5) 0.85 
Pfmdr1 Y184F 110 (90.9; 85.7-96.1) 107 (88.4; 82.6-94.2) 0.74 
Pfmdr1 D1246Y 113 (93.4; 88.9-97.9) 107 (88.4; 82.6-94.2) 0.77 
Pfmdr1 copy 
number 
84 (69.4; 61.0-77.7) 77 (63.6; 54.9-72.3) - 
 
6.3.2 Discussion 
We performed a comprehensive comparative in-vitro evaluation of DNA extraction from 
RDTs and assessed the field applicability for detection of genetic markers associated with 
drug resistance from used RDTs collected from symptomatic patients in Zanzibar. 
DNA extraction efficiency from in vitro cultured P. falciparum varied with RDT device and 
extraction method. Different designs of RDT devices affected the DNA extraction efficiency. 
In particular, DNA recovery from Paracheck-Pf was unsuccessful when using the simple 
elution method, whereas it worked well with the other two methods. It has previously been 
reported that plastic seals covering the nitrocellulose strip hamper DNA recovery [229]. The 
Chelex-100 extraction method in combination with the Cyt b or 18s real-time PCR performed 
best in our evaluation suggesting that Chelex is the preferable method for low density 
parasitaemias. However, the Chelex method is relatively labour intensive and the storage 
capacity for the DNA is a concern. The simple elution method on the other hand, is cheap and 
quick but was hampered by the small extraction volume not suitable for all devices and could 
also therefore not be thoroughly evaluated in our study. The high throughput ABI extraction 
method for RDTs was also labour-intensive and costly but provides on the other hand high 
quality and stable DNA. From our evaluation this extraction method seems to be more 
suitable for RDTs collected from symptomatic patients with higher parasite densities. 
The field analysis showed that collected RDTs are adequate alternatives to filter papers for 
DNA storage under field conditions. In areas of low endemicity where clinical trials are 
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logistically challenging to conduct, analysis of used RDTs, routinely taken for diagnosis 
would be an alternative for molecular surveillance. It also reduces the need for additional 
blood samplings of RDT positive individuals if only one finger prick is required for both 
malaria case detection and for preservation of biological material. DNA extracted from RDTs 
collected in the field could also be used for more sensitive parasite detection with PCR and 
for quality control of RDTs.  
 
6.3.3 Limitations 
To get a more robust comparison between the three extraction methods it would have been an 
advantage to use the same volume of elution buffer in all three. However, the blood volumes 
used in this study was in accordance with the published protocols for the three methods, 
meaning that the ABI method used a four times higher volume compared with simple elution, 
i.e. DNA was four times more diluted. A DNA quantification of the extracts with a qPCR 
method comparing the Ct-values would have added information in this study.  
In the article we claim that the higher detection limit by the ABI method compared to Chelex 
did not influence the field sample results when we compared RDT and filter paper extraction. 
However, we do not know the outcome if these samples would have been extracted with 
another (Chelex) method.   
 
6.4 STUDY 4 
Loop Mediated Isothermal Amplification (LAMP) accurately detects malaria DNA 
from filter paper blood samples of low density parasitaemias 
 
6.4.1 Results 
Fever patients 
Overall 115/865 (13.3%) patients were positive by nested PCR and another two were positive 
with real-time PCR. The geometric mean parasite density was 7491p/µL (range 6-782,400) as 
assessed by microscopy. All PCR positive samples were P. falciparum mono-infections, of 
which 105 (91%) were detected by Pan-LAMP and 101 (88%) by Pf-LAMP. There were 21 
samples with discordant nested PCR versus Pan and/or Pf-LAMP results. All 21 samples 
were positive when analysed with real-time PCR. After repeat PCR and LAMP analysis with 
Chelex re-extracted DNA from the 21 samples (and 21 control samples) 115 (98,3%) of the 
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117 real-time PCR positive samples were positive by both Pan-LAMP and Pf-LAMP (Table 
8)   
Asymptomatic individuals:  
Out of the 465 samples from the cross-sectional screening, 50 (11%) were positive by nested 
PCR and another four with real-time PCR, 33 P. falciparum, 13 P. malariae and 8 mixed P. 
falciparum/P. malariae infections. The geometric mean parasite density determined by qPCR 
was 10 p/µL (range 0-4972). Pf-LAMP had a sensitivity of 92.7% (95%CI 80.1-98.5) for 
detection of the 41 P. falciparum infections. Pan-LAMP had sensitivities of 97% (95%CI 
84.2-99.9) and 76.9% (95%CI 46.2-95) for detection of P. falciparum and P. malariae mono-
infections, respectively. There was no significant difference in parasite densities between the 
three Pan-LAMP negative (range 1-2p/µL) versus the ten Pan-LAMP positive (range 0-
3p/µL) P. malariae samples (p≥0.05).  Pan and Pf-LAMP both detected seven, whereas 
nested PCR detected five of the eight samples with mixed P. falciparum/P. malariae 
infections (Table 8). 
The detection limit for P. falciparum was ≤ 2 parasites/µL for both Pan and Pf-LAMP as 
assessed by serial dilutions of lab strain parasites. 
 
  
  59 
Table 8. Sensitivities and kappa analysis for detection of malaria DNA from fever patients 
and asymptomatic individuals with Pan and Pf-LAMP versus gold standard (real- time PCR 
corrected Cytochrome b nested PCR) 
Fever patients ABI-extracted DNA (n=865) 
 
Sensitivity % 
(95% CI) Kappa value 
Pan-LAMP 91.5 (84.8-95.8) 0.95 
Pf-LAMP 86.3 (78.7-92.0) 0.92 
  
Fever patients: including Chelex re-extracted DNA (n=823+42) 
 
Sensitivity % 
(95% CI) Kappa value 
Pan-LAMP 98.3 (94.0-99.8) 0.99 
Pf-LAMP 98.3 (94.0-99.8) 0.99 
  
Asymptomatic individuals  Chelex extracted DNA (n=465) 
 
Sensitivity % 
(95% CI) Kappa value 
Pan-LAMP all species 90.7 (79.7-96.9) 0.95 
Pan-LAMP  P.f.* 97   (84.2-99.9) 0.97 
Pan-LAMP  P.m.** 76.9   (46.2-95) 0.89 
Pf-LAMP   P.f.*** 92.7 (80.1-98.5) 0.96 
                            P.f.*= P. falciparum mono infections (n=33),  P.m.**= P. malariae mono infections (n=13),   
                                P.f.*** P. falciparum mono and mixed infections (n=41),  CI= confidence interval 
 
The specificities for both Pan and Pf LAMP were 100% in both study groups. 
 
6.4.2 Discussion 
In this study we have shown that LAMP had a high diagnostic accuracy for detection of low 
density parasitaemias from minute blood volumes preserved on filter papers, a relatively low-
cost and practical solution for population screening purposes. This supports the potential role 
of LAMP for improved passive and active malaria case detection in pre-elimination settings.  
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LAMP performed very well on samples recently extracted with the Chelex method but less 
well for samples with the column-based ABI-extraction method. Long storage and several 
freeze-thawing episodes may have influenced the quality of DNA suitable for LAMP more 
than for PCR, since several samples with microscopically detectable parasitaemias were 
negative with LAMP but positive with both PCRs. This shows that the quality of DNA 
extract could be of importance despite the use of Bst-polymerase, an enzyme considered 
suitable for simple and ruff extraction methods [216]. 
The LAMP kit evaluated in this study was easy to handle and interpret and could be a useful 
tool for screen and treat activities in areas of low endemicity/pre elimination. Considering 
that the relative importance of non-falciparum infections increases in such areas, screening 
with Pan-LAMP only, which had a slightly lower detection limit compared to Pf- LAMP 
[236] followed by Pf-LAMP analysis of Pan-LAMP positive samples may represent a cost 
effective strategy. However, at very low P. falciparum parasite densities the Pf-LAMP could 
then give a false negative result, leading to overestimation of the non-falciparum prevalence.  
 
6.4.3 Limitations 
The two sets of samples used in this trial were extracted with two different methods. The 
fever patient samples were extracted with the column based ABI high throughput method 
already in 2010. This method is considered suitable for long time storage and to produce a 
high quality DNA. However, these samples have since then been freeze-thawed several 
times. We could not re-extract with the same method neither use it for the asymptomatic 
individuals, since the method was then replaced by the Chelex-method in our laboratory. The 
samples with concordant PCR and LAMP results were not re-extracted, meaning we do not 
know the outcome if we had re-analysed these samples; however they were previously 
investigated with several PCR methods. 
   
6.5 OVERALL DISCUSSION STUDY 1-4 
The usefulness of new diagnostic tools like RDT and LAMP are highly dependent on the 
malaria transmission intensity in the area where they are going to be used.  The choice of 
diagnostic tool is also dependent on the target population, i.e. whether it is asymptomatic 
individuals or fever patients that are going to be tested. In study 1 and 2 we have evaluated 
the usefulness of P. falciparum specific RDT as diagnostic tool among fever patients in both 
a low and a moderately high endemic areas, however, from different perspectives. In study 1 
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our data suggest that probably there is need for a continuous quality control of RDT use, 
despite a relatively extensive pre-study training and in an area where the health infrastructure 
and surveillance system is relatively well functioning.  
In study 2 we thoroughly investigated parasite clearance after treatment with ACT both with 
microscopy, RDT and PCR. Parasite clearance time provides useful information in drug 
trials, where prolonged clearance could be an early sign of increased tolerance to the given 
antimalarial treatment. The evaluation of the two antigens HRP2 and pLDH for use in RDTs 
in an area where the risk of reinfection was relatively high, could also provide useful 
information for choosing an appropriate RDT device by malaria control programs in such 
areas.  
In study 3 we evaluated RDT from another perspective, namely as a source of parasite DNA. 
We could show how RDTs can be used for retrospective analyses with more sensitive 
methods such as PCR for parasite detection.  We could also show that RDT is a good 
alternative to filter papers for storage of DNA, already packed in individual casettes with 
minimal risk of contamination between samples.  Collection of used RDTs in low 
endemic/pre-elimination areas can be applied for more sensitive molecular methods both for 
improved case detection and surveillance.  
In study 4 we evaluated a new molecular method- LAMP, for detection of malaria parasites 
using a commercial kit. The evaluation of LAMP showed that it is a promising method, with 
equal high sensitivity compared to real-time PCR also when small blood volumes preserved 
on filter papers are used. However, the need for highly sensitive methods is primarily for 
screening of asymptomatic populations, whereas RDT and microscopy generally are 
sufficient tools for detection of symptomatic parasite carriers. The LAMP kit evaluated in this 
project needs, however, to be further evaluated under field conditions, especially for detection 
of low parasite densities in low transmission areas. User-friendliness and turn-around time are 
important aspects if LAMP is going to be useful in the future.  
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7 CONCLUSIONS 
7.1 OVERALL CONCLUSION 
The four studies in my doctoral project have provided new information regarding the 
usefulness of new diagnostic tools in different endemic contexts. To develop and determine 
the optimal methods for malaria diagnosis is a challenge. However, research and 
development for new and improved diagnostic methods together with better knowledge 
among users are promising opportunities in the fight against malaria.  
 
7.2 SPECIFIC CONCLUSIONS 
Study 1 
 The sensitivity of RDT in the hands of primary health care workers compared with 
both PCR and microscopy for P. falciparum case detection was relatively low in the 
new situation of low malaria transmission in Zanzibar. This highlights the need for 
improved quality control of RDT use in primary health care facilities as well as 
need for more sensitive point-of-care malaria diagnostic tools in Zanzibar.  
 
 Adherence to test results with antimalarial treatment in the study area of Zanzibar 
was generally excellent and the results also provide evidence that RDT can be 
reliably integrated in IMCI as a tool for improved childhood fever management. 
 
Study 2 
 Parasite clearance time after ACT treatment as estimated by PCR and microscopy 
was two days for the majority of children. 
   
 The LDH-based RDT was superior to HRP2-based for monitoring of treatment 
outcome and detection of recurrent P. falciparum infections after ACT treatment in 
a moderately high endemic area of Tanzania. These results may have implications 
for the choice of RDT devices in similar transmission settings for improved malaria 
case management.  
 
 There was no correlation between parasite density at enrolment and persistence of 
HRP2-based RDT positivity. 
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Study 3 
 RDT is a valuable source of parasite DNA which can be a useful tool for improved 
malaria case detection, molecular drug resistance surveillance, and RDT quality 
control. 
 
 The purpose of DNA extraction from RDTs should be considered when choosing 
which extraction method best suits the type of samples to be analyzed. 
 
 
Study 4 
 The LoopampTM MALARIA kit revealed high diagnostic accuracy for parasite 
detection among both fever patients and asymptomatic individuals with low parasite 
densities. 
 
 Using DNA extracted from minute blood volumes for the LAMP assay may be of 
value, particularly when blood sampling on filter paper from capillary finger pricks 
would be advantageous for practical and logistical reasons.  
 
 The LAMP method has a potential role for the implementation of active case 
detection activities in malaria pre-elimination settings.  
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8 PERSONAL REFLECTIONS AND FUTURE 
PERSPECTIVES 
I have a background as a biomedical technologist with a long experience of malaria 
microscopy. I have had the opportunity to participate in many clinical trials for malaria, both 
on site in Africa but also with quality control of blood smears sent to Sweden from the field. 
This experience has been invaluable for my understanding of all the problems and difficulties 
with achieving good quality of malaria microscopy under field conditions, and also for my 
doctoral project focusing on diagnosis. 
The diagnosis of malaria has during the last decade become one of the most important tools 
for surveillance and control. From being something the locals dealt with “down in Africa” it 
has now become a hot topic in the research community. The perception of how important a 
proper diagnosis is for correct management of malaria in combination with increased 
awareness that malaria microscopy, which was the only available tool, demanded good 
techniques and skilled personnel, something that was lacking in most areas suffering from the 
disease, led to the development of rapid diagnostic tests some twenty years ago. Many 
commercial companies saw the potential for this product on the global market endemic for 
malaria as well as from increased global travelling leading to more demands for good 
diagnostic tools also in non-endemic countries. The high and growing number of available 
RDT products and brands made WHO-FIND, to initiate the yearly RDT product testing 
program. This initiative has been very important for guiding and information regarding RDT 
use. The evaluation in combination with the competition between commercial producers and 
hundreds of research articles evaluating RDTs from different aspects, has resulted in the 
development of new and better products.  Access to a diagnostic tool that is easy to use, 
prompt, relatively cheap and sensitive as well as specific has had a major impact on the 
possibilities for a parasite based diagnosis.  
However, there are still a number of issues with the present RDTs available, which need to be 
considered if they are going to be useful tools in the future. The need for increased sensitivity 
is probably the most important; a detection limit of more than 50 p/µL for P. falciparum with 
significantly higher limits for the other species is not enough in the era of declining malaria 
transmission.  Specificity of HRP2 for detection of ongoing infection is also an issue, 
especially in high endemic areas. LDH-based P. falciparum detection would be a better 
option in such areas but until now it seems that most guidelines for malaria diagnosis 
recommend HRP2 based RDTs due to their slightly higher sensitivity. There are suggestions 
that a combo test with HRP2 and pLDH may be useful for treatment follow up [189, 240], 
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meaning when pLDH becomes negative the HRP2 positivity should be interpreted as 
remaining antigenemia. However, I think it would be challenging to ensure correct 
interpretations of such tests in most endemic areas, since health workers are aware of the 
lower HRP2 detection limit. The combo test detecting P. falciparum in either only the HRP2 
band or also in the pan-LDH band is not a good solution and still a common cause of 
confusion. There are a few recent developed RDTs detecting the non- falciparum species 
solely, excluding P. falciparum from the Pan-LDH that could be an option.  However, a test 
based on pLDH (or another antigen) with different combinations of species-specific detection 
of all five human malaria species with high sensitivity and specificity in an RDT format 
would be an optimal diagnostic tool in the future. This would also diminish the problems with 
other shortcomings of HRP2 based RDTs, such as gene deletions and prozone effect. 
In the era of decreased malaria transmission and with the possibility of achieving 
elimination in areas like Zanzibar there are urgent demands for field friendly and affordable 
tools for detection of the remaining parasite carriers. Molecular detection of parasite DNA 
with LAMP has recently shown to be promising also for use in mass screen and treat 
activities in Zanzibar (unpublished data). I think the LAMP-kit evaluated in this project has 
the potential to become very useful in the future. However, like for RDT the kit can only 
distinguish P. falciparum from Pan, detecting all four (five) human species. It is also a 
concern that Pan is slightly more sensitive than Pf-LAMP for P. falciparum at densities 
close to the detection limit of 2 p/µL which could lead to incorrect estimations of 
prevalence of the non-falciparum species. LAMP can also not determine parasite densities, 
due to the very efficient DNA amplification giving rise to equally high fluorescence or 
turbidity from very low densities as from very high. However, the use of a real-time 
turbidimeter could maybe be a future tool since time to start of increase in turbidity in the 
samples is dependent on the DNA concentration. The efficient amplification means a high 
risk of contamination; something that really has to be considered when the method is set up 
in laboratories as well as in field settings. Development of a robust high throughput system 
for extraction and analysis of large sample volumes is a priority if LAMP is going to be an 
even better tool for mass screen and treat activities.  There is also a need for specific 
detection of other malaria species, primarily P. vivax, which is a common cause of malaria 
infections in many areas, with the need for other control and elimination strategies. 
Finally, it is problematic to use a method as reference (gold) standard ( blood smear 
microscopy), which often is less sensitive than the methods being evaluated. 
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Abstract
Background: We assessed if histidine-rich-protein-2 (HRP2) based rapid diagnostic test (RDT) remains an efficient tool for
Plasmodium falciparum case detection among fever patients in Zanzibar and if primary health care workers continue to
adhere to RDT results in the new epidemiological context of low malaria transmission. Further, we evaluated the
performance of RDT within the newly adopted integrated management of childhood illness (IMCI) algorithm in Zanzibar.
Methods and Findings: We enrolled 3890 patients aged $2 months with uncomplicated febrile illness in this health facility
based observational study conducted in 12 primary health care facilities in Zanzibar, between May-July 2010. One patient
had an inconclusive RDT result. Overall 121/3889 (3.1%) patients were RDT positive. The highest RDT positivity rate, 32/528
(6.1%), was found in children aged 5–14 years. RDT sensitivity and specificity against PCR was 76.5% (95% CI 69.0–83.9%)
and 99.9% (95% CI 99.7–100%), and against blood smear microscopy 78.6% (95% CI 70.8–85.1%) and 99.7% (95% CI 99.6–
99.9%), respectively. All RDT positive, but only 3/3768 RDT negative patients received anti-malarial treatment. Adherence to
RDT results was thus 3887/3889 (99.9%). RDT performed well in the IMCI algorithm with equally high adherence among
children ,5 years as compared with other age groups.
Conclusions: The sensitivity of HRP-2 based RDT in the hands of health care workers compared with both PCR and
microscopy for P. falciparum case detection was relatively low, whereas adherence to test results with anti-malarial
treatment was excellent. Moreover, the results provide evidence that RDT can be reliably integrated in IMCI as a tool for
improved childhood fever management. However, the relatively low RDT sensitivity highlights the need for improved
quality control of RDT use in primary health care facilities, but also for more sensitive point-of-care malaria diagnostic tools
in the new epidemiological context of low malaria transmission in Zanzibar.
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Introduction
Zanzibar has recently undergone a rapid transition from high to
low transmission of Plasmodium falciparum malaria following wide
scale, high coverage implementation of combined malaria control
interventions [1]. In this new epidemiological context, efficient
malaria case detection and targeted malaria treatment with
artemisinin-based combination therapy (ACT) to fever patients
with parasitologically confirmed malaria infection is critical.
Therefore, Zanzibar introduced P. falciparum specific rapid
diagnostic testing (RDT), based on antigen detection of histi-
dine-rich protein 2 (HRP2), for confirmatory malaria diagnosis of
fever patients in all public health care facilities previously not
equipped with microscopy service [2]. Importantly, malaria RDT
has also been recently incorporated in the local version of the
integrated management of childhood illness (IMCI) guidelines of
2009 [3,4]. These guidelines are used for management of illness in
children aged 2–59 months in low and middle-income countries.
The performance of RDT as an integrated tool in IMCI for
improved childhood fever management in Africa and Zanzibar in
particular has previously not been evaluated.
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There are concerns regarding the usefulness of RDT, both with
regards to case detection with differences in test performances in
various epidemiological settings and to adherence to negative test
results among health care workers [5,6,7,8,9]. However, we have
previously shown that HRP2 based RDT aided diagnosis of fever
patients in primary health care facilities in Zanzibar was efficient
for P. falciparum detection when compared with blood smear (BS)
microscopy with a sensitivity of 92% and a specificity of 88%;
moreover, RDTs resulted in improved adequate treatment and
health outcomes [10]. Importantly, the previous study was
conducted when P. falciparum malaria was responsible for
approximately 30% of febrile illness in primary health care
facilities in Zanzibar [10,11]. This is in marked contrast to the
present situation, when overall ,3% of fever patients have
confirmed P. falciparum infection [12].
Based on the above, three critical scientific questions can be
identified: Firstly, does HRP2 based RDT remain an efficient tool
for P. falciparum detection in the new epidemiological context in
Zanzibar? This should be evaluated not only against conventional
BS microscopy but also against highly sensitive PCR as gold
standard, considering that the relative importance of parasitemias
below the detection limit of RDT/microscopy may increase in low
transmission settings [13,14,15]. Secondly, is malaria RDT, as an
integrated part of the recently adopted local version of the IMCI
algorithm, a reliable tool to both identify and rule out malaria
infection in children below five years of age? Thirdly, and
importantly, do primary health care workers continue to adhere to
RDT results when over 95% of the tests are negative and
alternative diagnostic tools for fever management are scarce?
The aim of this study was therefore to evaluate the usefulness of
HRP2 based RDT in the hands of primary health care workers,
including its performance within the local version of the IMCI
algorithm, for P. falciparum case detection, and adherence to test
results among fever patients in the new epidemiological context of
low malaria transmission in Zanzibar.
Methods
Study Design, Area and Sites
This work was a health facility based observational study
conducted in twelve primary health care facilities, six each in
North A (Unguja Island) and Micheweni (Pemba Island) districts
of Zanzibar, between May and July 2010. None of these health
facilities were part of our previous RDT study from Zanzibar [10].
The two study districts are mainly rural with approximately
100,000 inhabitants each. P. falciparum is the predominant malaria
species and Anopheles gambiae complex the main vector. Malaria
transmission has historically been stable with peaks related to the
seasonal rainfalls in March to May and October to December.
Following a successful malaria control programme the BS/RDT
positivity rate among fever patients has markedly declined during
the last decade in Zanzibar to reach 0.6% and 2.2%, respectively,
in North A and Micheweni districts in 2009 [12].
Public health care in the study area is delivered through twelve
primary health care units (PHCU) and one primary health care
centre (PHCC) per district. The PHCUs provide basic out-patient
care including malaria RDT for fever management, whereas the
PHCCs in addition to basic out-patient care also have facilities for
in-patient care and laboratory services, e.g. routine use of
microscopy for confirmatory malaria diagnosis.
The twelve study sites were purposely selected, i.e. one PHCC
and five PHCU from each district. This was done to ensure an
adequate manpower capacity, with at least two health workers
available per study site during the conduct of the trial, and to
provide a balanced geographical distribution of the study sites in
the respective districts.
Study Staff and Pre-study Training
A total of 33 nurses and clinical officers with formal prescription
rights from Zanzibar Ministry of Health were responsible for the
outpatient care in the twelve study sites. All study staff members
were previously trained in malaria case management by the
Zanzibar Malaria Control Programme (ZMCP). Based on
previous IMCI training, the health workers received either a six-
day refresher course or an eleven-day full course on the recently
adopted IMCI guidelines in Zanzibar in which malaria RDT has
been integrated in the algorithm [3]. In addition to the IMCI
training and prior to the study start, all study staff members also
received a one-week study specific training including good clinical
practice, ethical considerations and provision of informed consent,
data recording in case record forms (CRF), blood sampling for BS
and filter papers as well as performance and interpretation of
RDT (Paracheck PfH) according to the manufacturer’s instruc-
tions. During the pre-study training the study staff members were
encouraged to adhere to the IMCI guidelines for management of
children below five years of age and the national malaria
guidelines, which recommend anti-malarial medicines to be
prescribed based on laboratory confirmation of malaria [2].
However, they were free to manage patients according to their
own clinical judgement during the conduct of the trial. Prior to the
first enrolment a pilot study with ‘‘dummy runs’’ was conducted in
all participating study sites.
All health workers received a fixed monthly salary as top ups for
their study participation according to standard practice in
Zanzibar, whereas study participants did not receive any
incentives.
Patient Enrolment and Management
Patients were eligible if aged $2 months and presenting at the
study sites with fever, i.e. measured axillary temperature of
$37.5uC or a history of fever during the preceding 24 hours, and
willing to provide written informed consent (proxy consent from
parents/guardians for children) to participate in the study. Patients
were excluded and referred in case of any symptoms of severe
disease or danger signs. Patients were recruited Monday to Friday
between eight am to four pm by the study health worker on duty in
the respective study sites. Children aged 2–59 months, hereafter
referred to as ‘‘,5 years’’, were managed according to the local
IMCI guidelines. The study included a single visit for each
participant.
Upon enrolment a sealed envelope was opened containing a
study reference number and information on whether the
individual had been randomly selected for additional blood
sampling (see below). This was followed by a capillary finger prick
for performance of RDT. All RDT positive patients and a pre-
defined computer generated random sample (www.randomization.
com) of 20% of all study participants were subjected to additional
capillary blood sampling for malaria microscopy (thick BS) and
PCR (approximately100 mL spotted on a Whatmann 3 MM filter
paper).
Basic demographical data, axillary temperature (measured with
a digital thermometer), history of fever in the preceding 24 hours,
other symptoms, previous anti-malarial treatment (in case of
pregnancy use of intermittent presumptive treatment (IPTp)),
whether the patient slept under an insecticide treated nets/long
lasting insecticidal nets (ITN/LLIN) the night before study
enrolment and travel history (defined as having spent at least
one night outside the home Shehia, i.e. the smallest administrative
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unit in Zanzibar, in the last 28 days) were recorded in a CRF
together with information on RDT-result and clinical manage-
ment.
The RDT results were provided directly to the patients by the
study staff. Anti-malarial medicines according to national guide-
lines, i.e. artesunate-amodiaquine (first-line) or oral quinine
(second-line), antibiotics (cotrimoxazole, ampicillin, amoxicillin
or erythromycin) and antipyretics (e.g. paracetamol) were available
free of charge to all study participants. Patients and guardians
were encouraged to return if the clinical condition deteriorated or
if the fever persisted.
In case malaria parasitemia was first detected by first BS
microscopy reading and missed by RDT diagnostic (see below),
the result was reported to the health facility and the patient was
traced and offered treatment if he/she did not receive anti-
malarial medicines at the time of the study visit.
All CRFs were collected by trained health staff at the end of
each day and stored centrally in Zanzibar. During the conduct of
the study, no results were disclosed to the health workers.
However, after study completion, preliminary results were
disseminated to all health workers in both districts.
Laboratory Methods
RDT. We used Paracheck Pf (Orchid Biomedical Systems,
Goa, India) detecting P. falciparum specific HRP2 antigen, which
by the time of trial was the RDT device deployed by ZMCP. The
tests were performed and interpreted according to the manufac-
turer’s instructions. Very faint bands at the test line position were
to be assessed as a positive test result. Band intensity was not
recorded.
Blood smear microscopy. BS were prepared on site, stored
in slide boxes and transported daily to the district central level,
where all slides were stained with 5% Giemsa for 30 minutes and
examined under oil immersion (6100 magnification) by two
independent and experienced microscopists blinded to both the
RDT and each other’s microscopy result [16]. Asexual parasite
densities were calculated against 200 white blood cells (WBC),
assuming 8,000 WBC per microliter of blood. BS were defined
negative if no parasites were found after examining 100 high
power microscopy fields. BS with discordant results between the
two readers, i.e. positive versus negative, difference in species
diagnosis or a difference of .50% in parasite density, were re-
examined by a third expert microscopist at Karolinska Institutet,
Stockholm, Sweden. The mean of the two most concordant
parasite counts were used for calculating the final parasite density
[17]. Moreover, all BS from patients with discrepancies between
RDT and PCR results, RDT and BS results or PCR and BS
results were subjected to a third decisive microscopy reading at
Karolinska Institutet.
Filter paper. The blood samples (approximately 100 mL)
collected on filter papers (Whatmann 3 MM) were dried
thoroughly, put in individual zipped plastic bags containing
desiccant and stored in room temperature (,25uC) in Zanzibar
until completion of the study and then transported to Karolinska
Institutet for molecular analyses.
DNA extraction. DNA was extracted from three filter paper
punches (Ø 3 mm) using a modified version of the ABI 6100
Nucleic Acid Prep Station protocol (Applied Biosystems, Fresno,
CA) [18]. In samples with discrepancies between RDT and PCR
results, DNA was re-extracted from the filter papers using Chelex-
100 [19].
DNA extraction quality control. The presence of human
DNA was analysed by real-time PCR in case of PCR-negative
results in RDT positive samples [20].
Parasite detection by PCR. For the purpose of an ongoing
genotyping project all RDT positive samples were analysed with
three previously described P. falciparum specific nested PCR
methods targeting the four antimalarial drug resistance markers
P. falciparum multidrug resistance gene 1 (pfmdr1) N86Y, Y184F,
D1246Y and P. falciparum chloroquine resistance transporter gene
(pfcrt) K76T [21,22]. The RDT negative samples were screened in
duplicate for human plasmodial infection with an 18s real-time
PCR [23] Samples with a cycle threshold (Ct) value ,42 were
selected for species identification. Samples with discrepant RDT
and PCR results were re-extracted and subjected to a confirmatory
nested PCR analysis targeting Plasmodium cytochrome b [19]. PCR
positivity was defined as a positive PCR result that could be
validated by at least one other PCR method or by parasite
detection by microscopy.
Analysis of P. falciparum HRP2 deletion. All samples with
a negative RDT but a positive microscopy and/or PCR result
were subjected to PCR analysis of HRP2 deletion according to a
previously described protocol [24].
Adherence to RDT Results
Assessment of adherence to RDT results was done based on a
comparison between the reported RDT outcome and prescription
of anti-malarial drugs. Adherence was defined as prescription and
absence of prescription of anti-malarial drug (first or second line)
in RDT positive and negative patients, respectively.
Sample Size Calculation, Study Endpoints, Data
Management and Statistical Analysis
The sample size calculation was based on the primary endpoint,
i.e. adherence to malaria RDT results, with the assumption that
approximately 10% of the RDT negative patients are prescribed
ACT in Zanzibar [10]. The minimal sample size for independent
observations would be 864 patients when requiring a maximum
length of +/22% for a 95% confidence interval (CI). Considering
a potential clustering effect on health facility level we calculated
that a sample of minimum 3054 patients would allow for an intra-
cluster coefficient of slightly over 0.01 and still fulfil the given level
of precision.
Secondary endpoints included sensitivity, specificity, positive
and negative predictive values of HRP2 based RDT for P.
falciparum detection compared with both PCR and BS microscopy;
performance of malaria RDT as an integrated part of the local
IMCI algorithm in Zanzibar (assessed as a sub-group analysis of
sensitivity, specificity, positive and negative predictive values in
children aged ,5 years compared with other age groups); and
antibiotic and antipyretic treatment across age-groups, i.e. ,5, 5–
14 and .14 years, among RDT positive and negative patients.
Data were double entered in CSPro, validated using Microsoft
Excel and subsequently exported to STATA 12 software where all
statistical analyses were performed. All frequencies, proportions
and odds ratios (ORs) were calculated with 95% CIs and
corresponding p-values, as appropriate. Adjustments for clustering
on health facility level were done using mixed effect models.
To account for the fact that blood sampling for BS microscopy
and PCR among RDT negative patients only included a random
sample of 20%, we multiplied the absolute number of observations
in these groups with a factors of 5.14 and 5.01 in all calculations of
RDT sensitivity and specificity against PCR and microscopy,
respectively. The corresponding confidence intervals were, how-
ever, based on the true sample size. Statistical significances were
stated at the 5% level.
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Ethical Considerations
The study was conducted in accordance with the principles
stated in the latest version of the Declaration of Helsinki and Good
Clinical Practice [25]. It was approved by the Zanzibar Medical
Research Ethics Committee (ZAMREC) and the Regional Ethics
Committee, Stockholm, Sweden. The study is registered on
ClinicalTrials.gov with study identifier ‘‘NCT01002066’’.
Results
The flow of patients through the trial is outlined in Figure 1 and
baseline characteristics of the RDT positive and negative groups
are presented in Table 1. Among the 3890 patients enrolled one
was excluded due to an inconclusive RDT result. Overall 121/
3889 (3.1%) patients were RDT positive. The highest RDT
positivity rate, i.e. 32/528 (6.1%), was found in children aged 5–14
years. There was an uneven distribution of RDT positivity rates
between the two districts, i.e. North A 42/2225 (1.9%) and
Micheweni 79/1665 (4.7%), and also between their respective
study sites with 53 (67.1%) of all RDT positive patients in
Micheweni district reported from Tumbe PHCU only. RDT
positivity was statistically significantly associated with absence of
ITN/LLIN use [OR 4.78 (95% CI 3.24–7.02)] and history of
travel within the last 28 days [OR 3.27 (95% CI 2.05–5.07)]
(Table 1).
The distribution of positive RDT, PCR and BS results as well as
microscopy determined parasite densities across age groups are
shown in Table 2.
Figure 1. Study flow chart. (BS =blood smear, FP = filter paper, PCR=polymerase chain reaction.).
doi:10.1371/journal.pone.0072912.g001
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The RDT sensitivity, specificity, positive and negative predictive
values against PCR and BS microscopy are presented in Table 3.
There was no significant difference in RDT performance in
children aged ,5 years, i.e. tested and managed within the IMCI
algorithm, and other age groups (data not shown).
There were four and eleven RDT positive patients with negative
PCR and BS results, respectively. Importantly seven patients had
both positive RDT and PCR verified P. falciparum infection, but BS
microscopy could not detect parasitemia. Some, 6/739 (0.8%)
RDT negative patients had detectable parasitemia by BS
microscopy; all but one aged $5 years, of whom three were from
Tumbe PHCU (Micheweni). Four of these six patients had high
parasite densities, i.e. 3573, 14420, 25779, 50190 parasites/mL,
respectively, whereas the remaining two had low parasite counts of
ten and 50 parasites/mL each. All six were also positive by PCR,
five for P. falciparum and one for P. malariae. The P. malariae PCR
positive sample had a low parasite density of ten parasites/mL, as
determined by BS microscopy, i.e. insufficient to allow accurate
species identification. Further PCR analysis could not detect P.
falciparum HRP2 deletions in any of these samples. Four of the
RDT negative patients had a positive first BS microscopy reading.
They were all successfully traced at home and received treatment
with artesunate-amodiaquine. None had developed symptoms/
signs of severe malaria between day of study visit and time of
active follow-up.
Prescription of anti-malarial medicines, antibiotics and antipy-
retics by RDT result and age group are shown in Table 4. All 121
RDT positive, but only 3/3768 (0.1%) of RDT negative patients,
all aged .14 years, were prescribed anti-malarial medicines.
Overall adherence to RDT results was thus 3886/3889 (99.9%).
Table 1. Baseline characteristics.
RDT + RDT 2 Total (N)
District North A 42 (34.7%) 2182 (57.9%) 2224
Micheweni 79 (65.3%) 1586 (42.1%) 1665
Age 5 y 36 (29.8%) 1786 (47.4%) 1822
5–14 y 32 (26.4%) 496 (13.2%) 528
.14 y 53 (43.8%) 1472 (39.1%) 1525
Data missing 0 14 (0.3%) 14
Sex Male 65 (53.7%) 1611 (42.8%) 1676
Female 56 (46.3%) 2156 (57.2%) 2212
Data missing 0 2 (100%) 2
Pregnancy 3 (2.5%) 87 (2.3%) 90
RDT + RDT 2 P-value
Mean axillary temp.˚C 38.3 37.4 ,0.001
Proportion withaxillary temp.
$37.5uC
74 (66.7%) 1465 (41.5%) ,0.001
Data missing 10 (8.3%) 240 (6.4%) 0.350
ITN/LLIN use 65 (53.7%) 3193 (84.7%) ,0.001
Travel history #28 days 30 (24.8%) 356 (9.5%) ,0.001
Domestic 21 (17.4%) 325 (8.6%) 0.003
Abroad 9 (7.4%) 31 (0.8%) ,0.001
Domestic =History of travel within Zanzibar.
Abroad =History of travel outside Zanzibar.
ITN= Insecticide-treated nets.
LLIN = long-lasting insecticidal nets.
doi:10.1371/journal.pone.0072912.t001
Table 2. Distribution of P. falciparum positive rapid diagnostic test (RDT), polymerase chain reaction (PCR) and blood smear (BS)
microscopy results as well as microscopy determined parasite density across age groups.
Age groups Total
,5 y n = 1822 5–14 y n = 528* .14 y n = 1525*
RDT + 36 (2.0%) 32 (6.1%) 53 (3.5%) 121
PCR + 34 (1.9%) 34 (6.4%) 56 (3.7%) 124
BS + 31 (1.7%) 33 (6.3%) 52 (3.4%) 116
Geometric mean parasite density/mL
(range)
13815 (50–597,500) 14172 (12–782,400) 3739 (6–184,500)
*Data on specific age categories (5–14 y and .14 y) were missing from14 patients.
doi:10.1371/journal.pone.0072912.t002
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Among the 124 patients that were prescribed anti-malarial
medicines, 119 (96.0%) received artesunate-amodiaquine, four
(3.2%) quinine and the remaining one (0.8%) a combination of
artesunate-amodiaquine and quinine.
Antibiotics were prescribed to a total of 2218/3889 (57.0%)
patients, of whom 24 (1.1%) received prescription of more than
one antibiotic. Some 1338 (60.3%) received cotrimoxazole, 573
(25.8%) ampicillin/amoxicillin, 288 (13.0%) penicillin, 33 (1.5%)
erythromycin, 29 (1.3%) metronidazole and 18 (0.8%) ciproflox-
acin, respectively. RDT negative patients were overall statistically
significantly more likely to receive antibiotics than RDT positive
[OR 3.25 (95% CI 2.15–5.01)]. However, among children ,5
years of age the rate of antibiotic prescription was similar between
the groups, i.e. 57% and 58% in the RDT negative and RDT
positive group, respectively. Among RDT positive patients, no
statistically significant difference between children,5 years and
patients aged $5 years was observed [OR 1.36 (95% CI 0.77–
2.30)].’’
Antipyretics were prescribed to 1689/3889 (43.4%) patients of
whom 1558 (92.2%) received paracetamol and the remaining 122
(7.2%) non-steroidal anti-inflammatory drugs including acetylsa-
licylic acid. There was a balanced distribution of antipyretic
prescription between the RDT positive and RDT negative group.
However, children ,5 years were overall statistically significantly
less likely to receive antipyretics than patients aged $5 years [OR
0.22 (95% CI 0.19–0.26)].
Discussion
The rapid transition from high to low malaria transmission
recently observed in various areas of sub-Saharan Africa, including
Zanzibar, constitutes a major challenge to ensure sustained high
parasite-based P. falciparum diagnostic accuracy with malaria RDT
among fever patients and high adherence to RDT results among
health care workers. This is critical for safe and rational fever case
management, including targeted ACT treatment to patients with
confirmed malaria infection. The present study was therefore
undertaken to assess if HRP2 based RDT remains an efficient tool
for P. falciparum case detection among fever patients in Zanzibar,
not only against BS microscopy but also against highly sensitive
PCR, and if primary health care workers continue to adhere to
RDT results in the new epidemiological context of low malaria
transmission. Further, we scientifically evaluated, for the first time
in Africa, the performance of RDT as an integrated part of the
newly adopted IMCI algorithm in Zanzibar.
The observed diagnostic accuracy of HRP2 based RDT
(Paracheck-Pf) for P. falciparum detection in this study indicates a
relatively low sensitivity but a high specificity when compared with
both BS microscopy and PCR. Since our previous report from
Zanzibar [10], conducted when P. falciparum malaria was
responsible for approximately 30% of fever episodes, the sensitivity
of RDT against BS microscopy declined from 92% to 79%,
whereas the corresponding specificity increased from 88% to 99%.
The latter may reflect an overall reduced risk of repetitive malaria
infections and remaining antigenemia from a previous malaria
episode in the new low transmission context in Zanzibar.
However, the relatively low sensitivity of Paracheck-Pf, i.e. below
the reported sensitivity for P. falciparum detection for this RDT
device in the most recent WHO/FIND evaluation [26], is a
concern especially since the fact that similar observations have
been documented in other low transmission areas [14]. Even lower
RDT sensitivities than we observed have been reported from other
studies i.e. 65% against BS microscopy in Rufiji district of
Tanzania [27] and 69% against PCR in two Tanzanian hospitals
[8].
Table 3. Rapid diagnostic test (RDT) sensitivity, specificity, positive and negative predictive value against polymerase chain
reaction (PCR) and blood smear (BS) microscopy.
PCR + PCR – Total BS+ BS2 Total
RDT + 117 4 121 110 11 121
RDT – 7* 726* 733 6** 733** 739
Total 124 730 854 116 744 860
Sensitivity 76.5% (95% CI 69.0– 83.9%) 78.6% (95% CI 70.8–85.1)
Specificity 99.9% (95% CI 99.7– 100%) 99.7% (95% CI 99.5–99.9%)
Positive predictive value 96.7% (95% CI 91.8– 99.1%) 91.7% (95% CI 84.3–95.4%)
Negative predictive value 99.0% (95% CI 98.0– 99.6%) 99.2% (95% CI 98.8–99.5%)
*For calculations of sensitivity and specificity the absolute numbers in the RDT negative group were multiplied with a factor of 5.14 to account for that only a sub-
sample, i.e. 733 of 3768, in this group were subjected to blood sampling on filter paper for PCR.
**For calculations of sensitivity and specificity the absolute numbers in the RDT negative group were multiplied with a factor of 5.01 to account for that only a sub-
sample, i.e. 739 of 3768, in this group were subjected to blood sampling for BS microscopy.
doi:10.1371/journal.pone.0072912.t003
Table 4. Prescription of anti-malarial medicines, antibiotics
and antipyretics by rapid diagnostic test (RDT) result and age
group.
Prescription Age RDT + RDT 2 P-value
Anti-malarial
medicines
,5 y 36/36 (100%) 0/1786 (0%) ,0.001
5–14 y 32/32 (100%) 0/496* (0%) ,0.001
.14 y 53/53 (100%) 3/1472* (0.2%) ,0.001
Antibiotics ,5 y 20/36 (55.6%) 1032/1786 (57.8%) .0.999
5–14 y 8/32 (25.0%) 341/496* (68.8%) ,0.001
.14 y 6/53 (11.3%) 804/1472* (54.6%) ,0.001
Antipyretics ,5 y 14/36 (38.9%) 437/1786 (24.5%) 0.053
5–14 y 19/32 (59.4%) 278/496* (56.0%) 0.855
.14 y 34/53 (64.2%) 894/1472* (60.7%) 0.669
*Data on specific age categories (5–14 y and .14 y) were missing from14
patients.
doi:10.1371/journal.pone.0072912.t004
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The relatively low sensitivity may be at least partly due to sub-
optimal RDT performance of individual health care workers,
considering that approximately half of all RDT negative but BS
positive cases were reported from the same health facility. This
calls for improved systems for RDT supervision and quality
control in primary health care facilities, but also for more sensitive
point-of-care malaria diagnostic tools. Other factors, unrelated to
health care workers performance, such as presence of P. falciparum
HRP2 deletions and sequence variation as well as the so called
‘‘prozone effect’’, need to be considered as a potential cause of the
relatively low RDT sensitivity, particularly since the HRP2 based
RDT failed to detect four cases of relatively high P. falciparum
density, i.e. 3573, 14420, 25779 and 50190 parasites/mL,
respectively [24,28,29]. Importantly, we did not detect any case
of P. falciparum HRP2 deletions in these samples, which is in
contrast to observation from Mali in West Africa [30]. However,
HRP2 sequence variation was not analysed, since previous studies
have not been able to link RDT sensitivity with sequence variation
in clinical malaria infections with parasite densities $200
parasites/mL. Whether a prozone effect, defined as a false-negative
result in an immunological reaction due to an excess of either
antigens or antibodies, occurred in any of our samples could not
be assessed retrospectively since blood was not available for serial
dilution. Of note is though that the prozone phenomenon has
previously been described primarily in patients with P. falciparum
hyperparasitemia ($250,000 parasites/mL) [31].
This study confirms our previous observations from Zanzibar of
an excellent adherence to RDT results among primary health
workers [10]. It is indeed reassuring that health care workers in
Zanzibar continue to rely on RDT results in a context where
overall 97 out of 100 tests are negative and scarce tests facilities for
diagnosing alternative causes of fever causes are available. With
our results in mind and considering the contradictory reports of
adherence to RDT results from various levels of health care and
epidemiological settings in sub-Saharan Africa [5,6,8,32], we have
conducted a qualitative pilot study to explore context specific
determinants of RDT perception among health care workers in
Zanzibar in order to improve the understanding of factors
influencing adherence to RDTs [33]. However, it should be
acknowledged that the health care workers enrolled in our study
all received a relatively extensive pre-study training. Moreover,
they are all working in an area where other malaria research
activities have been conducted in recent years. These factors may
have contributed to the high adherence to RDT results, which
may not necessarily be representative for the general primary
health care worker in Zanzibar.
The incorporation of malaria RDT in IMCI provides an
opportunity for improved childhood fever case management in
Africa. This study is, to our knowledge, the first scientific evidence
from sub-Saharan Africa that RDT can be reliably integrated in
IMCI. There was neither any difference in RDT performance nor
in adherence to RDT test results in children ,5 years of age
compared with other age groups. The ability of HRP2 based RDT
to reliably rule out malaria infection in a low transmission setting is
critical. However, to ensure a sustainable adherence to particularly
RDT negative results, health care workers need to be trained and
equipped with tools for improved management of non-malarial
fevers. A prerequisite for such improved non-malarial fever
management is to study the etiology of acute uncomplicated
fevers in rural settings of Zanzibar. Such studies, which are
ongoing, will in addition provide data on antibiotic requiring
bacterial infections among fever patients in Zanzibar. This is
critical, since the observed antibiotic prescription rate of 55–65%
among RDT negative patients in all age groups as well as RDT
positive children ,5 years of age (in the form of dual treatment
with ACT) probably represents a substantial overuse, which may
fuel development and spread of antibiotic resistance.
Our observation of low P. falciparum parasite prevalence among
fever patients in Zanzibar is coherent with official programmatic
data [12]. Interestingly, the highest RDT positivity rate was found
in children aged 5–14 years, not in children ,5 years.
Furthermore, there was an apparent uneven spatial distribution
of RDT positivity rate both within and between the study districts.
These changing malaria epidemiological patterns, together with
the association between the risk of RDT positivity and absence of
ITN/LLIN use as well as travel history, need to be considered in
future malaria control activities in Zanzibar.
In summary, the sensitivity of HRP-2 based RDT in the hands
of primary health care workers compared with both PCR and
microscopy for P. falciparum case detection was relatively low,
whereas adherence to test results with anti-malarial treatment was
excellent. Moreover, the results provide evidence that RDT can be
reliably integrated in IMCI as a tool for improved childhood fever
management. However, the overall relatively low RDT sensitivity
highlights the need for improved quality control of RDT use in
primary health care facilities, but also for more sensitive point-of-
care malaria diagnostic tools in the new epidemiological context of
low malaria transmission in Zanzibar.
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Abstract
Background: Rapid diagnostic test (RDT) is an important tool for parasite-based malaria diagnosis. High specificity
of RDTs to distinguish an active Plasmodium falciparum infection from residual antigens from a previous infection is
crucial in endemic areas where residents are repeatedly exposed to malaria. The efficiency of two RDTs based on
histidine-rich protein 2 (HRP2) and lactate dehydrogenase (LDH) antigens were studied and compared with two
microscopy techniques (Giemsa and acridine orange-stained blood smears) and real-time polymerase chain reaction
(PCR) for assessment of initial clearance and detection of recurrent P. falciparum infections after artemisinin-based
combination therapy (ACT) in a moderately high endemic area of rural Tanzania.
Methods: In this exploratory study 53 children < five years with uncomplicated P. falciparum malaria infection were
followed up on nine occasions, i.e., day 1, 2, 3, 7, 14, 21, 28, 35 and 42, after initiation of artemether-lumefantrine
treatment. At each visit capillary blood samples was collected for the HRP2 and LDH-based RDTs, Giemsa and
acridine orange-stained blood smears for microscopy and real-time PCR. Assessment of clearance times and
detection of recurrent P. falciparum infections were done for all diagnostic methods.
Results: The median clearance times were 28 (range seven to >42) and seven (two to 14) days for HRP2 and LDH-
based RDTs, two (one to seven) and two (one to 14) days for Giemsa and acridine orange-stained blood smear and
two (one to 28) days for real-time PCR. RDT specificity against Giemsa-stained blood smear microscopy was 21% for
HRP2 on day 14, reaching 87% on day 42, and ≥96% from day 14 to 42 for LDH. There was no significant
correlation between parasite density at enrolment and duration of HRP2 positivity (r = 0.13, p = 0.34). Recurrent
malaria infections occurred in ten (19%) children. The HRP2 and LDH-based RDTs did not detect eight and two of
the recurrent infections, respectively.
Conclusion: The LDH-based RDT was superior to HRP2-based for monitoring of treatment outcome and detection
of recurrent infections after ACT in this moderately high transmission setting. The results may have implications for
the choice of RDT devices in similar transmission settings for improved malaria case management.
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Background
Parasite-based Plasmodium falciparum diagnosis is gen-
erally recommended by the World Health Organization
(WHO) to target artemisinin-based combination therapy
(ACT) to patients with confirmed malaria infections [1].
This is important in order to prevent overuse of ACT,
reduce costs, minimize development and spread of anti-
malarial drug resistance and to improve management of
other causes of fever [2,3]. The availability of malaria
rapid diagnostic tests (RDTs) constitutes an opportunity
for parasite-based malaria diagnosis in rural African set-
tings beyond the reach of microscopy services [4].
Malaria RDTs are based on detection of parasite anti-
gens. The main antigen targeted is histidine-rich protein
2 (HRP2), which has proven to be a highly sensitive and
stable marker for identification of P. falciparum infec-
tion. However, a concern with HRP2-based RDTs is the
presence of residual antigenaemia resulting in persistent
positive test results during several weeks after a success-
ful treatment [5,6]. This is of particular concern in
moderate/high transmission areas where false positive
RDTs may frequently result in provision of anti-malarial
treatment to patients who are not malaria infected. This
phenomenon may also impair health workers trust in
and adherence to RDT results [7,8].
Another antigen used in RDTs is parasite-specific
lactate dehydrogenase (LDH), either species specific, i.e.,
P. falciparum LDH (PfLDH) and Plasmodium vivax
(PvLDH), or pan-Plasmodium (pLDH), detecting all five
human malaria species [9]. LDH-based RDTs have gen-
erally been shown to be less heat stable and sensitive
than HRP2-based RDTs for detection of P. falciparum,
but they are more specific since LDH is rapidly cleared
from the blood following a successful anti-malarial treat-
ment. Consequently, LDH-based RDTs do not remain
positive after parasite clearance [2,10]. Interestingly,
some recently available PfLDH-based RDTs have shown
sensitivities and heat stabilities similar to HRP2-based
RDTs [11-14].
Previous RDT studies in this particular field have
mainly focused on post-treatment clearance and have
primarily followed patients until the tests have become
negative [12,13]. Thus, insufficient data are available on
the efficiency of RDTs to identify recurrent infections
after recently cleared infections in moderate/high trans-
mission areas. This may be of particular importance in
an era of increasing drug resistant malaria [15]. The aim
of this study was therefore to investigate clearance and
detection of recurrent P. falciparum infections of HRP2
and LDH-based RDTs during 42 days after initiation of
artemether-lumefantrine treatment in children with un-
complicated malaria in a moderately high endemic area
of rural Tanzania. Furthermore, since no previous study
has included clearance by polymerase chain reaction
(PCR) as a comparator, this was done to allow a more
comprehensive evaluation of RDT for monitoring of
anti-malarial treatment outcome. The entire assessment
herein reported thus included two RDTs (HRP2 and
LDH-based) for antigen detection, compared with two
microscopy techniques (Giemsa-stained thick blood
smears and acridine orange-stained thin blood smears)
for whole parasite detection and real-time PCR for de-
tection of parasite DNA.
Methods
Study site and population
This health facility-based study was conducted during
the peak seasons for malaria transmission, in June to
September 2009 and July to October 2010 at Mlandizi
health centre, Kibaha district and during March to
May 2011 in Fukayosi dispensary, Bagamoyo district,
both located in Coast Region, Tanzania. Artemether-
lumefantrine was introduced as first-line treatment for
uncomplicated malaria in 2006 in the study area,
whereas RDT had not yet been implemented for
parasite-based malaria diagnosis. At the time of the
trial malaria transmission was considered to be moder-
ately high in both study sites.
The Mlandizi health centre provides basic in- and out-
patient care for a population of approximately 33,000.
Laboratory services, including malaria microscopy, are
available during office hours. The monthly blood smear
positivity rate among febrile children < five years of age
was 33% (range 20-48%) and 15% (range 11-21%) during
the sampling period in 2009 and 2010, respectively.
There was a period of artemether-lumefantrine stock-out in
Mlandizi in 2009. During this period patient recruitment
was stopped. There was an on-going insecticide-treated
bed net campaign in the area markedly reducing the inci-
dence of malaria among children < five years between 2009
and 2010.
Fukayosi dispensary provides basic outpatient care for
a population of about 7,000. Malaria microscopy service
is available seven days a week. Malaria blood smear posi-
tivity rate was 19% (74/384) among febrile children < five
years of age during the conduct of the trial.
Participating laboratory staff and study nurses at the
two study sites received one day’s training in perform-
ance and interpretation of both RDTs before the start of
the study.
Study design and sample collection
Children between six and 59 months presenting at the
study sites with fever, i.e., measured axillary temperature
of ≥37.5°C or a history of fever during the preceding
24 hours, and a positive screening blood slide for P.
falciparum mono-infection with a parasite density of
2,000-250,000/μL, and willing/able to comply with the
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42 days follow-up were eligible to participate in the
study. Children with a history of anti-malarial drug
intake within two weeks or symptoms/signs of severe
disease were excluded. Written informed consent was
obtained from a parent/guardian of all enrolled children.
At enrolment, i.e., day 0, a complementary finger-prick
capillary blood sample was taken for two thick and thin
smears, and two RDTs. In addition, approximately 50 μL
of blood was spotted on a filter paper. All enrolled
children were treated with artemether-lumefantrine
(Coartem®) in standard doses based on body weight,
according to national treatment guidelines [16]. Only
the initial drug dose was given under supervision. En-
rolled children were requested to return for clinical re-
view and blood sampling on days 1, 2, 3, 7, 14, 21, 28, 35
and 42, or anytime if condition deteriorated or fever re-
occurred. At each follow-up visit all day 0 blood tests
were repeated, except for the Giemsa-stained thin smear,
which was used for confirmation of P. falciparum
mono-infection solely on day 0. A case record form was
completed at enrolment by a clinical officer, with clinical
and demographic information, including age, sex and in-
formation on use of insecticide-treated bed nets. Body
temperature, symptoms and prescription of drugs were
recorded in the case record forms on all visits.
Whenever fever and/or any other symptoms/signs of
disease re-occurred during follow-up, a Giemsa-stained
blood slide was to be read directly at the health centre
and if positive for P. falciparum the child was retreated
with artemether-lumefantrine.
The only incentive given to the study participants was
bus fares to cover travel costs during follow up visits.
Laboratory procedures
Rapid diagnostic tests
Two RDTs, ParaHIT ®f (Span Diagnostics Ltd, Surat,
India), detecting P. falciparum-specific HRP2 antigen
(hereafter referred to as HRP2) and CareStart™ Malaria
(G0151), (Access Bio, Inc, NJ, USA), detecting P. falcip-
arum-specific LDH antigen (hereafter referred to as
LDH), were performed and interpreted on site according
to the manufacturer’s instructions. ParaHit was, at the
time of the study, approved by the Tanzanian National
Malaria Control Programme and was the most deployed
RDT. The single Pf CareStart test was chosen based on
the heat stability and performance of the CareStart pan-
LDH test in the WHO product testing 2009, where it
was among the best performing LDH-based tests for P.
falciparum detection [17]. Both RDTs are two band
tests, i.e., one test band specific for P. falciparum and
one control band.
A laboratory technician or study nurse, blinded to
any Giemsa-stained blood smear result, performed,
interpreted and recorded the RDT results. Very faint
bands at the test line position were to be defined as posi-
tive. Band intensity was not recorded. In case the control
line did not appear, the result was considered invalid
and the test was repeated. The RDT kits were stored
at <30°C prior to use, the temperature being recorded
daily.
Giemsa-stained blood smear microscopy
One of the two thin blood smears collected on day 0
and the thick blood smears from all sampling points
were stained with 5% Giemsa for 20 minutes at the
health facilities, after which they were transported once
weekly to Muhimbili University of Health and Allied
Sciences (MUHAS) in Dar es Salaam. The day 0
Giemsa-stained thin smear was examined for confirm-
ation of P. falciparum mono-infection. One of the two
thick smears was examined by two independent, experi-
enced microscopists, who were unaware of the RDT re-
sults, at MUHAS. A total of 200 microscopic fields
(×100 magnification) were examined before a smear was
considered negative. Asexual parasite densities were cal-
culated by counting parasites against 200 white blood
cells (WBC), assuming 8,000 WBC/μL of blood. If less
than 10 parasites were detected per 200 WBC, estimates
were made against 500 WBC [18]. Gametocytaemia was
assessed by reading 200 microscopic fields. All blood
slides with discrepant results, defined as >50% difference
in parasite density or a positive versus negative result
between the readers, were subjected to a third
blinded reading at Karolinska Institutet (KI), Sweden. In
addition, all blood slides from children showing a nega-
tive thick blood smear and a positive PCR at the same
time point, as well as a random sample of 10% of all
blood slides, plus the blood slides from the time point of
each participant with the last CareStart positive, and the
first CareStart negative results, were subjected to mi-
croscopy reading at KI for quality control. The mean of
the two most concordant counts were used to calculate
the final parasite density [18]. In case of discrepancy re-
garding positive versus negative results between the first
two readers and the third, the third reading at KI was
defined as decisive.
Acridine orange blood slide microscopy
The thin blood smears from all sampling points were
subjected to acridine orange staining and reading at
Muhimbili University Hospital. The thin smears were
fixed in methanol. A solution of 0.01% acridine orange
in phosphate buffer (pH 7.2) with 5% glycerine was then
applied to the smears, which were read in a fluorescence
microscope at ×40 magnification [19]. The results were
recorded as either positive or negative, i.e., parasite
counts were not assessed. The microscopists were un-
aware of all previous RDT and microscopy results.
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DNA detection by PCR
Approximately 50 μL of blood seeded on a filter paper
(Whatman 3MM®) from all sampling points were col-
lected for molecular analysis. The filter papers were
dried and put in individual plastic bags and transported
to KI. The filter papers were stored at <30°C until
processed. Three 3-mm punches (approximately 10–
15 μL) from each filter paper sample were extracted with
a modified version of the ABI 6100 Nucleic Acid Prep
Station protocol (Applied Biosystems, USA) as previ-
ously described [20]. DNA was eluted in 200 μL of
buffer. All samples were analysed for presence of Plas-
modium DNA by an 18S rDNA probe based real-time
PCR assay [21]. A cut-off value for positivity was set at a
cycle threshold (Ct) of <40. All samples were run in
triplicates. Samples where one out of three had a Ct-
value <40 were repeated in triplicates with the same
real-time PCR. Samples with repeated single Ct-values <40
or a Ct average of >38.5 were subjected to a confirmatory/
decisive P. falciparum-specific nested PCR [22]. Two posi-
tive P. falciparum controls (5, 10 or 50 parasites/μL) as well
as negative controls were included in each 96-well PCR
plate.
PCR genotyping to distinguish re-infections from
recrudescence
Filter-paper blood spots from patients with recurrent
PCR positivity during follow-up were re-extracted using
the Chelex-100 method [23]. Stepwise genotyping with
three highly polymorphic genetic markers, i.e., the mero-
zoite surface protein (msp) 1, msp 2 and glutamate rich
protein (glurp) was performed according to standard
protocols to differentiate re-infection (new infection)
from recrudescence (treatment failure). For each marker,
recrudescence was defined as the presence of at least
one matching allelic band and re-infections were de-
fined as the absence of any matching allelic band in
samples at enrolment (day 0) and at day of recurrent
infection [24,25].
Definition of clearance time and recurrent infections
Clearance time was defined as the first sampling day
after initiation of treatment when a test result was nega-
tive. There were two exceptions to this. First, when a
RDT result turned negative for one sampling day,
followed by a positive RDT result again the following
sampling day, the negative result was ignored if the PCR
and/or BS results did not indicate presence of a recur-
rent infection. Second, when one negative PCR result
was followed by a positive PCR result the following sam-
pling day up to day 7, the negative result was ignored.
From day 14 and onwards the clearance time was calcu-
lated from the first day with negative result.
Recurrent infection was defined as detection of P. fal-
ciparum DNA (PCR) confirmed by a positive Giemsa-
stained blood smear microscopy and/or LDH during
follow-up after the initial infection had been cleared.
Study outcomes and statistical analysis
The primary outcomes were clearance time and detec-
tion of recurrent infection with the five diagnostic tests.
Secondary outcomes included specificity of the two
RDTs against Giemsa-stained blood smear microscopy
(gold standard), identification of PCR-adjusted re-infection/
recrudescence among the recurrent infections and correl-
ation between parasite density at enrolment and persistence
of HRP2. In the calculation of correlation between day 0
parasite densities and duration of HRP2 positivity, seven
children were included who had cleared HRP2 positivity
before they were lost to follow-up. These seven children
were not included in any other analysis.
The study was considered exploratory, which pre-
cludes a power calculation. A sample of ≥50 children
was predefined.
Data were entered in Microsoft Excel® and analysed
using STATA 12® software. Categorical variables were
compared using Fisher’s exact test. Pearson linear corre-
lations were calculated in SPSS. Sensitivity and specifi-
city of acridine orange against Giemsa-stained blood
smear microscopy (gold standard) and both microscopic
methods against PCR (gold standard) was calculated.
Statistical significance was stated at the 5% level and
95% confidence intervals (CI) are presented.
Ethical considerations
The study was conducted in accordance with the Declar-
ation of Helsinki and Good Clinical and Laboratory Prac-
tices. It was approved by the Directorate of Research and
Publications, MUHAS (Ref.No.MU//RP/AEC/Vol.XIII/142)
and the Regional Ethics Committee, Stockholm, Sweden.
The study is registered at www.clinicaltrials.gov with
study identifier NCT01843764.
Results
Study subjects
The flow of patients through the trial is outlined in
Figure 1. Two children were excluded from the analysis
due to high parasite densities at enrolment, i.e., 992,000
and 494,400/μL. Another 16 children were not able to
fulfil the stipulated follow-up, the most common reason
being leaving the study area or long distance to the
health centre.
All children were positive with both RDTs at day of
inclusion. Baseline characteristics of the 53 children
included in the analysis are presented in Table 1.
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Clearance time
The calculations for HRP2 clearance are based on the 43
children without recurrent infection during follow-up,
since eight of the ten children with parasite recurrence
remained HRP2-positive from enrolment up to the time
of recurrent infection. All other tests, i.e., LDH, Giemsa
and acridine orange-stained blood smears as well as
PCR cleared before parasite recurrence. Consequently,
clearance calculations for these tests are based on data
from all 53 children. The median clearance times for the
five diagnostic tests are presented in Figure 2 and their
respective positivity rates at each sampling point are
shown in Figure 3.
The geometric mean clearance time for HRP2 was
26.4 (95% CI 23.0-30.3) days. One patient cleared HRP2
by day 7 and three remained positive up to day 42 (last
day of follow-up). The false positivity rates for HRP2
against PCR on days 14, 21, 28, 35 and 42 were 80% (32/
40), 64% (27/42), 43% (18/42), 24% (10/42) and 7% (3/
41), respectively. All PCR positive results were also
Figure 1 Flow of patients through the study.
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HRP2-positive throughout the study. There was no sig-
nificant correlation between parasite density at enrol-
ment and duration of HRP2 positivity (r = 0.13, p = 0.38)
(Figure 4). For LDH the mean clearance time was
5.5 days (95% CI 4.5-6.7). No significant correlation
between parasite density at enrolment and duration of
LDH positivity was observed (r = 0.21, p = 0.11).
The mean clearance time for Giemsa-stained blood
smears was 2.0 days (95% CI 1.8-2.3). Four children (8%)
remained positive by microscopy until day 3. Two children
were microscopy positive day 2 and 3, respectively, with
parasite densities of 16 and 32/μL each. However, PCR was
negative for both samples at these time points. There was
no significant association between clearance times of
Giemsa-stained blood smears and HRP2 (p = 0.50).
Acridine orange-stained blood smears had a mean
clearance time of 2.1 days (95% CI 1.9-2.3). The mean
clearance time for PCR was 2.9 days (95% CI 2.3-3.6).
Persistent PCR positivity up to day 7, 14 and 21 was ob-
served in one, one and two children, respectively. In two
of these four children, solely gametocytes were detected
by Giemsa-stained blood smear microscopy at two and
three sampling points, respectively, during the time of
persistent PCR positivity.
Recurrent infections
Ten children had recurrent P. falciparum infection
during the 42 day follow-up as assessed by PCR,
Giemsa-stained blood smear and/or LDH. One recurrent
infection was defined as recrudescence, six as re-
infections, whereas three were undetermined by PCR
genotyping (Table 2). Eight of these ten children had
remaining HRP2 positivity from the initial infection.
Thus, only two recurrent infections, both occurred on
day 35, were detected by HRP2. Conversely, LDH
detected eight (80%) recurrent infections at the day of
parasite recurrence. Furthermore, one additional child
had a positive LDH result on the following visit.
Giemsa-stained blood smear microscopy identified eight
of the ten recurrent infections, whereas acridine orange
detected one. PCR identified all ten infections at the
time of parasite recurrence. However, six more patients
experienced a single occasion of PCR positivity during
follow-up between days 21 and 42. All these six children
were asymptomatic by the time of the transient PCR
positivity. Except for two patients who were still HRP2-
positive, all other tests were negative at the time of PCR
positivity. Thus, none of the six children fulfilled the def-
inition of recurrent infection. Cumulative positivity by
Table 1 Baseline characteristics of the 53 children
included in the analysis
Age in months, mean 42 (range 10–59)
Sex male/female 35/18
Axillary temperature °C, mean 37.7 (range 37.0-39.0)
Axillary temperature ≥37.5°C 83% (44/53)
Duration of fever, mean days 2.5 (range 1–4)
Other complaints* 64% (34/53)
Geometric mean parasite density /μL 37,640 (range 2,000-250,000)
Sleeping under insecticide-treated
bed net
85% (45/53)
*vomiting n = 18.
abdominal pain n = 9.
cough n = 11.
diarrhoea n = 3.
Figure 2 Median clearance times for the five diagnostic tests. N = number of patients included in the analysis. BS = Giemsa-stained blood
smear. AO = acridine orange-stained blood smear. * Last day of follow-up = day 42.
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the respective diagnostic tests for the ten recurrent in-
fections detected during follow-up is shown in Figure 5.
Five children had fever at the time of detection of recur-
rent infection (Table 2). Four of them had their Giemsa-
stained blood smear read on site and were immediately di-
agnosed and retreated with artemether-lumefantrine. The
fifth child did not have the blood smear read on site due to
symptoms of respiratory tract infection. This child received
antibiotics and improved clinically.
Sensitivity and specificity
The specificities of HRP2 and LDH against Giemsa-
stained blood smear microscopy between days 3 and 42
are shown in Table 3. Compared with PCR the overall
(days 0–42) sensitivities and specificities were 68% (95%
CI 61–75) and 99% (CI % 98–100) for Giemsa, and 61%
(95% CI 53–68) and 98% (95% CI 96–99) for acridine
orange-stained blood smear microscopy, respectively.
The sensitivity and specificity of acridine orange against
Figure 3 Positivity rates at each sampling point by the five diagnostic tests. HRP2 data represent 43 patients and the remaining diagnostic
tests 53 patients. HRP = HRP2 based RDT. LDH = LDH based RDT. BS = Giemsa-stained blood smear. AO = acridine orange-stained blood smear.
PCR = real-time PCR.
Figure 4 Correlation between parasite density at enrolment and duration of HRP2 positivity. N = 52, including 43 children without re-
infection, two with cleared positivity before re-infection and seven with cleared positivity before being lost to follow-up. Correlation coefficient
(r) = 0.13 (p = 0.38).
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Giemsa-stained blood smear microscopy were 81%
(95 CI 73–88) and 97% (95% CI 95–98).
Discussion
The efficiency of two P. falciparum-specific RDTs, i.e.,
HRP2 and LDH were studied for assessment of clear-
ance and detection of recurrent infections during 42 days
after initiation of artemether-lumefantrine treatment.
This was done through a comparison with two micros-
copy techniques and real-time PCR. HRP2 had a
significantly longer median clearance time (28 days)
compared with LDH (seven days). Due to persistent
HRP2 positivity from the initial infection, only two out
of the ten children with recurrent P. falciparum infec-
tions during follow-up were identified by HRP2, whereas
LDH was able to recognize eight at the time of parasite
recurrence. Acridine orange blood smear microscopy did
not provide any additional information compared with
the other tests used in this study.
Clearance
Long clearance times for HRP2-based RDTs after ACT
treatment have previously been shown [6,26,27], with
remaining HRP2 positivity by day 35 in up to 73% of
Table 2 Characterization of the ten recurrent Plasmodium falciparum infections detected during follow-up
Diagnosis
day
Symptom Diagnostic tool Parasites New infection/
PCR Giemsa LDH-RDT /μL Recrudescence2
1 14 A + + 80 New
2 21 A + + + 1,600 New
3 21 R + + undertermined
4 21 1 + + 1 600 recrudescence
5 21 F + + undertermined
6 28 A + + + 316,000 new
7 28 F + + + 229,600 new
8 35 F + + + 61,240 undertermined
9 35 F + + + 9,800 new
10 35 F + + + 33,920 new
A = asymptomatic F = fever R = respiratory tract infection.
1turned positive with fever following visit.
2PCR corrected outcome.
Figure 5 Cumulative positivity by the diagnostic tests for the ten recurrent Plasmodium falciparum infections detected during follow-up.
BS = Giemsa-stained blood smear. AO = acridine orange-stained blood smear.
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patients despite efficacious treatment. Initial parasite
density has been suggested to influence the duration of
HRP2 positivity, but a patient’s immune status may also
be a contributing factor [28].
Similarly with the present findings, a relatively rapid
clearance of LDH has previously been documented
[10,12]. It has been claimed that especially HRP2 but
also LDH are released by immature gametocytes, which
may result in persistent positive test results [5,29]. How-
ever, this opinion has been challenged by others who
argue that the number of gametocytes after ACT treat-
ment are too few to cause persistent positivity [30]. Im-
portantly, in our this study, only four solely gametocyte
carriers were detected by Giemsa-stained blood smear
microscopy, of whom three and none were HRP2 and
LDH positive, respectively, during gametocyte carriage.
Expert blood smear microscopy remains gold standard
for estimation of parasite clearance in clinical trials of
anti-malarial drugs. Blood smear positivity by day 3, i.e.,
72 hours after initiation of ACT treatment, was observed
in 4/53 (8%) of the patients. This is a relatively uncom-
mon finding among African children treated with
ACT for uncomplicated malaria [27,31]. The prolonged
Giemsa-stained blood smear positivity may be explained
by poor compliance since only the initial artemether-
lumefantrine dose, i.e., one out of six doses, was given
under supervision. Similarly, the relatively long mean
PCR clearance time observed may possibly be explained
by poor compliance. The presence of gametocyte car-
riage in patients with prolonged PCR positivity during
follow-up may also have influenced the PCR clearance
time.
Parasite density day 0 and persistent HRP2
No correlation was observed between parasite density at
enrolment and duration of HRP2 positivity. This is in
contrast to several previous publications that report a
strong positive correlation [5,6,26,27]. However, these
studies have generally included a wider range of parasite
densities down to <1,000/μL, where clustering has shown a
shorter HRP2 clearance time in parasitaemias <10,000/μL.
Conversely, Choidini et al. identified a wide range of
HRP2 concentrations at equal parasite densities both
in panels of cultures and of field isolates [32]. Varying
HRP2 concentrations may be dependent on factors
such as the duration of infection, the total parasite
biomass including the sequestered parasites [33] and
anti-HRP2 immune response.
Detection of recurrent infections
In the moderately high transmission area where the
study was conducted, ten (19%) children had recurrent
infection detected between days 14 and 35 during
follow-up. All recurrent infections were detected by
PCR, whereas both the LDH-based RDT and Giemsa-
stained blood smear detected eight, HRP2 identified two
and acridine orange smear microscopy identified only
one of these infections at the time of parasite recurrence.
Few other studies have looked at the efficiency of RDTs
for detection of recurrent infections during follow-up
after anti-malarial treatment. Maxay et al. found in a
study performed in Thailand that 40/92 (43%) patients
experienced recurrent infection during a 28-day follow-
up [5]. All these patients had persistent HRP2 positivity
from enrolment up to day of recurrent infection.
RDTs for assessment of treatment outcome
The usefulness of RDTs for monitoring of anti-malarial
treatment, i.e., clearance time as well as identification of
treatment failure/re-infection, is highly dependent on
test specificity. HRP2-based RDTs appear not to be a
sufficient tool for this. LDH, with a limited but still lon-
ger clearance time as compared with blood smear mi-
croscopy, may be useful but for detection of prolonged
parasite clearance as a sign of emerging artemisinin
tolerance/resistance, it is probably not sufficient.
RDTs for case detection
Sensitivity and specificity of the HRP2 and LDH antigens
for case detection are highly dependent on malaria en-
demicity [27,28]. In high endemic areas HRP2 generally
shows a low specificity, especially among febrile chil-
dren, because a large proportion of residents have
remaining antigenaemia from previous infections. The
generally higher parasite densities observed in high en-
demic areas may also cause longer HRP2 clearance times
affecting the specificity. However, Abeku et al. showed
that in an area of high transmission the specificity in-
creased towards the end of the rainy seasons, and in
older age groups probably due to increased HRP2 anti-
body levels in the population. In low endemic areas the
specificity of HRP2 among febrile patients generally
Table 3 Specificities of the Plasmodium falciparum HRP2
and LDH-based rapid diagnostic tests against Giemsa-
stained blood slide microscopy (gold standard) between
days 3 and 42
HRP2 LDH
Day % CI 95% % CI 95% p-value
3 NA 20/49 41 27-56
7 NA 40/53 76 62-86
14 11/52 21 11-35 51/52 98 90-100 <0.0001
21 17/50 34 21-49 48/50 96 86-100 <0.0001
28 29/49 59 44-73 49/49 100 93-100 <0.0001
35 35/50 70 55-82 48/50 96 86-100 <0.005
42 45/52 87 74-94 50/52 96 87-100 >0.05
NA = not applicable.
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increases due to the low malaria incidence and thus the
low risk of detecting remaining antigenaemia after
cleared infections. LDH, on the other hand, which has
shown a comparatively lower sensitivity for detection of
P. falciparum infections with densities <200/μL, may in
areas of low transmission where parasite densities gener-
ally are lower especially among asymptomatic cases [34],
be a less efficient diagnostic tool than HRP2.
Other limitations with HRP2-based RDTs are the gen-
etic diversity, including the deletions recently described
among African P. falciparum isolates [35,36], as well as
false HRP2 negative results due to the prozone effect
[37]. To date, no genetic LDH diversity/deletion has
been described and LDH-based RDTs are not susceptible
to any prozone effect [38,39]. All these factors should be
considered for the choice of RDT in a specific epidemio-
logical setting.
What does the present study add to the knowledge base
of RDTs?
Previous RDT studies in this particular field have mainly
followed up the study participants until the RDTs have
become negative [12,13]. Conversely, all five diagnostic
tests were assessed up to day 42 after treatment initi-
ation in this report. This study design provides a more
comprehensive assessment both of clearance times and of
recurrent malaria infections for all diagnostic methods,
and importantly assesses the efficiency of the two RDTs
to detect recurrent malaria infections, which has previ-
ously not been reported. Eight of the ten recurrent in-
fections in this study were recognized by LDH at the
day of infection and another one on the following sam-
pling day, whereas HRP2 detected only two of the recur-
rent infections. These results, in combination with the
significantly shorter median clearance time of LDH
compared with HRP2, provide evidence for the former
to be a better tool for monitoring of anti-malarial treat-
ment outcome among children with symptomatic infec-
tion in this moderately high endemic area. In addition,
this study is the first to incorporate PCR as a compara-
tor for assessment of clearance.
Limitations
A general limitation when assessing performance of
parasite based diagnostic tests that indeed detect differ-
ent things such as antigens (RDT), DNA (PCR) or whole
parasites (microscopy) is that the results are not fully
comparable. Furthermore, this is a small study with a
limited number of patients with recurrent infections
detected during follow-up.
Conclusion
The LDH-based RDT was superior to HRP2-based for
monitoring of treatment outcome and detection of
recurrent infections after ACT in this moderately high
transmission setting. The results may have implications
for the choice of RDT devices in similar transmission
settings for improved malaria case management.
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Abstract
Background: The need for new malaria surveillance tools and strategies is critical, given improved global malaria
control and regional elimination efforts. High quality Plasmodium falciparum DNA can reliably be extracted from
malaria rapid diagnostic tests (RDTs). Together with highly sensitive molecular assays, wide scale collection of used
RDTs may serve as a modern tool for improved malaria case detection and drug resistance surveillance. However,
comparative studies of DNA extraction efficiency from RDTs and the field applicability are lacking. The aim of this
study was to compare and evaluate different methods of DNA extraction from RDTs and to test the field
applicability for the purpose of molecular epidemiological investigations.
Methods: DNA was extracted from two RDT devices (Paracheck-PfW and SD Bioline Malaria Pf/PanW), seeded
in vitro with 10-fold dilutions of cultured 3D7 P. falciparum parasites diluted in malaria negative whole blood. The
level of P. falciparum detection was determined for each extraction method and RDT device with multiple nested-
PCR and real-time PCR assays. The field applicability was tested on 855 paired RDT (Paracheck-Pf) and filter paper
(WhatmanW 3MM) blood samples (734 RDT negative and 121 RDT positive samples) collected from febrile patients
in Zanzibar 2010. RDT positive samples were genotyped at four key single nucleotide polymorphisms (SNPs) in
pfmdr1 and pfcrt as well as for pfmdr1 copy number, all associated with anti-malarial drug resistance.
Results: The P. falciparum DNA detection limit varied with RDT device and extraction method. Chelex-100 extraction
performed best for all extraction matrixes. There was no statistically significant difference in PCR detection rates in DNA
extracted from RDTs and filter paper field samples. Similarly there were no significant differences in the PCR success
rates and genotyping outcomes for the respective SNPs in the 121 RDT positive samples.
Conclusions: The results support RDTs as a valuable source of parasite DNA and provide evidence for RDT-DNA
extraction for improved malaria case detection, molecular drug resistance surveillance, and RDT quality control.
Keywords: Plasmodium falciparum, Malaria, Rapid diagnostic test, DNA extraction, Molecular surveillance
Background
The World Health Organization has recommended the
use of malaria rapid diagnostic tests (RDTs) for prompt
and accurate parasitological confirmation of Plasmodium
falciparum malaria in settings where microscopy services
are not available. However, the ability to detect individuals
with asymptomatic low density parasitaemia, i.e., below
detection limit of both RDTs and microscopy (~100 para-
sites/μL blood), in low endemic settings has been increas-
ingly acknowledged as a challenge to achieve malaria
elimination [1]. In this context there is a need for novel sen-
sitive molecular tools and strategies for improved malaria
case detection. Furthermore, molecular tools for monito-
ring the selection of genotypes associated with anti-malarial
drug resistance are critical since they may provide an early
warning system of development and spread of tolerance/
resistance to artemisinin-based combination therapy (ACT)
before clinical treatment failures are apparent.
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The possibility of recovering parasite DNA from RDTs
was first shown by Veron et al. [2]. Thereafter, two add-
itional methods of DNA extraction from RDTs have been
published [3,4] suggesting that RDTs are a reliable source
for parasite DNA preservation. This provides an opportu-
nity for improved molecular surveillance and RDT quality
control. However, and importantly, comparative studies on
the efficiency of the published DNA extraction methods
from RDTs are lacking. This is critical since there is evi-
dence that the efficiency of DNA extraction may be highly
influenced by choice of extraction matrix and method
[3-6]. Furthermore, comprehensive studies are needed to
investigate whether wide-scale collection of RDTs can pro-
vide the basis for modern molecular surveillance of ma-
laria, including both improved malaria case detection and
anti-malarial drug resistance genotyping.
The aims of this study were, therefore, to evaluate two
published DNA extraction methods, in comparison with a
previously unpublished, high-throughput method (Ferreira
P E, unpublished data), and to assess the field applicability
of RDT-DNA extraction for molecular surveillance, in
comparison to DNA extraction from filter paper.
Methods
RDT-DNA extraction methods
Three DNA extraction methods from RDTs were eva-
luated: 1) A simple elution method [3]; 2) Chelex-100 ex-
traction [4]; and, 3) a previously unpublished method
following a modified version of the protocol “isolation of
DNA from fresh or frozen whole blood” employing an ABI
PRISM 6100 Nucleic Acid PrepStation™ and NucPrep re-
agents (Applied Biosystems, USA) (Ferreira P E, unpub-
lished data). In brief, for the third method, the biological
samples were lysed in three-fold volume of NucPrep re-
agents. The lysate mixture was incubated for 1h (instead of
10 min) at 58°C, and the lysed samples were incubated at
4°C overnight before preforming the extraction (as pre-
viously reported) [7]. On day two, the solid material was
separated from the lysate by passing the content through a
5 mL syringe. The full lysate was flowed through one col-
umn per sample in a DNA purification tray II (Applied
Biosystems, USA) by three consecutive loadings. DNA
washing was performed as recommended by the manufac-
turer. Incubation with DNA elution solution 1 was in-
creased from three to five minutes. The final DNA
containing elution volume was 200 μL for ABI extraction,
50 μL in the simple elution method and ~190 μL in the
Chelex-100 extraction (after deduction of 5% Chelex-100
from a total volume of 200 μL).
RDT devices
DNA extraction was compared from two RDT devices of
clinical importance in Zanzibar: Paracheck-PfW (Orchid
Biomedical Systems, Goa, India) and SD-Bioline Malaria
Ag P.f/PanW (Standard Diagnostic, Inc, USA). Paracheck-
Pf has been widely used in sub-Saharan Africa, and was
the first RDT to be implemented in Zanzibar in 2006.
Zanzibar has recently changed to SD-Bioline P.f/Pan as
this test also detects species other than P. falciparum.
Plasmodium falciparum in vitro samples and analysis
Both RDT devices were seeded according to the manufac-
turers’ instructions with 5 μL of 10-fold serial dilutions of
laboratory cultured 3D7 P. falciparum (200,000-0.02 para-
sites/μL) as well as with malaria negative whole blood
(negative control). For comparison, WhatmanW 3MM fil-
ter paper was seeded in parallel with 5 μL (approximately
equivalent to one 3-mm punch) of the serial dilution.
Parasite cultures and malaria negative whole blood were
lysed by freeze-thawing prior to serial dilution.
The RDTs and filter papers were allowed to air dry for a
minimum of 16 hours at room temperature (20°C), where-
after RDT cassettes were opened using a thin metal spatula.
The nitrocellulose strip was held at the buffer pad with for-
ceps and cut into 3 × 3 mm pieces using scissors. In be-
tween each sample, forceps and scissors were washed in
70% ethanol and dried on clean tissue paper, to minimise
cross-contamination during sample preparation. RDT pre-
paration was in accordance with the worldwide antimalarial
resistance network (WWARN) guidelines, with minor
modifications [8]. DNA extraction was compared from four
different RDT fragments (Figure 1), all including the pro-
ximal third of the nitrocellulose strip that has been reported
to generate best results upon DNA extraction [3]. DNA
was extracted using the three methods described above.
The P. falciparum DNA detection limits were deter-
mined using three PCR techniques: 18S ribosomal DNA
(rDNA) nested PCR [9], cytochrome b nested PCR [10],
and 18S rDNA probe-based real-time PCR [11]. The
same volume of DNA was used from each extraction
method (2-5 μL depending on PCR). The P. falciparum
detection limits were determined as the lowest consecu-
tive positive sample in the dilution series.
Field study sampling
The field samples were collected during an RDT effective-
ness study conducted in 12 public health facilities, six each
in North A and Micheweni districts, Zanzibar, May-July
2010 (Shakely et al., submitted). Febrile patients were
tested for P. falciparum malaria with Paracheck-Pf. In pa-
rallel approximately 100 μL of blood was spotted onto
Whatman 3MM filter paper. Paired RDT and filter paper
samples were available from 121 RDT positive and 734
RDT negative patients. Informed consent was obtained
from enrolled patients or parent/guardians of children.
The study was conducted in accordance with the Decla-
ration of Helsinki [12] and Good Clinical Practice [13].
The study is registered as NCT01002066. Ethical approvals
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were obtained from the ethical committee in Zanzibar
(ZAMREC/ST/0021/09) and the Regional Ethics Commit-
tee in Stockholm, Sweden (2009/387-31). All samples were
stored at room temperature with desiccants until the time
of DNA extraction. Samples were transported to Karolinska
Institutet, Sweden, August 2010, where DNA extraction
from RDTand filter paper samples was conducted in paral-
lel within six months after sample collection.
Field sample analysis
DNA was extracted from the paired RDT and filter paper
field samples (N=855) using the ABI PRISM 6100 Nucleic
Acid PrepStation™ method. DNA was extracted from the
distal two thirds (Figure 1C) of the RDT strip, containing
~5 μL blood, as described above, and from three 3-mm
punches of filter paper, containing ~15 μL blood, as de-
scribed previously [7].
RDT negative samples (N=734) were screened using an
18S rDNA real-time PCR assay, that detects all five species
of Plasmodium [14]. Samples were pooled two by two in
384 well plates. Each PCR was performed twice at diffe-
rent time points. Pools with a single Cycle threshold (Ct)
value <40, or a Ct average <42 were selected for multiplex
species identification for P. falciparum, Plasmodium vivax,
Plasmodium ovale and Plasmodium malariae. Samples
were considered PCR positive if positive in the species
identification analysis.
Single nucleotide polymorphisms (SNPs) in pfcrt K76T,
pfmdr1 N86Y, Y184F and D1246Y were analysed with pre-
viously described PCR-RFLP methods in all RDT positive
samples (N=121) [15-17]. An infection was defined as
mixed when both alleles were present at a particular locus.
Pfmdr1 copy number was determined by the comparative
ΔΔCt method following a TaqMan probe-based real-time
PCR [18]. Samples were considered PCR positive if posi-
tive in at least one PCR.
All PCRs were run in parallel on RDT and filter paper
extracted DNA.
Statistical analysis
SNP genotyping outcomes were compared between RDT
and filter paper extracted DNA by kappa analysis (κ).
The SNP and haplotype prevalences were analysed and
published elsewhere [17]. The spread of Ct values below
Figure 1 RDT fragments used for DNA extraction. Each panel
shows Paracheck-Pf (top) and SD-Bioline Malaria Ag P.f/Pan
(bottom). The RDTs are orientated with the buffer pad and sample
site to the left (proximal end), and the absorption pad to the right
(distal end). The fragments used for extraction are outlined by the
black boxes A) 1cm B) Proximal C) Distal D) Whole.
Table 1 Sensitivity of RDT-DNA extraction methods in
in vitro cultured parasites
RDT Fragment Simple elution Chelex-100 ABI
Paracheck-Pf
1 cm § 2 200
Proximal NA 20 200
Distal NA NA 20
Whole NA NA 20
SD-Bioline Malaria P.f/Pan
1 cm 2 2 20
Proximal NA 2 20
Distal NA NA 20
Whole NA NA 20
Filter paper
5 μL blood spot 200 2 200
Lowest achieved parasite detection levels (parasites/μL) for DNA extraction
from Paracheck-Pf, SD-Bioline Malaria P.f/Pan and from 5 μL blood spotted on
filter paper.
§ = Not estimated due to negative results.
NA = Not applicable, the size of the RDT fragment used for extraction was
limited by the extraction volume.
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the cut-off of Ct 35, in the TaqMan probe-based real-
time PCR for determining pfmdr1 copy number, were
compared by Wilcoxon rank-sum test, as there were
many incomplete pairs. All calculations were done with
Stata/SE 12.0, StataCorp LP USA. Statistical significance
was defined as p<0.05.
Results
In vitro cultured parasites - sensitivity of RDT-DNA
extraction methods
The P. falciparum DNA detection limit varied with RDT
device and extraction method (Table 1). When following
the respective protocols, Chelex-100 extraction preformed
best for both RDT devices as well as for extraction from fil-
ter paper, with a detection limit of two parasites/μL. The
ABI extraction method had a 10-fold higher detection limit
of 20 parasites/μL. DNA extraction was generally more ef-
ficient from SD-Bioline Malaria Ag P.f/Pan than from
Paracheck-Pf. The simple elution method was unsuccessful
for DNA extraction from Paracheck-Pf. Increasing the size
of the nitrocellulose strip fragment (as seen in Figure 1)
did not improve the level of detection. The method of
P. falciparum detection influenced the detection limit by
one to two log units (see Additional file 1). DNA extraction
from RDTs was generally equal to or better than DNA ex-
traction from an equal volume (5 μL) of blood spotted on
filter paper.
Field samples - parasite detection and drug resistance
genotyping
There was no significant difference in PCR detection
rates in DNA extracted from RDTs and filter paper. Out
of 855 paired RDT and filter paper field samples, 118
(13.8%; CI 95% 11.4-16.2%) were PCR positive in both
groups of samples (κ=0.94). Among the RDT negative
field samples (N=734), three (0.4%; CI 95% 0.0-0.9%)
and six (0.8%; CI 95% 0.1-1.5%) were PCR positive from
RDT and filter paper extracted DNA, respectively
(κ=0.44). Among the 121 RDT positive field samples,
115 (95.0%; CI 95% 91.1-99.0%) and 112 (92.6%; CI 95%
87.8-97.4%) were PCR positive (κ=0.50). No observed
difference was found in the ability to detect low density
Table 2 PCR success rates and agreement of genotyping outcomes in field samples
RDT PCR success rates N = 121 (%; CI 95%) Filter paper PCR success rates N = 121 (%; CI 95%) Kappa value
Pfcrt K76T 114 (94.2; 89.9-98.5) 104 (86.0; 79.6-92.3) 0.72
Pfmdr1 N86Y 112 (92.6; 87.8-97.4) 109 (90.1; 84.6-95.5) 0.85
Pfmdr1 Y184F 110 (90.9; 85.7-96.2) 107 (88.4; 82.6-94.3) 0.74
Pfmdr1 D1246Y 113 (93.4; 88.8-97.9) 107 (88.4; 82.6-94.3) 0.77
Pfmdr1 copy number 84 (69.4; 61.0-77.8) 77 (63.6; 54.9-72.4) -
Analyses of single nucleotide polymorphisms and pfmdr1 gene copy numbers associated with anti-malarial drug resistance, from RDT and filter paper extracted
DNA collected from 121 RDT positive field samples.
Figure 2 Genotyping outcomes for RDT and filter paper extracted DNA at four key drug-resistance associated SNPs. Stacked bar graph
comparing the genotyping outcomes for RDT and filter paper extracted DNA for pfcrt K76T, pfmdr1 N86Y, pfmdr1 Y184F and pfmdr1 D1246Y. Blue
colour represents pfcrt K76, pfmdr1 N86, Y184 and D1246, whereas red represents mixed infections, and green represents pfcrt 76T, pfmdr1 86Y,
184F and 1246Y, respectively.
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parasitaemia (<100 parasites/μL), although the numbers
were too small to allow for statistical analysis (12 PCR
positives in both RDT and filter paper extracted DNA).
There were no significant differences in PCR success
rates and genotyping outcomes for the respective SNPs in
the 121 RDT positive samples (Table 2). Furthermore,
there was no difference between RDT and filter paper
extracted DNA in the overall ability to detect mixed infec-
tions (Figure 2). Similarly, no statistically significant differ-
ences in the distribution of real-time PCR Ct values below
Ct 35 from RDT and filter paper extracted DNA were ob-
served (PFAM=0.10; PVIC=0.24). No sample contained mul-
tiple pfmdr1 copy number.
Discussion
This is to date the most comprehensive comparative
study of DNA extraction efficiency from malaria RDTs
and assessment of the field applicability of RDT-DNA ex-
traction for molecular surveillance, including detection
of infections and key genetic markers associated with
anti-malarial drug resistance.
DNA extraction efficiency from in vitro cultured
P. falciparum varied with RDT device and extraction
method. The same level of parasite detection as seen in
previous publications was not achieved in this study [3,4].
Different designs of RDT devices affected the DNA ex-
traction efficiency. In particular, DNA recovery from
Paracheck-Pf was unsuccessful when employing the sim-
ple elution method, supporting as previously reported that
plastic seals covering the nitrocellulose strip hamper DNA
recovery [3].
The cost, time, final template volume and the purpose
for DNA extraction should be considered when choosing
extraction method. Although simple elution is the cheapest
and fastest alternative, it is a crude method of DNA extrac-
tion and its use may be limited by RDT design and choice
of PCR [3]. Chelex-100 is relatively inexpensive. The
higher sensitivity observed with Chelex-100 extraction in-
dicates that this method is particularly suitable for low
density parasitaemia in low endemic settings. However, the
Chelex-100 method is moderately labour-intensive and the
DNA may be of lower quality than DNA extracted with
commercially available column-based extraction kits [6].
Another concern is the storage capacity of Chelex-100
extracted DNA, which is thought to be more susceptible
to DNA degradation during sample freeze-thawing [19].
Conversely, ABI extraction is a high throughput method
providing high quality DNA, but at a substantial cost and
requiring specialised equipment. This method had a higher
P. falciparum detection level when compared with Chelex-
100, perhaps explained by loss of DNA on the column.
However, this did not appear to have influenced the field
sample results (see below). Thus, ABI extraction could be
suitable for analyses of RDT positive, symptomatic malaria
patients enrolled in clinical trials. The final DNA containing
volume is also important to take into consideration, as
the concentration of the DNA will affect the parasite de-
tection limits.
In the field analysis, RDTs provided DNA of equal qua-
lity as filter papers, suggesting that RDTs are a valuable al-
ternative to filter paper for DNA storage in the field. High
PCR success rates were obtained from DNA extracted
from RDTs, for key loci in pfcrt and pfmdr1 associated with
anti-malarial drug resistance. SNP and haplotype preva-
lences were analysed and discussed elsewhere [17].
Wide scale collection of used RDTs is currently being
implemented as an integral part of molecular surveil-
lance of malaria in Zanzibar.
Increased deployment of RDTs in health care facilities
and cross-sectional surveys facilitates passive and active
collection of biological material for molecular surveil-
lance. The advantages of using RDTs for DNA storage
include reducing invasive procedures in the field. RDTs
require just one finger prick for both malaria case detec-
tion and preservation of biological material. DNA sto-
rage on filter papers, on the other hand, requires an
initial finger prick for malaria case detection by RDT or
microscopy, followed by a second finger prick, for indi-
viduals with a positive diagnosis for collection of blood
on filter paper. Multiple blood sampling can especially be
problematic in small children and may increase the risk of
mixing/miss-labelling of samples during collection. RDTs
are also easily stored and have either a plastic or card-
board case that protects against cross-contamination. A
disadvantage of RDT-DNA extraction is the limited
amount of biological material (5–15 μL blood). This
makes RDT-DNA extraction a “one shot operation” with
no possibilities for re-extraction, unlike filter paper sam-
pling where a larger amount of blood is usually collected
(50–100 μL).
Conclusions
The results support RDTs as a valuable source of para-
site DNA and provide evidence for RDT-DNA extraction
for improved malaria case detection, molecular drug re-
sistance surveillance, and RDT quality control. However,
the purpose of DNA extraction should be considered
when choosing which extraction method best suits the
type of samples to be analysed.
Additional file
Additional file 1: Sensitivity of RDT-DNA extraction methods in
in vitro cultured parasites. Description: Raw data showing detection
levels for the three PCR methods used in the in vitro part of the study.
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Accurately Detects Malaria DNA from Filter Paper Blood
Samples of Low Density Parasitaemias
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Abstract
Background: Loop mediated isothermal amplification (LAMP) provides an opportunity for improved, field-friendly detection
of malaria infections in endemic areas. However data on the diagnostic accuracy of LAMP for active case detection,
particularly low-density parasitaemias, are lacking. We therefore evaluated the performance of a new LAMP kit compared
with PCR using DNA from filter paper blood spots.
Methods and Findings: Samples from 865 fever patients and 465 asymptomatic individuals collected in Zanzibar were
analysed for Pan (all species) and Pf (P. falciparum) DNA with the Loopamp MALARIA Pan/Pf kit. Samples were amplified at
65uC for 40 minutes in a real-time turbidimeter and results were compared with nested PCR. Samples with discordant
results between LAMP and nested PCR were analysed with real-time PCR. The real-time PCR corrected nested PCR result was
defined as gold standard. Among the 117 (13.5%) PCR detected P. falciparum infections from fever patients (mean parasite
density 7491/mL, range 6–782,400) 115, 115 and 111 were positive by Pan-LAMP, Pf-LAMP and nested PCR, respectively. The
sensitivities were 98.3% (95%CI 94–99.8) for both Pan and Pf-LAMP. Among the 54 (11.6%) PCR positive samples from
asymptomatic individuals (mean parasite density 10/mL, range 0–4972) Pf-LAMP had a sensitivity of 92.7% (95%CI 80.1–98.5)
for detection of the 41 P. falciparum infections. Pan-LAMP had sensitivities of 97% (95%CI 84.2–99.9) and 76.9% (95%CI 46.2–
95) for detection of P. falciparum and P. malariae, respectively. The specificities for both Pan and Pf-LAMP were 100% (95%CI
99.1–100) in both study groups.
Conclusion: Both components of the Loopamp MALARIA Pan/Pf detection kit revealed high diagnostic accuracy for parasite
detection among fever patients and importantly also among asymptomatic individuals of low parasite densities from
minute blood volumes preserved on filter paper. These data support LAMPs potential role for improved detection of low-
density malaria infections in pre-elimination settings.
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Background
In areas of sub-Saharan Africa where malaria elimination is
targeted, new tools and strategies are needed to achieve this
ambitious goal. A critical component to pursue malaria elimina-
tion is to identify and treat all malaria parasite carriers, both
symptomatic patients and asymptomatic individuals through
passive and active case detection, respectively [1]. Importantly,
during the transition from malaria control to pre-elimination and
eventually elimination, the relative importance of low-density
parasitaemias as a reservoir of on-going transmission is expected to
gradually increase [2,3,4]. Conventional point-of-care malaria
diagnostic tools, i.e. microscopical investigation of stained blood
smears and rapid diagnostic tests (RDTs), are not sensitive enough
for reliable detection of low-density parasitaemias, considering
their limit of detection of approximately 100 parasites/mL of blood
in field use [5,6,7]. Conversely, highly sensitive diagnostic tools like
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PCR are hampered by their complexity, need for specialized
laboratory infrastructure and know-how, relatively long time-to-
result and thus lack of field friendliness [8].
Newly described molecular based diagnostic methods, such as
loop-mediated isothermal amplification of DNA (LAMP), provide
an opportunity to raise the target of both efficient passive and
active malaria case detection to include also low-density parasit-
aemias in field settings of endemic areas [2,5,9]. The new
Loopamp MALARIA Pan/Pf detection kit ((LMC 562, Eiken
Chemical Co., Ltd. Tokyo, Japan) consists of two separate
reagents tubes containing vacuum dried reaction mixtures with
primers targeting the mitochondrial DNA sequences of all human
Plasmodium species (Pan-malaria) and Plasmodium falciparum
(Pf), respectively. The kit is designed to address the need for a
molecular test that achieves higher sensitivity and specificity than
microscopy and RDT and at the same time it is more field-friendly
than PCR since it employs temperature stable vacuum dried
reagents requiring no cold transport chain, is easily reconstituted
on site and neither requires a thermocycler for amplification nor a
gel imaging system for result reading [5,10]. The Bacillus
stearothermophilus (Bst) polymerase used in the LAMP method is
also considered more robust than Taq polymerase with regards to
inhibition of the reaction, making it suitable for simple and rapid
DNA extraction methods [11]. A feasibility study has previously
demonstrated that the Loopamp MALARIA Pan/Pf kit can
amplify Plasmodium DNA in less than 40 minutes from samples
containing as low as 2 parasites per microliter (p/mL) of blood,
with a sensitivity and specificity of 93.3% and 100%, respectively,
using nested PCR as reference standard [12]. A recent field study
conducted in a high transmission area of Uganda using venous
blood samples from fever patients has also shown that technicians
without previous molecular training could reliably perform LAMP
in a simple laboratory space without specialized equipment after a
short training period [5]. Under these conditions LAMP had
sensitivity and specificity equivalent to nested PCR performed
upon paired samples in a reference level laboratory, but with a
significantly faster time-to-result.
Both these studies employed liquid blood from venipuncture
[12]. However, convincing evidence that the LAMP method can
reliably detect parasite DNA extracted from finger prick blood
samples spotted and dried onto filter paper from asymptomatic
carriers of low parasite densities (necessary for an effective field
screening programme) is lacking. Moreover, the performance of
LAMP for overall improved malaria case detection in low-
endemic/malaria pre-elimination settings remains to be shown.
The aim of this study was therefore to evaluate the accuracy of the
Loopamp MALARIA Pan/Pf kit as a comparator to PCR for
detection of malaria parasite carriers in Zanzibar, a malaria pre-
elimination setting of sub-Saharan Africa. Samples were derived
from archived dried blood spots collected both from fever patients
attending primary health care facilities and asymptomatic
individuals participating in a cross-sectional survey.
Methods
Study design, blood samples and their origin
This comparative study on the diagnostic accuracy of the
Loopamp MALARIA Pan/Pf detection kit for detection of pan-
Plasmodium and P. falciparum DNA, respectively, versus PCR as
reference standard, included a total of 1330 archived blood
samples collected on filter papers, of which 865 originated from
fever patients and 465 from asymptomatic individuals in Zanzibar.
The study was conducted according to the STARD (Standards
for reporting of Diagnostic Accuracy Studies) guidelines [13].
Fever patients. The 865 blood samples were collected from
fever patients presenting at primary health care facilities in two
districts, i.e. North A (Unguja Island) and Micheweni (Pemba
Island), in Zanzibar, 2010. All patients were enrolled in a
previously published malaria RDT study [14]. Briefly, 3890 fever
patients (defined as either documented axillary temperature $
37.5uC at enrolment or history of fever during the preceding
24 hours) aged $2 months were tested for P. falciparum malaria
with a histidine rich protein 2 (HRP2) detecting RDT (Paracheck-
Pf,Orchid Biomedical Systems, India). Overall, 121 (3.1%)
patients were RDT positive. Blood smears for microscopy and a
blood spot on filter paper (WhatmanTM3MM, GE Health care,
UK) for molecular analysis were collected from capillary finger
pricks, from all RDT positive patients and 744 (,20%) randomly
selected RDT negative patients. All RDT positive samples were
previously analysed with three standard P. falciparum specific
nested PCR methods [14], whereas the RDT negative samples
were screened in duplicate for human plasmodial infection with an
18 s real-time PCR [15]. In total 122 of the 865 (121 RDT
positive+744 RDT negative) patients were PCR positive for P.
falciparum. No other species was found. Four of the 121 (3.3%)
RDT positive patients were negative by PCR, whereas five of the
744 (0.7%) RDT negative patients were positive by PCR [14]. All
samples were analysed with Cyt b nested PCR in association with
the LAMP assays.
Asymptomatic individuals. The 465 blood samples were
selected from asymptomatic individuals participating in a com-
munity based cross sectional survey conducted in North A and
Micheweni districts in Zanzibar, 2011. A total of 2977 individuals
were screened with a PfHRP2/pan-Plasmodium lactate dehydro-
genase (pLDH) based RDT (SD-BioLine Malaria Ag P.f/
Pan,Standard Diagnostic, Inc, Republic of Korea). Blood was
also collected on filter paper (Whatman 3MM) and subsequently
analysed with a nested [16] and a real-time PCR, both targeting
the Cytochrome b (Cyt b) gene. The RDT positivity rate was 13/
2977 (0.4%), of which 6 (46%) samples were confirmed positive by
PCR, all P. falciparum mono- infections. The corresponding
overall PCR positivity rate was 65/2977 (2.2%), 61 (93.8%) were
detected by nested PCR and additionally four by real-time PCR.
All 65 PCR positive samples and 400 randomly selected PCR
negative samples were included in the present analysis. Prior to the
present study, DNA was re-extracted with the Chelex method
from all 65 original PCR positive samples due to insufficient
amount of remaining DNA.
Molecular analyses
DNA extraction from dried blood spots on filter
paper. Fever patients: DNA was extracted from three Ø
3 mm filter paper punches, equivalent to approximately 10–
15 mL blood, using a modified version of the column-based ABI
6100 Nucleic Acid Prep Station protocol (Applied Biosystems,
Fresno, CA) [17]. Each DNA sample was eluted in 200 mL of
buffer and stored in 220uC until use.
Asymptomatic individuals: DNA was extracted from one Ø
3 mm filter paper punch, equivalent to approximately 3–5 mL
blood. Each filter paper was suspended in 0.5% saponin PBS
buffer (Sigma, St Louis, MO), washed in 16 PBS buffer (Gibco,
Paisley, UK), boiled in 100 mL of 10% Chelex (Bio-Rad, Hercules,
CA) H2O solution at 95uC for 10 min and centrifuged [18]. The
supernatant containing DNA was obtained and transferred to a
new plate, and stored at 220uC before further molecular analysis.
PCR methods. Nested PCR: Cyt b nested PCR as described
by Steenkeste et al, 2009 [16] was performed on all samples prior
to the LAMP assay. Briefly, primer pairs of 59-TAATGCCTA-
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GACGTA TTCCTGATTATCCAG-39/59-
TGTTTGCTTGGGAGC TGTAATCATAATGTG-39 and 59-
GAGAATTATGGAGT GGATGGTG-39/59-TGGTAATTGA
CATCCAATCC-39 were used in the first and nested PCR,
respectively. PCR master mix was prepared [16] using 5 mL of
extracted DNA and PCRs was run on the ABI Thermal Cycler
2700 using the same cycling conditions for the first and nested
PCR runs except for the extension step. The conditions were 95uC
for 3 min; 40 cycles of 95uC for 15 sec, 60uC for 1 min and 72uC
for 1.5 min (first PCR) or 1 min (nested PCR); and final extension
at 72uC for 5 min. The nested PCR products were visualized
under UV light after gel electrophoresis, and positive PCR
products were subjected to a Restriction Fragment Length
Polymorphism (RFLP) assay for species identification [19]. The
detection limit for Cyt b nested PCR was estimated to
approximately 2 p/mL as assessed by P. falciparum 3D7
laboratory culture dilution series seeded on filter papers.
Real-time PCR: A recently developed Cyt b real-time PCR was
performed on the Pan and/or Pf-LAMP/nested PCR discordant
samples, using the primer pairs of 59-TGGTAGCA-
CAAATCCTTTAGGG-39 and 59-TGGTAATTGACATC-
CAATCC-39 targeting the Cyt b gene of the five human
Plasmodia species (unpublished data). The real-time PCR master
mix was prepared containing 5 mL of extracted DNA, 16 iTaq
Universal SYBR Green Supermix (Bio-Rad Laboratories, Hercu-
les, CA), and 0.25 mM of each primer in 20 mL volume, and run
on the ABI Prism 7000 system. The real-time PCR conditions
were 95uC for 4 min; 40 cycles of 95uC for 15 sec, 60uC for
1.5 min with fluorescence detection; 72uC for 5 min; and melting
curve acquisition. The real-time PCR results were analysed by
both the melting curve and gel electrophoresis. Positive real-time
PCR products were digested by FspBI enzyme (Thermo Fisher,
Waltham, MA) in RFLP assay for species identification.The RFLP
reaction was carried out in a total reaction volume of 20 mL
including 5 mL of real-time PCR products and 5 units of FspBI
enzyme in 16 reaction buffer in accordance with manufacture
instructions. After overnight digestion in 37uC, the RFLP products
were run on 2% agarose gel followed by visualization in Gel-doc
system (Bio-Rad). The detection limit for Cyt b real-time PCR was
estimated to approximately 1 p/mL as assessed by P. falciparum
3D7 laboratory culture dilution series seeded on filter papers.
Quantitative PCR determined parasite densities. All
nested PCR positive samples from asymptomatic individuals were
subjected to parasite density determination by P. falciparum 3D7
dilutions and quantitative PCR (qPCR) targeting the Plasmodium
18S rRNA gene [20]. Firstly, filter papers (Whatman 3MM) were
prepared by diluting laboratory cultured P. falciparum 3D7 to
densities of 20000, 2000, 200, 20 and 2 p/mL, spotting 30 mL from
each density in the dilution series on to a separate filter papers and
air dried. Secondly, filter papers were subjected to Chelex
extraction and qPCR quantification targeting 18S rRNA gene
using plasmid standards. Thirdly, a standard curve was developed
by plotting known density to quantified 18S copy numbers.
Fourthly, asymptomatic DNA samples were quantified by the 18S
qPCR using plasmid standard [20], and the parasite densities were
calculated by the acquired 18S copy numbers and the standard
curve.
LAMP procedures
All DNA samples were analysed with the Loopamp MALARIA
Pan/Pf detection kit according to standard operating procedures
provided by FIND and the manufacturer’s instructions (available
at: http://www.finddiagnostics.org/export/sites/default/
programs/malaria-afs/docs/SOPs_LAMP_Malaria_AUG12.pdf)
[21]. Samples were analysed individually for Pan and Pf using
separate reaction-tubes containing specific primers. In brief, 30 mL
of DNA samples (diluted 1:6) were added to each Pan and Pf
reaction tube. Each set of six samples were analysed along with a
negative and a positive control included in the kit. After mixing the
DNA solution with the dried reagents, the LAMP reaction tubes
were incubated at 65uC for 40 minutes followed by a 5-minute
enzyme-inactivation at 80uC in an LA-500 turbidimeter (Eiken
Chemical). Results were electronically recorded from the ampli-
fication curves in the control unit. An increase in turbidity
exceeding 0.1 Optical Density (OD) units per second was scored as
positive [22]. In case a sample showed invalid result (questionable
curve) or the controls did not show expected results the whole strip
of eight tubes were re-analysed.
Limit of detection
Parasite densities of P. falciparum (3D7) laboratory strain
cultures were assessed by microscopy and diluted to concentrations
of 2000-0.2 p/mL and seeded on filter papers. Detection limits for
the Loopamp MALARIA Pan/Pf kit were determined after DNA
extractions with Chelex and found to be #2 parasites/mL for both
Pan and Pf-LAMP.
Lot testing
Incoming quality check (IQC) for lot release was performed for
the two lots of Loopamp MALARIA Pan/Pf detection kit used
during the trial with two P. falciparum samples of 5 and 50 p/mL,
one P. malariae sample and three negative samples.
Re-testing of blood samples with discordant LAMP and
PCR results
For the 865 fever patients, DNA samples with discordant Cyt b
nested PCR versus Pan and/or Pf-LAMP results were subjected to
DNA re-extraction with the Chelex method and re-testing with
Cyt b nested PCR and Pan and Pf-LAMP. Any samples which
continued to give discordant results were then re-amplified by Cyt
b real-time PCR in triplicate. DNA samples from asymptomatic
individuals with discordant results between nested PCR versus Pan
and/or Pf-LAMP were also re-amplified by Cyt b real-time PCR
in triplicate.
Reference PCR methods
The method used for comparison of PCR versus Pan and Pf-
LAMP was Cyt b nested PCR, herein referred to as reference
standard. Cyt b real-time PCR corrected nested PCR result was
defined as gold standard for evaluation of LAMP in this study.
Blinding of samples
The person performing the LAMP assays and re-testing of
discordant PCR and LAMP samples was blinded to all clinical
data and previously obtained results by all other diagnostic
methods (microscopy, RDT and PCRs). All samples were
anonymized before testing and re-testing.
Ethical considerations
Sample collections were conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice [23,24] and
approved by the Zanzibar Medical Research Ethics Committee
(ZAMREC/ST/0021/09) (ZAMREC/0001/JUNE/011) and the
Regional Ethics Committee, Stockholm (2009/387-31). All
participants in both studies gave written informed consent for
their participation. For children, proxy-consents from parents/
legal guardians were obtained. The RDT study on fever patients
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[14] is registered on ClinicalTrials.gov with study identifier
‘‘NCT01002066’’.
Data management, sample size calculation and statistical
analysis
Data were entered and statistical analyses performed using
STATA v.12 (Stata Corp, Texas, USA). The primary endpoint
was to assess the accuracy with which the Loopamp MALARIA
Pan/Pf detection kit detected Plasmodium DNA in fever patients
and asymptomatic individuals using dried blood spots collected on
filter paper in a malaria pre-elimination setting. The power
calculation was based on the assumption that LAMP (both Pan
and Pf reactions) should have an average sensitivity of 90% and
specificity of 95% when compared with PCR. The proposed
sample size, including 121 RDT positive fever patients and 61
asymptomatic PCR positives, would then provide confidence
intervals (CIs) within 10% of the sensitivity point estimate (83.6–
94.1% and 80.0–95.3%, respectively). Specificity was estimated
much more narrowly given that the 748 fever patient RDT
negatives and 400 asymptomatic PCR negatives would provide
CIs of 93.2–96.3% and 92.4–96.7%, respectively. Sensitivity,
specificity, negative (NPV) and positive (PPV) predictive values of
the respective Pan and Pf-LAMP assay with corresponding 95%
CIs were calculated using real-time PCR corrected nested PCR as
gold standard. When calculating the Pf-LAMP sensitivity,
specificity, NPV and PPV for the asymptomatic individuals, P.
malariae mono-infections were not included. The corresponding
calculations for Pan-LAMP were based on P. falciparum and P.
malariae mono-infections only, i.e. the eight mixed infections were
not included in the calculations. Data were also analysed after
stratification by covariates that may influence the diagnostic
accuracy of LAMP (e.g. parasite density and presence of non-
falciparum species).The immediate commands of cii was used to
calculate the 95% CI (STATA v.12). Pairwise determination of
non-equivalence between final outcome (including re-extraction)
of Pan and Pf-LAMP as well as for Pan-LAMP and Pf-LAMP
individually versus nested PCR for detection of parasite DNA was
determined by the McNemar test. Statistical significance was
defined as p,0.05. Kappa statistics for agreement between the
methods were also performed.
Results
Baseline characteristics of the included subjects are presented in
Table 1 and the study flow is outlined in Figure 1.
Fever patients
Overall 115/865 (13.3%) fever patients were positive by Cyt b
nested PCR. The geometric mean parasite density (p/mL)
determined by blood smear microscopy was 7491 (range 6–
782400). All 115 nested PCR positives were P. falciparum mono-
infections, of which 105 (91%) were detected by Pan-LAMP and
101 (88%) by Pf-LAMP. Two nested PCR negative samples were
positive by Pan-LAMP (Figure 1).
There were thus 21 samples with discordant nested PCR versus
Pan and/or Pf-LAMP results. Among these, five had negative
blood smears and the remaining 16 microscopy positive samples
had parasite densities assessed by microscopy ranging from 9 to
5331 p/mL (Table 2). All 21 samples were positive when analysed
with real-time PCR in triplicate.
After repeat PCR and LAMP analysis with Chelex re-extracted
DNA from the 21 discordant and 21 randomly selected
concordant negative samples as controls, four discordant samples
remained, i.e. Pan and Pf-LAMP positive/nested PCR negative.
Among these, two samples had parasite densities of 3930 and 679
p/mL, respectively, as assessed by microscopy whereas the other
two were negative. All these four samples were again determined
positive by Cyt b real-time PCR, see table 2 for detailed results.
Two patients negative by Pan and Pf-LAMP were after Chelex-
extraction also negative by Cyt b nested PCR. Both samples were
negative by microscopy (Table 2). Nested PCR detected 15/21
(71%) of the real-time PCR positive re-extracted samples. All 21
previously concordant negative samples remained negative when
re-analyzed.
Asymptomatic individuals
Overall 50/465 (11%) asymptomatic individuals were positive
by Cyt b nested PCR, 29 samples were determined positive for P.
falciparum, 16 for P. malariae and five for P. falciparum/P.
malariae mixed infections. The geometric mean parasite density
(p/mL) determined by qPCR was 10 (range 0–4972). Pan-LAMP
was positive for 49 (10.5%) and Pf-LAMP for 38 (8.2%) subjects.
There were 12 samples with discordant nested PCR and Pan and/
or Pf-LAMP results. Their detailed results including qPCR
determined parasite densities are presented in Table 3.
The 12 discordant samples along with the same number of
randomly selected concordant negative samples as controls were
re-analysed with Cyt b real-time PCR in triplicate. This resulted in
another 4 PCR positives among the discordant samples. Among
these 54 (50+4) PCR positive samples, the RFLP assay with FspBI
digestion showed 33 P. falciparum, 13 P. malariae and 8 mixed P.
falciparum/P. malariae infections. Out of the 41 (33+8) P.
falciparum real-time PCR positive samples, 38 (93%) and 34
(83%) were positive by Pf-LAMP and nested PCR, respectively.
Pan-LAMP was positive in 49/54 (91%) of all PCR positive
samples and in 32/33 (97%) and 10/13 (77%) of the PCR
determined P. falciparum and P. malariae mono-infections,
respectively. Nested PCR was positive for all 13 P. malariae
samples. There was no significant difference in parasite densities
between the three Pan-LAMP negative (range 1–2 p/mL) versus
the ten Pan-LAMP positive (range 0–3 p/mL) P. malariae samples
(p$0.05). Pan and Pf-LAMP both detected seven, whereas nested
PCR detected five of the eight samples with mixed P. falciparum/
P. malariae infections. All 12 previously concordant negative
samples remained negative when re-analysed.
Sensitivities and Specificities for LAMP
Fever patients. The sensitivity, specificity and predictive
values for parasite detection in ABI-extracted samples for Pan and
Pf-LAMP versus real-time PCR corrected nested PCR (gold
standard) are presented in Table 4. Final outcome for Pan and Pf-
LAMP among fever patients including the results from the analysis
using Chelex re-extracted DNA samples (823+42) and the
respective kappa-values are also presented in Table 4. Statistical
equivalence between the performance of Pan versus Pf-LAMP and
between Pan-LAMP and Pf-LAMP individually versus nested
PCR for detection of P. falciparum DNA revealed p-values of
1.00, 0.13 and 0.13, respectively.
Asymptomatic individuals. The sensitivity, specificity and
predictive values for parasite DNA detection for the respective Pan
and Pf-LAMP compared with the defined PCR gold standard are
presented in Table 4. Statistical equivalence between the perfor-
mances of Pan versus Pf-LAMP and between Pf-LAMP versus
nested PCR for detection of P. falciparum among asymptomatic
individuals revealed no significant difference, with p-values of 1.00
and 0.29, respectively. Similarly, the performance of Pan-LAMP
versus nested PCR for detection of all malaria positives also
showed equivalence (p= 1.00).
LAMP Detection of Low Malaria Parasite Densities
PLOS ONE | www.plosone.org 4 August 2014 | Volume 9 | Issue 8 | e103905
Discussion
The Loopamp MALARIA Pan/Pf detection kit evaluated in
this study revealed high diagnostic accuracy both with Pan and Pf-
LAMP for parasite DNA detection among fever patients and
asymptomatic individuals from filter paper blood samples collected
in Zanzibar. This is, to our knowledge, the first evidence of high
diagnostic accuracy of LAMP using parasite DNA extracted from
minute blood volumes spotted on filter paper from fever patients
Figure 1. Flow chart of study. Reference standard=Cytochrome B nested PCR. Gold standard=Cytochrome B real-time PCR corrected
nested PCR.
doi:10.1371/journal.pone.0103905.g001
Table 1. Baseline characteristics of fever patients and asymptomatic individuals.
Fever patients (n = 865) Asymptomatic individuals (n = 465)
Median age 19 (2 months-92 years) 14 (1month-85 years)
Sex male %/female % 42/58 40/60
RDT positive (P. falciparum) 121 13
RDT positive (non P. falciparum) ND 0
Microscopy positive (all species) 116 ND
Geometric mean parasite density* p/mL 7491 (6–782,400) ND
PCR positive (all species) 122 65
Geometric mean parasite density** p/mL ND 10 (0–4972)
*determined by microscopy,
**determined by quantitative PCR,
ND=not done, p/mL = parasites/microliter, values in ( ) = range.
doi:10.1371/journal.pone.0103905.t001
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and importantly asymptomatic low-density parasitaemias. These
data support LAMPs potential role for improved passive and
active malaria case detection in pre-elimination settings.
The LAMP method has previously been evaluated against
microscopy and PCR among symptomatic patients suspected of
having malaria infection, already diagnosed malaria cases and
from samples obtained from malaria cultures using larger blood
volumes [10,11,12,22,25] showing sensitivities and specificities .
90%. Importantly, the present study shows similar high diagnostic
accuracy from asymptomatic individuals using minute blood
volumes preserved on filter paper. This is in agreement with a
recently published study using a RealAmp assay with high
diagnostic accuracy with DNA extracted from dried blood spots
from asymptomatic individuals in Thailand, although on a very
small number of positive samples [26].
The Loopamp MALARIA Pan/Pf detection kit has previously
been shown to be stable, user-friendly and robust [22]. The kit is
also considered safe with minimal risk of contamination [12,27].
The high amplification capacity provides highly sensitive parasite
detection with either a turbidimeter or under UV-light after
40 minutes incubation. Moreover, the high amplification capacity
of LAMP makes the obtained results easy to interpret; with a few
Table 3. Asymptomatic individuals with discordant results.
ID Parasites/mL* Pan LAMP Pf LAMP Nested PCR Real-time PCR
1 3 + + - Pf
2 3 + + - Pf
3 10 + + Pm Pf/Pm
4 ,1 + + - Pf
5 5 2 2 Pf/Pm Pf/Pm
6 5 + + Pm Pf/Pm
7 2 2 2 Pm Pm
8 3 + + Pm Pf/Pm
9 1 + 2 - Pf
10 2 2 2 Pf Pf
11 1 2 2 Pm Pm
12 2 2 2 Pm Pm
*determined by quantitative PCR, Pf = Plasmodium falciparum Pm= Plasmodium malariae,
P/mL = parasites/microliter, + positive, 2 negative.
Outcome summary of asymptomatic individuals with discordant results between.
Pan and/or Pf-LAMP and nested PCR using Chelex extracted DNA.
doi:10.1371/journal.pone.0103905.t003
Table 4. Sensitivities, specificities, positive and negative predictive values and kappa analysis.
Fever patients ABI-extracted DNA (n = 865)
Sensitivity % (95% CI) Specificity % (95% CI) PPV % (95% CI) NPV % (95% CI) Kappa value
Pan-LAMP 91.5 (84.8–95.8) 100 (99.5–100) 100 (96.6–100) 98.7 (97.6–99.4) 0.95
Pf-LAMP 86.3 (78.7–92.0) 100 (99.5–100) 100 (96.4–100) 97.9 (96.6–98.8) 0.92
Fever patients: including Chelex re-extracted DNA (n = 823+42)
Sensitivity % (95% CI) Specificity % (95% CI) PPV % (95% CI) NPV % (95% CI) Kappa value
Pan-LAMP 98.3 (94.0–99.8) 100 (99.5–100) 100 (96.8–100) 99.7 (99.0–100) 0.99
Pf-LAMP 98.3 (94.0–99.8) 100 (99.5–100) 100 (96.8–100) 99.7 (99.0–100) 0.99
Asymptomatic individuals Chelex extracted DNA (n = 465)
Sensitivity % (95% CI) Specificity % (95% CI) PPV % (95% CI) NPV % (95% CI) Kappa value
Pan-LAMP all species 90.7 (79.7–96.9) 100 (99.1–100) 100 (92.7–100) 98.8 (97.2–99.6) 0.95
Pan-LAMP P.f.* 97 (84.2–99.9) 100 (99.1–100) 100 (89.1–100) 99.8 (98.7–100) 0.97
Pan-LAMP P.m.** 76.9 (46.2–95) 100 (99.1–100) 100 (69.2–100) 99.3 (97.9–99.9) 0.89
Pf-LAMP P.f.*** 92.7 (80.1–98.5) 100 (99.1–100) 100 (90.7–100) 99.3 (98.0–99.9) 0.96
P.f.* = P. falciparum mono infections (n = 33), P.m.** = P.malariae mono infections (n = 13), P.f.*** P. falciparum mono and mixed.
infections (n = 41), CI = confidence interval, PPV = positive predictive value, NPV= negative predictive value.
Sensitivities, specificities, positive and negative predictive values and kappa analysis for detection of malaria DNA from fever patients and asymptomatic individuals with
Pan and Pf-LAMP versus gold standard (real- time PCR corrected Cytochrome b nested PCR).
doi:10.1371/journal.pone.0103905.t004
LAMP Detection of Low Malaria Parasite Densities
PLOS ONE | www.plosone.org 7 August 2014 | Volume 9 | Issue 8 | e103905
parasites per microliter of blood generating equally high turbidity
or fluorescence as high-density parasitaemias [12].
In the present study, LAMP performed less well on DNA
samples extracted with an automated ABI platform. However,
LAMP analysis of the same blood samples, but DNA extracted
with Chelex resulted in an excellent agreement between PCR and
LAMP and importantly, we did not find any false positive LAMP
results.
Among asymptomatic individuals, both Pan and Pf-LAMP had
high sensitivities in identifying infections with low parasite
densities. LAMP appeared also to be a better tool to identify
mixed P. falciparum/P. malariae infections compared to nested
PCR. Moreover, Pan-LAMP appeared to have slightly lower
sensitivity in detecting low-density P. malariae infections com-
pared to nested PCR, on the other hand LAMP was superior for
P. falciparum detection. Our results are in accordance with a
previous evaluation of Pan and Pf-LAMP for detection of the
various Plasmodium species showing a detection limit of 2–5 p/mL
for all human malaria species [12]. Similarly with the results
retrieved from fever patient samples, no false positive LAMP result
(specificity and PPV 100%) was detected among the asymptomatic
individuals.
Our results show that the Loopamp MALARIA Pan/Pf
detection kit may represent a promising opportunity for improved
malaria case detection in screen and treat activities within malaria
pre-elimination settings. Considering that the relative importance
of non-falciparum infections appear to increase in such areas [2,7]
screening with Pan-LAMP only, which also has a slightly lower
detection limit compared to Pf-LAMP (5 versus 7.5 DNA copies/
test) [21], may represent a cost effective strategy followed by Pf-
LAMP analysis of Pan-LAMP positive samples. However, there is
a need for vivax-specific LAMP assays especially in areas outside
Africa where P.vivax infections predominate [26]. Previous studies
have demonstrated high diagnostic accuracy of LAMP with fresh
or frozen blood [10,11,12,22,25]. The present study provides
evidence that the LAMP kit performs equally well with blood
samples from finger pricks collected and stored on filter paper, a
low-cost and practical solution for population screening purposes.
However, simpler and faster sample preparation for LAMP has
been evaluated in the field [5]. Such simplification of sample
processing and thus at low cost and improved throughput of high
number of samples represents a priority if LAMP is going to be a
useful tool in areas aiming at malaria elimination. Importantly,
and based on our data, future field evaluations of the LAMP assays
for detection of asymptomatic low-density parasite carriers need to
be conducted. Further studies on the impact on overall transmis-
sion of low-density parasite detection by LAMP followed by
adequate treatment need to be conducted.
Limitations
In this study two sets of DNA samples previously extracted with
two different methods and stored at 220uC were used. Samples
from fever patients were extracted with a column-based ABI
method, a high throughput set-up used in our laboratory at the
time of the trial [14,17]. This method has been replaced by the
Chelex-100 extraction method in our laboratory. The discordant
samples between nested PCR and LAMP were therefore re-
extracted using the latter method. The concordant ABI extracted
PCR positive and negative samples which were not re-extracted,
were earlier investigated with several nested and real-time PCR
methods [14].
Long storage of frozen DNA extracted with the ABI method, in
combination with several freeze-thawing episodes may have
influenced the DNA quality suitable for the LAMP reaction more
than for ordinary PCRs since several samples with microscopically
detectable parasitaemias were negative for Pan and/or Pf-LAMP,
but positive for Cyt b nested and real-time PCR. When recently
extracted DNA with the Chelex method was used both Pan and
Pf-LAMP showed even higher sensitivity than nested PCR.
Conclusion
Both components, Pan- and Pf-detection, of the Loopamp
MALARIA kit evaluated in this study revealed high diagnostic
accuracy for parasite detection among both fever patients and
asymptomatic individuals. This study provides, to our knowledge,
the first published evidence of high diagnostic accuracy of LAMP
for parasite detection from minute blood volumes spotted on filter
paper from asymptomatic individuals in a population where
elimination strategies such as focal screening and treatment may
be of value, particularly when blood sampling on filter paper from
capillary finger pricks would be advantageous for practical and
logistical reasons. These data support LAMPs potential role for the
implementation of active case detection activities in malaria pre-
elimination settings.
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